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Abstract 
 
Aims:  
To study induction of remission and reduction in relapse rate of 
childhood Crohn’s disease with quality of life (QOL) assessment in 
subjects on long term continuous oral supplementation with 
ACD004. 
 
Methods:  
This study was performed in two phases. In Phase A, ACD004 was 
used to assess effectiveness based on proportion of full remission at 
8 weeks. Children then reintroduced food over a 4 week phase 
reducing their ACD004 intake to 30% RDA, subsequently enrolling 
into randomised controlled part of the trial (Phase B), to assess 
reduction in relapse rate whilst receiving continuous oral ACD004 
supplementation compared to no supplementation. Secondary 
objectives of this study were to examine QOL, safety, tolerance and 
growth. 
 
Results:  
42 children were enrolled in Phase A with 78.6% (n=33) achieving 
remission with a significant improvement in endoscopic, histologic 
and QOL scores. One child developed refeeding syndrome. A 
further 8 children relapsed during the food reintroduction phase and 
25 children were enrolled in the Phase B RCT. 12 were randomised to 
remain supplemented and 13 had no supplementation. Only 1/3rd of 
the calculated study power (n=72) was met due to collapse of trial 
following withdrawal of funding. 8/12 in the supplemented and 
10/13 in the non-supplemented group relapsed by first year. At 2 
years, 4/12 in the supplemented and 2/13 in the non-supplemented 
group were in remission. Deterioration in IBD and systemic QOL 
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symptoms related to disease were seen; however there was no 
change in emotional and social functioning. 
 
Conculsions:  
ACD004 is an effective remission inducing agent, which also 
improves QOL despite significantly limiting children’s diet. Due to 
early collapse of trial, its role as a supplement remains uncertain; no 
benefit seen with limited trial recruitment. In the long-term, 
emotional and social domains in QOL remain unaltered, despite 
relapse which may be due to disease acceptance.
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1.1    Background and aims of the thesis 
 
1.1.1 Background 
 
Chronic inflammatory bowel diseases encompass a group of 
conditions which cause inflammation in the intestinal tract 1. This 
group includes Crohn’s disease and ulcerative colitis. 
Characteristically, Crohn’s disease may involve any part of the 
gastrointestinal tract (compared to ulcerative colitis which is limited 
to the colon). Both are life long conditions commonly running a 
relapse and remitting course. As we begin to understand these 
conditions better, we now know that the aetiology is complex and 
multifactorial involving a combination of genetic predisposition, 
dysregulated immune response and environmental influences 2.  
 
25% of inflammatory bowel disease patients present in childhood or 
adolescence 3,4. The median age of presentation is between 10 and 
14 years 5-9. The reported incidence varies from 0.3-10.9/100,000 7,10-15 
with an increasing incidence most recently reported by Benchemol 
16 in both Crohn’s disease (23.9–31.6 / 100,000 and Ulcerative colitis 
(16.2–19.7 /1000,000) in Canada between the years 1994 - 2005. 
 
Children with inflammatory bowel disease can present with a myriad 
of intestinal symptoms with some even being asymptomatic. 
Commonly reported symptoms of Crohns disease in children include 
abdominal pain, weight loss and diarrhoea 17. As paediatric Crohn’s 
disease commonly presents between the ages of 10-14, linear 
growth may be particualry impaired which may also be associated 
with lack of pubertal development. The relapsing and recurring 
bowel symptoms can affect day to day functioning which includes 
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education, social functioning and employment for young adults 18,19. 
In addition, children face regular visits to the hospital, blood testing, 
endoscopies and treatments. The resulting quality of life (disease 
status forms one aspect of the total QOL assessment) may be poor. 
 
The aim of treatment of inflammatory bowel disease in children is to 
achieve and maintain remission with the minimum of ‘drug’ side 
effects. Corticosteroids have always been the mainstay treatment 
for active disease but when used over long periods result in 
osteoporosis 20 and stunted growth 21. Over years there has been a 
shift towards using nutritional treatments in Crohn’s disease and  in 
1971 for the first time, enteral nutrition was used to improve nutrition 
of a child with active Crohn’s disease 22. Noticeable improvement in 
nutrition was associated with resolution of inflammation. The first 
feed Conded 72H®, was a sucrose based liquid elemental diet and 
did not taste nice; an issue with elemental feeds to date. It was 
administered as a continuous infusion via a nasogastric tube. 
Consequently, better tasting polymeric (whole protein) feeds were 
developed to avoid nasogastric tube usage 23. Nutritional approach 
to treatment has significant advantages as it not only optimises 
nutrition but also controls active intestinal inflammation with a 
reduction in pro-inflammatory cytokines 24. Although cross-sectional 
studies show a poor quality of life during active disease state 25, It 
however remains unknown if these therapies result in an 
improvement in quality of life over time during the course of the 
treatment. Also, retrospective studies show that supplement enteral 
feeding taken daily can help to maintain remission 26. There are 
however no prospective studies to support its use as maintenance 
treatment. 
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More recently, there has been accumulating evidence of beneficial 
effects with n-3 fats and its anti-inflammatory properties 27. Nestle 
produced a new polymeric feed ACD004 with higher n-3 : n-6 ratio 
compared to the used CT3211 feed (Modulen IBD®) with a view to 
offer better anti-inflammatory profile in an enteral feed. I used 
ACD004 in the study described in this thesis.   
 
1.1.2 Study summary 
 
Objective: Study induction of remission and reduction in relapse rate 
of childhood Crohn’s disease with quality of life (QOL) assessment in 
subjects on long term continuous oral supplementation with 
ACD004. 
 
Subjects: 27 children in phase A increasing to 72 children (aged 5 to 
19 inclusive) with newly diagnosed or relapsing Crohn’s disease. 
 
Study design: the study will be performed in two phases and 
initiated in two centres. 
Phase A: Prospective and open 
Phase B: Prospective, open, controlled and randomised 
 
Product: ACD004 exclusively for 8 weeks (Phase A), then ACD004 
supplements versus usual diet (Phase B) 
 
Treatment duration: Exclusive enteral supplementation with ACD004 
for 8 weeks (Phase A), then gradual food re-introduction over a 
period of 4-6 weeks followed by a randomised intervention period of 
2 years (108 weeks)(Phase B). 
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Evaulation criteria: 
 
Phase A:  
 Efficacy (remission or relapse after 8 weeks of treatment),  
 short term safety,  
 growth  
 quality of life 
 
Phase B: 
 Reduction in relapse rate,  
 long term safety,  
 growth  
 quality of life 
 
 27 
 
1.2 Definition of inflammatory bowel disease 
 
1.2.1    Introduction 
 
All inflammatory bowel conditions are defined and differentiated 
mainly on the basis of histology. This underlies the importance of 
endoscopy and biopsy, in making a diagnosis. Each inflammatory 
disease can be further sub classified by anatomical distribution of 
inflammation such as proctosigmoiditis or pancolonic inflammation 
in cases of ulcerative colitis. Crohn’s disease may also be classified 
on the basis of disease behaviour such as penetrating or fistulating. 
This has been discussed in detail in the following sections. 
 
1.2.2    Crohn’s disease 
 
Crohn’s disease is characterized by patchy transmural inflammation 
affecting any part of the gastrointestinal tract 28,29. A secure or 
definite diagnosis can be made on the basis of following 
observations 30: 
 Presence of characteristic histology with non-caseating 
granulomata. When present these are a useful histological 
marker as they tend to be absent in other forms of 
inflammatory bowel disease. In a recent study granulomas 
were found to be present in 61% of the children at diagnosis 
31; however their significance on disease process remains 
unknown. In this study granulomas were more frequent in 
untreated children and their presence was not affected by 
age. Presence of a NOD2 mutation does not confer an 
increased risk to developing granulomas 32. Equally its 
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presence does not predict future need for surgery 33. It is 
important to consider that crypt associated  giant cells and 
granulomas can occur in ulcerative colitis and are unreliable 
for differentiating between Crohn’s and ulcerative colitis 34. 
Although presence of pericryptal granulomas should alert one 
to the diagnosis of Crohn’s disease, their presence is not itself 
diagnostic for Crohn’s disease. Their presence in ulcerative 
colitis may be reflective of the mild nature of colitis 35. 
Surawicz suggested that pericryptal granulomas may form as 
a result of mucin from damaged crypts, different from 
granuloma formation in Crohn’s disease 36. 
 The presence of terminal ileal ulceration on endoscopy and 
histological ileitis with a characteristic radiological 
appearance 
 The presence of characteristic histology after intestinal 
resection (non-caseating granulomas and fissuring 
ulceration).  
 A probable or presumptive diagnosis may be made when 
radiological investigations show the typical abnormalities 
found in Crohn’s disease in a child who has clinical features to 
suggest its presence 30. 
 
Crohn’s disease may also be defined and described by location of 
inflammation (terminal ileal, ileocolonic, colonic, upper 
gastrointestinal) and pattern of disease (inflammatory, fistulating, 
structuring).  
An international working party for the World congress convened in 
September 1998 and produced a classification of Crohn’s disease 
called the ‘Vienna classification’. A working party was formulated 
which included gastroenterologists (adult) from Europe, UK, Israel, 
Canada and USA. The classification content was debated as to 
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whether to include fixed or variable criteria. The fixed criteria are 
characteristics of the disease such as location e.g. colonic, ileal etc. 
The variable criteria include changing features like the symptoms of 
the disease. These may change on day to day basis. After an initial 
agreement the classification was based on fixed criteria and five 
international meetings were held between 1996 and 1998. The task 
force on disease quantitation of the International Organisation for 
the study of Inflammatory Bowel Disease (IOIBD) at the same time 
was considering the potential for developing a standardized IBD 
database and classification to assist in genetic studies and clinical 
trials. In January 1998 the IOIBD in conjunction with the Crohn’s and 
Colitis foundation of America sponsored a meeting in New York City 
in which this working party was also represented. 
After common consensus and a review of 413 consecutive cases 
three variables were selected. Two of these variables include 
location of inflammation and pattern of disease, which have been 
described in the preceding sections. A third variable, ‘age at 
diagnosis’ was also selected (age less than or above 40) which is not 
relevant to paediatric practice 37. The Vienna classification is given 
in table 1.2.2.1. 
Louis E et al have suggested that location of Crohn’s disease as 
defined by Vienna classification is a relatively stable phenotype 
which seems suitable for phenotype-genotype analyses. The group 
studied 297 Crohn’s patients and found ileal Crohn's disease to be 
more often stricturing, compared to colonic or ileocolonic Crohn's 
disease which was more often penetrating; this was already the 
case at diagnosis and became more prominent after 10 years 38. 
Veloso et al in Porto in a study of 480 patients found that ileocolonic 
disease was diagnosed at a relatively earlier age which also had a 
lower probability of remaining in remission during the disease course; 
patients with colonic disease needed less surgical or steroid 
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treatments. They concluded that grouping of patients with Crohn’s 
disease according to the Vienna Classification and/or the clinical 
activity in the year after diagnosis is useful in predicting the 
subsequent course of disease 39. 
This phenotype classification has been validated for use in adults 
and has not been used to assess disease response to treatments or 
prognosticate future progress in any paediatric studies. 
The ESPGHAN (European society of paediatric gastroenteorolology 
hepatology and nutrition) working group on paediatric IBD had its 
first meeting in Taormina, Italy in 2002. Various aspects of paediatric 
IBD from diagnosis to management with future plans of holding a 
database were discussed in this meeting. This was followed by 3 
meetings in Porto and one in Prague. The final working group 
consisted of 23 working paediatric gastroenterologists from 19 
centres in 12 European countries. Primary aims were to establish 
consensus based criteria for the diagnosis of IBD and to reach 
agreement regarding diagnostic work up in a new IBD patient. The 
second aim was to collect uniform phenotypic data on patients 
based on resources generally available throughout Europe. The 
Porto criteria for endoscopic and histologic diagnosis are listed in 
table 1.2.2.2 40. 
At the time of submission and writing of this thesis, very recently, the 
Montreal Classification has evolved which takes into consideration 
the younger age group 41. A1 group described in the Vienna 
classification as < 40 years, has been redefined in the Montreal 
classification and further subdivided into A1 as below 17 years of 
age and A2 between 17 and 40 years of age. The general principles 
in the new classification particularly regarding definition of ileal, 
colonic and ileocolonic groups still remain the same, with additional 
allowance to incorporate coexistence of small bowel and distal 
disease in one group. This was decided as disease groups were 
 31 
considered to be mutually exclusive with no allowance for overlap. 
The differences between the two classifications are highlighted in 
table 1.2.2.3. The Montreal classification has been used to 
characterise adult and early onset inflammatory bowel disease by 
Van Limbergen 42. In this study childhood-onset inflammatory bowel 
disease was different to adult Crohn’s disease by extensive 
instestinal involvement and rapid early disease progression. The 
natural history of Crohn’s disease was described by the EPIMAD 
group using the Montreal classification who again described 
Crohn’s disease to be more aggressive in the younger age group 43.  
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Table 1.2.2.1    The Vienna classification of Crohn’s disease 37 
 
Age at diagnosis 1:  A1, < 40 years 
A2, ≥ 40 years 
 
Location 2:   L1, Terminal ileum 3 
L2, Colon 4 
L3, Ileocolon 5 
L4, Upper G I6 
 
Behaviour:   B1, Non stricturing non penetrating 7 
B2, Stricturing 8 
B3, Penetrating 9 
 
1 The age when diagnosis of Crohn’s disease was first definitively established 
by radiology, endoscopy, pathology or surgery. 
 
2 The maximum extent of disease involvement for a location at any time 
before the first resection. Minimum involvement for a location is defined as 
any aphthous lesion or ulceration. Mucosal erythema or oedema is 
insufficient. For classification at least both, a small bowel and a large bowel 
examination are required. 
 
3 Disease limited to the terminal ileum (the lower third of the small bowel) with 
or without spill into caecum. 
 
4 Any colonic location between caecum and rectum with no small bowel or 
upper gastrointestinal involvement. 
 
5 Disease of the terminal ileum with or without spill over into caecum and any 
location between ascending colon and rectum. 
 
6 Any disease location proximal to the terminal ileum (excluding the mouth) 
regardless of additional involvement of the terminal ileum or colon. 
 
7 Inflammatory disease which never has been complicated at any time in the 
course of disease. 
 
8 Stricturing disease is defined as the occurrence of constant luminal 
narrowing demonstrated by radiologic, endoscopic or surgical pathologic 
methods with pre-stenotic dilatation or obstructive signs/symptoms without 
presence of penetrating disease at any time in the course of disease. 
 
9 Penetrating disease is defined as the occurrence of intra-abdominal or 
perianal fistulas, inflammatory masses and/or abscesses at any time in the 
course of disease. Perianal ulcers are also included. Excluded are 
postoperative intra-abdominal complications and perianal skin tags.
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Table 1.2.2.2    Endoscopy and histology in inflammatory bowel disease – 
Porto criteria  
 
 Crohn’s disease Ulcerative colitis 
Endoscopy (& 
visualizations of oral 
and/or perianal 
lesions 
Ulcers (aphthous, linear or 
stellate) 
Cobblestoning 
Skip lesions 
Strictures 
Fistula 
Abnormalities in oral and/ or 
perianal regions 
Segmental distribution 
Ulcers 
Erythema 
Loss of vascular pattern 
granularity 
Friability 
Spontaneous bleeding 
Pseudopolyps 
 
Continuous with variable 
proximal extension from 
rectum 
 
Histology*  Submucosal (biopsy with 
sufficient submucosal tissue) 
or transmural involvement 
(surgical specimen) 
Ulcers, crypt distortion 
Crypt abscess 
 
Granulomas (non-
caseating, non-mucin) 
Focal changes (within 
biopsy) 
Patchy distribution 
(biopsies) 
 
Mucosal involvement 
 
 
Crypt distortion 
Crypt abscess 
Goblet cell depletion 
Mucin granulomas (rare) 
Continuous distribution 
 
* Histology for both Crohn’s disease and Ulcerative colitis included 
acute and chronic inflammation with architectural changes, loss of 
glands and branching of crypts. Crohn’s disease abnormalities in oral 
region included lip swelling, gingival hyperplasia, aphthous ulcers; 
Crohn’s disease abnormalities in perianal region included tags, fissures, 
fistulae and abscess. 
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Table 1.2.2.3    Differences between the Vienna and Montreal Classification 
 
 Vienna Montreal 
Age at diagnosis A1 below 40y 
A2 above 40y 
A1 below 17y 
A2 between 17 and 40y 
A3 above 40y 
Location L1 ileal 
L2 colonic 
L3 ileocolonic 
L4 upper 
L1 ileal 
L2 colonic 
L3 ileocolonic 
L4 isolated upper disease* 
Behaviour B1 non-stricturing, non-
penetrating 
B2 stricturing 
B3 penetrating 
B1 non-stricturing, non-
penetrating 
B2 stricturing 
B3 penetrating 
p perianal disease modifier† 
 
* L4 is a modifier that can be added to L1-3 when concomitant upper 
gastrointestinal disease is present 
† “p” is added to B1-3 when concomitant perianal disease is present 
 
 
1.2.3    Ulcerative Colitis 
 
Ulcerative colitis is an important differential diagnosis of Crohn’s 
disease and sometimes may be difficult to differentiate from Crohn’s 
colitis. Definite ulcerative colitis is defined histologically by acute 
inflammation with severe crypt cell distortion and diffuse goblet cell 
depletion. Inflammation is generally diffuse and solely mucosal, with 
increased vascularity; not necessarily present in all cases 30.  
Probable ulcerative colitis is indicated by 30: 
Diffuse mucosal inflammation with only mild or moderate crypt 
distortion, mucosal atrophy or mucous depletion 
Diffuse acute and chronic inflammation with increased vascularity 
but little mucous depletion suggesting a resolving phase. 
 
Both the Rome and Vienna classfications have not addressed 
subclassification of Ulcerative colitis. The Montreal classification 
incorporates a system of subclassifying Ulcerative colitis on the basis 
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of extent of disease extent and severity (see tables 1.2.3.1 and 
1.2.3.2). Disesase definition based on disease extent is liable to 
change (progress or regress) with time. Sub-classification on based 
on disease severity may be useful to determine disease behaviour 
over time with direct relevance to clinical management. 
 
Table 1.2.3.1   Montreal classification of extent of Ulcerative colitis 
Extent Anatomy 
E1 Ulcerative 
proctitis 
Involvement limited to the rectum (that is proximal 
extent of inflammation is distal to the rectosigmoid 
junction 
E2 Left sided UC 
(distal UC) 
Involvment limited to a proportion of the colorectum 
distal to the splenic flexure 
E3 Extensive UC 
(pancolitis) 
Involvment extends proximal to the splenic flexure 
 
 
Table 1.2.3.2   Montreal classification of severity of Ulcerative colitis 
Severity Definition 
S0 Clinical 
remission 
Asymptomatic 
S1 Mild UC Passage of 4 or fewer stools (with or without blood), 
absence of any systemic illness and normal inflammatory 
markers (ESR) 
S2 Moderate 
UC 
Passage of more than 4 stools per day but with minimal 
signs of systemic toxicity 
S3 Severe 
UC 
Passage of at least 6 bloody stools daily, pulse rate of at 
least 90/minute, temperature of at least 37.5 C, 
Haemoglobin of less than 10.5 g/100ml and ESR of at least 
30mm/hr 
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1.2.4    Indeterminate colitis and Inflammatory bowel disease 
unclassified (IBDU) 
 
5-15% of patients with IBD affecting colon have some features of 
both Crohn’s and ulcerative colitis but not classifiable in one 
particular category. This has been termed as indeterminate colitis 28. 
This diagnosis is made after carefully considering clinical radiological 
endoscopic and pathological criteria for diagnosis.  
Sands’ has described a histological appearance of crypt atrophy to 
be definitively suggestive of IBD but crypt distortion a probable IBD. 
If there is mucin preservation at ulcer edge or in the crypts with 
infiltration of neutrophils, this would suggest indeterminate colitis 29. 
Historically, Price introduced the term ‘indeterminate colitis’, for the 
first time in 1978, to refer to a subgroup of approximately 10–15% of 
IBD cases in which there was difficulty in distinguishing between 
ulcerative colitis and Crohn’s disease in the excised colectomy 
specimen because features of typical severe ulcerative colitis were 
replaced by deep ulcers—often with knife-like fissures—relative 
rectal sparing, and transmural inflammation 44. Transmural 
inflammation was present in most cases of indeterminate colitis but 
only related to areas of severe ulceration. Interestingly, 2/3rds of the 
cases from Price’s series turned out to be ulcerative colitis in future 
follow up 45. Approximately half of cases described by Price had 
uneven disease that fell into two patterns, both similar to Crohn’s 
disease. 
The Montreal working party has recommended that the term 
‘indeterminate colitis’should only be used for colectomy specimens 
where pathologists are unable to make a diagnosis after full 
examination. Instead they have introduced the term ‘inflammatory 
bowel disease type unclassified’ (IBDU) is suggested for patients in 
whom there is evidence on clinical and endoscopic grounds for 
 37 
inflammatory bowel disease affecting the colon but not the small 
bowel. In addition there are no definitive histological and 
endoscopic features to favour either Crohn’s disease or Ulcerative 
colitis.  
The definition of IBDU may be difficult to adopt universally as it is 
most likely to be interpreted according to the level of available 
expertise. Some patients may have colitis that cannot be 
subclassified into Crohn’s disease or Ulcerative colitis despite 
investigations at referral centres by a multidisciplinary team of 
gastroenterologists, pathologists and surgeons. IBDU may however 
be used loosely and more commonly in less specialized centres, 
which otherwise would have been diagnosed Ulcerative colitis or 
Crohn’s colitis if investigated by a more expert team 46. Needless to 
say this may therefore lead to inappropriate case ascertainment 
and prognostication. 
One should be cautious in making a diagnosis of IBDU in the 
following circumstances: 
• Fulminant or refractory IBD – in the initial cohort of indeterminate 
colitis, 2/3rds progressed to develop ulcerative colitis 45 
• Chronic phase of IBD – this is simply highlighted by the fact that 
when IBD is inactive, only minimal histological changes are 
found, making it difficult to diagnosis either Crohn’s disease or 
ulcerative colitis 47 
• Treated cases of IBD – drugs like azathioprine and infliximab can 
induce mucosal healing 48,49 
• Earliest stages of IBD – UC especially in children may initially 
present with atypical features with relative or complete rectal 
sparing, with patchy disease 47,50-52 
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Table 1.2.4.1 shows a list of conditions causing colitis in children. 
These should be diagnostically considered and excluded to avoid 
such patients being labelled as IBDU. 
Lastly I would like to comment on role of serology in making an 
affirmative diagnosis in indeterminate colitis. Jossens et al 
prospectively studied 97 adult patients with indeterminate colitis with 
serology for ASCA and ANCA. Diagnosis changed to a UC/CD in 
32% of these patients. A study of serology showed ASCA+/pANCA- 
to predict CD in 80% of patients and ASCA-/pANCA+ to predict 
Ulcerative Colitis in 63.6%. 48.5% did not show antibodies against 
ASCA or pANCA. Most of these patients remained diagnosed with 
IC during their further clinical course, defining perhaps not only a 
histological but also a distinct clinico-serological entity 46. 
 
 
Table 1.2.4.1 Causes of colitis in children 
 
 
• Inflammatory bowel disease (Crohn’s disease and Ulcerative colitis) 
• Infective colitis 
• Amoebic colitis 
• Cow’s milk or allergic colitis 
• Autoimmune colitis 
• Chronic granulomatous disease 
• Immunodeficiency 
• Behcet’s disease 
• Hirschsprung’s colitis 
• Metabolic disorders
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1.3    Epidemiology of paediatric Crohn’s disease 
 
1.3.1    Incidence of paediatric Crohn’s disease 
 
The incidence of paediatric Crohn’s disease reported in the British 
Isles during 1998 and 1999 was 3.1/100,000 per year 53. Although 
there are no previous prospective reports for comparison, 
retrospective studies from Scotland show a change in incidence 
from 2.3 to 2.5 15,54-56; the second study was conducted 7 years after 
the completion of the first. A more significant increase has been 
reported in Wales from 2.5 to 3.1 57,58, the latter being a prospective 
report following the initial retrospective study, from the region. See 
table 1.3.1.1. 
Reports from other centres in Europe, outside UK, show a similar 
increase in incidence in paediatric Crohn’s disease. These are also 
listed in table 1.3.1.1 and include figures from France, Sweden, 
Norway and Denmark. 
Table 1.3.1.1    Incidence of paediatric Crohn’s disease in Scotland, Wales, UK 
and France 
Key: R= retrospective, P= prospective 
Location Study years CD Study type 
Scotland 1968-1983 56 
1990-1992 54 
1981-1995 55 
1981-1997 15 
2.3 
2.5 
2.5 
2.3 
R 
R 
R 
R 
Wales 1989-1993 57 
Jan 1995 – 30th Mar 1997 58 
2.5 
3.1 
R 
P 
British Isles 1998-1999 53 3.1 P 
France Brittany 1994-1997 59 1.6  
France, Nord-Pas de 
Calais 
1984-1989 60 
1988-1990 61 
1988-1999 6 
2.1 
2.4 
2.3 
P 
P 
P 
Sweden 
Sweden, Northern 
Stockholm 
1984-1995 8 
1990-2001 7 
1.3 
4.9 
P 
R 
Norway 1984-1985 9 2.5 P 
Denmark 
Netherlands 
1962-1987 62 
1999-2001 63 
0.2 
2.1 
R 
P 
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1.3.2    Difficulty in interpreting and comparing different 
epidemiological studies 
 
Comparison between different epidemiological studies is not easy 
and a change in incidence should be interpreted with care. Various 
factors may influence the reported incidence to vary from the true 
incidence of disease in a particular region. These are listed as 
follows: 
Epidemiologic studies may be conducted retrospectively or 
prospectively. Data may be under-reported in retrospective studies, 
with an added disadvantage that there may be no way to cross-
check and verify ambiguous facts. A previous retrospective report 
should certainly be compared with caution to for example, a 
present day prospective report. 
The upper limit of paediatric age tends to vary in different practicing 
units and epidemiologic studies, from as low as 14 to as high as 17 
years (Table 1.3.1.1). Because of the well described, steep rise in 
incidence in the teenage years this difference can be very 
important. 
Crohn’s disease will often present with non-specific symptoms and 
as a result there may be a delay in making the first diagnosis. In a 
recent study from the British Isles a median delay of 5 months (mean 
11 months) has been described. One fifth of the children had 
symptoms for more than a year 17. In the same context an adult 
gastroenterologist may not be skilled to recognise growth failure or 
pubertal delay and the subtle clinical features of non-classical 
Crohn’s disease. Delay in diagnosis and recognition may have an 
impact on the reported incidence compared to a true incidence 
depending on the cut-off age used for a study. This is explained in 
the following hypothetical example: 
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Let us assume that an adolescent with onset of Crohn’s disease at 
15 year of age presents early to a specialist gastroenterology unit, 
undergoes initial investigations and is diagnosed without delay. The 
same child in a different area may ignore the initial symptoms, wait 
to be referred and seen by a specialist. The whole process in the 
second case may last well over a year; the patient will then be older 
than 16 years at the time of diagnosis. Even the best designed 
prospective study, with a cut off age of 16, would naturally include 
this child in one area but exclude in another. This illustrates that not 
only the differential cut off age in various studies may impact on the 
reported incidence, but also local practices and ease of availability 
of a paediatric gastroenterology service may influence it. 
Similarly, caution is needed whilst comparing a study of 2000 with a 
study (for example) from the early 1970s. There is now increased 
awareness and ability to investigate suspected inflammatory bowel 
disease in children with use of gastroscopy, ileocolonoscopy and 
barium investigations. As these investigations were not readily 
available in the past this makes comparison of present day 
epidemiologic studies with studies from 20 years ago difficult. 
True population based registries of paediatric Crohn’s are scarce 
and most reports are a result of relatively crude hospital based 
figures.   
As many as 15% of children are initially diagnosed as indeterminate 
colitis, which then may later evolve to become either CD or UC, 
which then may happen after the age of 16. 
Lapidus’s work highlights the above described fallacies 64. In 1997 he 
showed an increase in Crohn’s disease incidence between 10-14 
years of age but a decrease between 15-19 years (comparison of 
years 1980-84 and 1985-89). The authors maintain that colonoscopy 
was adopted as early as the 1970’s in Sweden; hence the 
diagnostic tools used to make a diagnosis have remained uniform. If 
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the diagnostic tool is a constant in this equation, then an alternative 
logical explanation, other than a true increase/decrease, is that the 
15-19 year group in the 1985-1989 period had their diagnosis made 
earlier, reflecting a relative increase in incidence of the 10-14 year 
age group but relative decrease of incidence in the 15-19 year age 
group 64,65. A true increase in this case should have reflected as an 
increased incidence not only in the 10-14 year age groups but also 
in the 15-19 year age groups. 
 
1.3.3    Geographical variation 
 
There is a striking geographical variation in distribution of Crohn’s 
disease. It is recognized that Scandinavian descent confers an 
increased risk of inflammatory bowel disease. ‘Viking’ is a native 
Scandinavian term for Norse warriors who raided the coasts of 
Scandinavia, the British Isles, and other parts of Europe between the 
late 8th and 11th century. They travelled to the west and Varangians, 
who were best known as the Varangian Guards of the Byzantine 
emperors, to the east. This period of European history (generally 
dated to AD 793 - AD 1066) is referred to as the Viking age. History 
shows that the Vikings settled in Scotland, Scandinavia and 
Minnesota. These are areas with high incidence of inflammatory 
bowel disease (Table 1.3.1.1). 
Earlier observations from the 1960s and 1970s show a north south 
gradient of inflammatory bowel disease. However, more recently 
(1991 – 1993), Shivananda et al in their 20 centre European 
collaborative study (EC funded) are less sure of the north south 
differences. They feel that at present there is a lesser difference 
possibly indicating an increase in incidence in the south in recent 
years followed by stabilisation of incidence in the north 66. This 
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stabilization of incidence in the North, could represent better 
availability of diagnostic techniques during the period assessed. 
There is also a suggestion of a west east gradient within Europe. 
Adult studies show that the current incidence in Poland, Russia and 
the former Yugoslavia is similar to that of Western Europe in the 1940s 
and 1950s 67.  
In Australia, there has been a recent report which shows a rising 
incidence in paediatric Crohn’s disease. There seems to be a striking 
difference when figures from 2001 are compared with 1971 
(0.128/100,000/year (1971)-2/100,000/year (2001). The study was 
conducted in children from Victoria (Australia) with data collection 
from Royal Children's Hospital, or Monash Medical Center, 
Melbourne, Victoria. As discussed in early sections of this chapter, 
availability of a paediatric gastroenterologist and use of endoscopy 
may have played a role in this increase 68. 
Lastly, inflammatory bowel disease is relatively rare in continents of 
Asia and Africa. Recently there has been a report of ulcerative 
colitis from Punjab, India emphasizing that this may reflect a 
problem of under reporting rather than non-existence of the disease 
in the areas 69. Stringent measures for diagnosis are scant due to 
unawareness of the disease and notable absence of any robust 
epidemiological data. 
 
1.3.4    Gender and age 
 
Crohn’s disease tends to be commoner in adult females by 20-30% 
when compared to adult males 65. Due to unexplained reasons, 
reports from paediatric studies generally show this ratio to be 
inversed 17,57. This could suggest a different disease process but has 
yet to be established. The peak incidence for Crohn ‘s disease is 
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observed in late adolescence or young adulthood with a smaller 
second peak in the sixth decade 65. 
 
1.3.5    Races and ethnic groups 
 
Jews are susceptible to Crohn’s disease and in particular Ashkenazi 
Jews are at an increased risk 70. Ashkenazi Jews are descendants of 
the medieval Jewish communities of the Rhineland. Many later 
migrated eastward, forming communities in Germany, Poland, 
Austria, Eastern Europe and elsewhere between the 10th and 19th 
centuries. Interestingly in the 11th century the Ashkenazi comprised 
3% of the world’s Jewish population which increased to 92% by 1931. 
Currently they make up approximately 80% of the Jews world-wide. 
A significant proportion of Jews who migrated from Europe to other 
continents, particularly the United States, in the past two centuries 
are Eastern Ashkenazim. Their incidence rate for Crohn’s disease 
varies in the world but nevertheless tends to be three to four times 
greater than the ‘White’ population. 
In the UK it has been reported that the proportion of children with 
UC is higher in South Asian patients than Caucasian 53,71 however in 
one centre, with 100% ascertainment, the phenotype of IBD was 
identical between South Asian (of Bangladesh origin) and 
Caucasian children 72. British children of Bangladeshi origin with IBD 
have equal proportion of Crohn’s (58%) and UC/IC (42%) to 
Caucasian children. However children of Indian origin (resident in 
Leicester, UK) have a higher incidence of UC/IC (67%). The IBD 
phenotype in British children of South Asian origin varies by the 
country of their parent’s birth. This implies important genetic 
differences between these countries and demonstrates that studies 
need to define the ethnicity more precisely both for genetic and 
epidemiological research 73. 
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1.3.6    Genetics 
 
1.3.6.1    Genome wide linkage analysis (GWLA) and genome wide 
association studies (GWAS) 
 
If a disease runs in the family, one can look for genetic markers (DNA 
sequence) that run exactly the same way in the family (for family 
specific traits). Genes causing disease, in proximity to these markers, 
can be identified by genome wide linkage studies. Nine IBD 
susceptibility loci have been discovered and replicated to varying 
extent (IBD 1-9). Some are specific for UC (such as IBD 2) 74-76 others 
for CD (IBD1) 77,78. Despite initial promise shown by these linkage 
studies and the discovery of the NOD2 in 2001 subsequent progress 
has remained slow. This is due to low resolution of GWLS where areas 
millions of base pairs long are tested. In addition the strongest signals 
in this type of scanning tend to come from recessive and highly 
penetrant diseases.  
This has however changed with the advent of Genome wide 
association studies (GWAS), which is an approach that involves 
looking at alleles different in the case population compared to the 
controls. It is now possible to look at differences in the whole 
genome with the completion of the Human Genome Project in 2003 
79 and International HapMap Project in 2005 80-82. To date over 50 IBD 
disease genes /loci have been identified. 
 
1.3.6.2   Family History and early onset inflammatory bowel disease 
 
One of the first clues towards a significant genetic component in IBD 
was the twin concordonce studies. In twins 44-58% concordance 
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has been reported for monozygotic twins compared with 0-3.8 % in 
dizygotic twins demonstrating the greater importance of genetic 
over environmental factors 83,84. This is less strong in UC with 
monozygotic twins having 14-19 % concordance and 0-5 % in 
dizygotic twins 84,85. The lifetime risk of Crohn’s disease for first degree 
relatives has been shown to be 7 % in non-Jewish, white and 16.8 % 
in Jewish white families 86. 
Polito et al reported that 30% of those presenting under the age of 
20 had a family history compared with 14 % of those presenting over 
40 87. Childhood onset inflammatory bowel disease appears to have 
a distinct phenotype with male predominance 6,7,88 compared to 
female preponderance in adults 89,90. In addition there is evidence 
to support extensive intenstinal involvement (panenteric Crohn’s 
disease 91,92 with rapid early progression with early requirement of 
immunomodulatory drugs. Children diagnosed below 8 years of age 
show significantly less ileal disease and more isolated colonic 
disease than their older counterparts 93-95.  
Genetically, IBD5 variants have been shown to be associated with 
growth indices in early onset disease and a more severe phenotype 
96,97. Two SNPs, rs3024505 (IL10 region) and rs917997 (IL18R1, IL18RAP) 
showed genome wide significance for CD in early onset population, 
but not in the adult disease 98. In addition SNPs near ORMDL3 and 
ICOSLG were shown to be significant for early onset UC having only 
previously been implicated in adult CD 99. 
 
1.3.6.3 Defects in bacterial handling in Crohn’s disease 
 
1.3.6.3.1   NOD2 
 
After fine mapping of the IBD1 region, seminal studies in 2001 
identified the gene encoding NOD2 (which has now been renamed 
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as CARD15 (Caspase and Recruitment Domain) on chromosome 
16q (IBD1 locus) as being important in white but not Asian patients 
100. 10-30 % of white CD patients are heterozygous for one of the 
three common variants of CARD15 (compared with 8-15% of 
controls); 3-15 % are homozygote or compound heterozygote (0-1 % 
of controls).  Homozygous or heterozygous carriage of the common 
variants of CARD15 has been associated with early onset CD (as 
well as stricturing disease and ileal involvement) 101-103.  
NOD2/CARD15 is an intracellular PRR (patern recognition receptor) 
that recognises muramyl dipeptide (MDP) a product of bacterial 
cell wall degradation. The recognition of MDP is facilitated through 
the LRR domain of the NOD2 protein 104. This bond then triggers an 
intracellular signalling. It has been shown that NOD2/CARD15 has 
expression limited to Paneth cells 105 in the intestinal crypts.  
 
1.3.6.3.2   NLRP3 
 
The NLRP3 gene (1q44) encodes the cryopyrin protein which then 
regulates the enzyme caspase-1. Caspase-1 activates the pro-
inflammatory cytokine IL1β. The NLRP3 gene thus controls 
inflammation. Villani and group recently reported effect of 6 CD 
mutations on NLRP3 expression on peripheral blood mononuclear 
cells 106. The rs4353135 genotype has been significantly associated 
with altered expression and homozygosity of the risk allele at 
rs6672995 which results in decreased levels of IL1β following 
stimulation with lipopolysaccharides. 
 
1.3.6.4    IL23 and Th17 signalling 
 
Using GWAS, Duerr et al 107 reported a strong association between 
Arg381Gln (a non-synonymous SNP, rs11209026) in the IL23 receptor 
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gene (IL23R) and Crohn’s disease susceptibility. This variant has 
shown to be protective for the development of IBD (like ankylosing 
spondylitis), although other signals within the gene also confer 
disease susceptibility idependent of the SNP 108. Taylor et al 109 
genotyped multiple SNPs in IL23R identifying IL23R risk and protective 
haplotypes compared to Arg381G1n alone. 
Both IL23 and IL12 play an important role in development of naı¨ve 
Crohn’s disease4+ T cell differentiation. Variations in the IL12 and IL23 
pathways might lead to an aberrant early immune response to 
microbial encounter. IL12 drives naı¨ve Crohn’s disease4+ T cells to a 
Th1 phenotype, however in the presence of IL23 they adopt the 
Th17 phenotype (drives autoimmune inflammation in animal 
models), characterised by the production of IL17, tumour necrosis 
factor and IL6 110,111. Some specific bacterial components such as 
peptidoglycan exert a differential regulatory effect on antigen 
presenting cells in increasing IL23 gene expression but not IL12 which 
explains that even subtle imbalances can result in inflammation 112. 
Earlier in the differentiation of the Th17 subset, ICOSLG (the molecule 
inducible costimulator ligand also known as B7-H2) binds with T cell 
receptor (ICOS) leading to T cell activation 113. ICOSLG is a member 
of the B7 family co-stimulatory molecules. It is a transmembrane 
protein with extracellular IgC and IgV domains. The ICOS and 
ICOSLG interaction is not only essential in early differentiation of the 
naïve T cells but is likely to be important in the careful balance 
between IL-10 producing regulatory cells and Th17 population 114. 
Functional assays in IBD patients show that IL-17 producing cells and 
the levels of Th17 related cytokines IL-17 and IL-22 are increased in 
IBD patients 115-117. 
 
1.3.6.5 Autophagy in pathogenesis of Crohn’s disease 
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Autophagy is a process by which cell digests parts of their own 
cytoplasm for inhouse-keeping purposes. mTOR, is a kinase which 
critically regulates autophagy. Under starvation conditions, mTOR 
inhibition leads to activation of the autophage cascade to provide 
an alternative energy source by recycling intracellular organelles. 
Defective autophagy is now considered to play a role in 
pathogenesis of Crohns’ disease. Two genes are associated, which 
are described as follows. 
 
1.3.6.5.1   ATG16L1 
 
GWAS have implicated association of Crohn’s disease with ATG16L1 
gene 118,119. The ATG16L1 gene provides instructions for making a 
protein called ATG16 autophagy related 16-like 1. This protein is part 
of a larger family of proteins that are required for autophagy. At 
least one variation in the ATG16L1 gene is associated with an 
increased risk of Crohn disease. This increased risk has been found 
primarily in Caucasian (white) populations. The identified ATG16L1 
variation changes a single protein building block (amino acid) in a 
critical region of the ATG16L1 protein. Specifically, it replaces the 
amino acid threonine with the amino acid alanine at protein 
position 300 (written as Thr300Ala or T300A) 118. The gene is expressed 
in the intestine and particularly strongly in Crohn’s disease, CD4+ T 
lymphocytes. Hampe and colleagues have demonstrated 
expression of ATG16L1 mRNA and protein in the colon, small 
intestine, intestinal epithelial cells and leucocytes 118. Lees and 
colleagues have demonstrated downregulation of ATG16L1 mRNA 
in colonic CD biopsies compared with healthy controls in their large 
microarray dataset. Recently gene-trap mutations in ATG6L1 in two 
mouse lines have shown defective intestinal autophagy and 
disruption of granule exocytosis pathways in Paneth cells 120,121. 
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1.3.6.5.2   IRGM 
 
IRGM was identified as a gene implicated in pathogenesis of Crohns 
disease in the WTCC GWAS. Two non-functional SNPs (rs13361189 
and rs4958847) on chromosome 5q33.1 were strongly associated 
with CD 122. The increased risk has been primarily found in Caucasian 
(white) populations. Although there is more work done on 
pathogenesis, simplistically IRGM gene variations may result in the 
cells ability to abrogate harmful bacteria effectively. 
 
1.3.6.6   Developmental genes 
 
Genetic studies show evidence that signalling pathways critical to 
normal mammalian gut development are dysregularted in IBD 
pathogenesis. There is a role for NK2 transcription factor-related, 
locus 3 (NKX2.3) 123,124 and glioma associated oncogene homolog 1 
125 (transcriptional regulator of the hedgehog signalling pathway) in 
inflammatory bowel disease. 
 
1.3.6.7   Intracellular Tyrosine Phosphatases 
 
1.3.6.7.1   PTPN2 
 
The WTCCC study has identified PTPN2 as a CD susceptibility gene 
which encodes the cytosolic T-cell protein, tyrosine phosphatase 
(TCPTP). It acts by dephosphorylating and inactivating its targets, 
hence TCPTP is a key negative regulator of inflammatory responses 
126. 
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T cell protein tyrosine phosphatase can regulate signalling pathways 
that are induced by various growth factors (eg EGF) and cytokines 
(eg TNFα). MAPK (mitogen activated protein kinases), a negative 
control for TNFα, is one of the target proteins inactivated by TCPTP 
127. MAPK inactivation results in propagation of inflammation. 
 
1.3.6.7.2   PTPN22 
 
Meta-analysis by Barrett 128 demonstrates evidence for association 
of PTPN22 gene with Crohn’s disease. In Crohn’s this SNP is protective 
129 and is expressed on many haemopoietic cells, notably T cells. 
PTPN22 encodes a protein tyrosine phosphatase which affects the T 
cell receptor signalling pathway. 
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1.4    Paediatric Crohn’s disease – symptoms, complications 
and assessment 
 
1.4.1    Presenting symptoms 
 
1.4.1.1    Introduction 
 
Paediatric Crohn’s disease classically presents with diarrhoea, 
weight loss and abdominal pain. A recent survey of paediatric 
Crohn’s disease in Great Britain and Ireland, however, shows that 
only one quarter of CD present with these features and nearly half 
did not report diarrhoea 17. There can be a delay in recognizing and 
making a diagnosis on the basis of classical features alone. A 
median delay of 5 months has been reported from the onset of 
symptoms to time of diagnosis. In addition, a fifth of these patients 
were reported to have symptoms for more than one year 17. The 
commonest reported intestinal symptoms in order of frequency 
reported in this series were: abdominal pain (72%), weight loss (58%) 
and diarrhoea (56%) 17. Moreover lethargy was found in 27%, of the 
children. 
 
1.4.1.2    Abdominal pain 
 
The abdominal pain is characteristically periumbilical and colicky. It 
may vary in character and site depending on location of inflamed 
bowel such as gastric inflammation may result in epigastric and 
extensive colonic disease in lower/ left-sided abdominal pain. Eating 
may not cause pain in gastritis alone but also trigger it via the 
gastrocolic reflex (presence of food in the stomach normally triggers 
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intestinal peristalsis). If this triggers contraction of inflamed bowel, it 
will cause pain. Urgency and tenesmus are well described in 
children with distal colitis. Acute appendicitis is a major differential 
diagnosis particularly in children with ileal and caecal involvement. 
 
1.4.1.3    Anorexia, weight loss and growth 
 
Anorexia is a symptom of Crohn’s disease which may lead to 
misdiagnosis as these children may be considered to be suffering 
from anorexia nervosa. Of the children with Crohn’s disease, 58% 
have lost weight at presentation 17. This is likely to be due to 
decreased intake a consequence of raised pro-inflammatory 
cytokines (e.g.; TNF, IL-6) known to cause anorexia. Malabsorption 
seems to be only a minor factor contributing to weight loss. Mild 
steatorrhoea was found only in 24% of patients with ileal disease, 
26% with ileocolonic involvement and 17% with Crohn’s colitis 130. 
A review of growth physiology shows that growth hormone mediates 
release of IGF-1 from the liver. IGF-1 in turn mediates the growth 
hormone’s effects on growth plates. There is a well-recognised 
association between impaired growth in Crohn’s disease and low 
IGF-1 131,132. Factors known to suppress IGF-1 include malnutrition 133, 
cytokines 134,135 and corticosteroids 136. IL-6 mediated decrease in 
IGF-1 production represents a major potential mechanism of short 
stature 137. IL-6 has also shown to have a direct adverse affect on 
the epiphyseal growth plate. 
It is likely that appropriate linear growth in children with Crohn’s 
disease may be best achieved by control of intestinal inflammation 
with adequate nutrition 138 and minimal use of corticosteroids. A 
recent Cochrane review reflects paucity evidence, though some 
growth benefit is shown with use of nutritional therapies in children 
with Crohn’s disease 21. 
 54 
 
1.4.2    Extraintestinal manifestations 
 
1.4.2.1    Introduction 
 
Crohn’s disease does not only affect the intestine. It may cause 
systemic effects known as extraintestinal manifestations. The 
common target organs are skin, joints, liver, eye and bone. They 
tend to be commoner with colonic Crohn’s rather than isolated 
small bowel disease 139,140. The extraintestinal manifestations can be 
broadly divided into two groups; one which follows active Crohn’s 
disease activity and a second group with manifestations un-related 
to active disease. For example erythema nodosum tends to be 
related to active disease although does not reflect severity of 
disease as opposed to pyoderma gangrenosum, which tends to be 
unrelated to the disease process. 
There is also a third group of extraintestinal manifestations, which are 
a result of complications of the disease process. Examples include 
nephrolithiasis and ureteric obstruction 141,142. 
 
These are described in detail as follows: 
 
1.4.2.2    Joints 
 
Arthralgias are commoner than arthritis and affect about 15% of 
patients with Crohn’s disease 140. The knees, hips and ankles are 
most commonly involved. These arthralgias are related to disease 
process and improve with treatment of disease. An exception to this 
is HLA B27 arthritis, a cause of juvenile ankylosing spondylitis, which is 
unrelated to disease activity 140,143. In HLA B27 arthritides the 
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distribution of joint disease tends to be different with involvement of 
hips or sacroiliac joints 143. 
Arthropathies can be pauciarticular (type I) when it affects less than 
5 joints or polyarticular (type II) with involvement of more than 5 
joints. The type I arthropathy is similar to the post dysenteric reactive 
arthritis and is self limiting. This, however also tends to coincide with 
episodes of active IBD. Type II arthropathy on the other hand 
generally persists for months or years and runs a course independent 
of IBD. It is also associated with uveitis but not the other 
extraintestinal manifestations. In contrast, type I arthropathy is 
associated with extraintestinal manifestations other than uveitis 143. 
In adults 6% of patients with a seronegative spondyloarthropathy will 
develop IBD, but patients with normal gut histology at the time of the 
arthropathy do not go on to develop IBD 144-146. 
 
1.4.2.3    Skin 
 
Erythema nodosum and pyoderma gangrenosum are well-
described skin complications in children 140. In a recent series 
reported from the British Isles, 6/379 (0.02%) were reported to have 
erythema nodosum or some form of rash 17. Erythema nodosum is 
the commonest skin lesion associated with inflammatory bowel 
disease and clinically appears in conjunction with active disease. 
Histological examination of the lower dermis of the skin lesion shows 
a moderate lymphohistiocytic infiltrate and direct 
immunoflorescence for immunoglobulins and complement may 
reveal perivascular deposits 147. Erythema nodosum usually responds 
to treatment with corticosteroids. 
Pyoderma gangrenosum is a chronic ulcerating skin disorder which 
can appear as a severe and debilitating complication sometimes 
more severe than the underlying inflammatory bowel disease. 
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Lesions typically occur on extensor surfaces of lower extremities and 
described in adult patients with severe disease and colonic 
involvement. High doses of steroids are effective but in severe cases 
successful use of cyclosporine, mycophenolate and infliximab has 
been described 148-152. 
 
1.4.2.4    Eye 
 
Ocular lesions may be present in young patients and comprise of 
episcleritis, uveitis and orbital myositis. Hofley reported uveitis in 6.2% 
of the children (n= 97) with Crohn’s disease. These cases were mild, 
asymptomatic and self-resolving. Frequency of uveitis was found to 
be higher in children with IBD having other extraintestinal 
manifestations (15%) than in those without (3.1%; p<0.10) 153.  
 
1.4.2.5    Liver 
 
Primary sclerosing cholangitis is classically described with ulcerative 
colitis and rarely so with Crohn’s disease. When present it may 
precede onset of bowel symptoms and tends to be unrelated to 
bowel inflammation 154-156. 
 
1.4.2.6    Osteoporosis 
 
The World Health Organisation defines osteoporosis as bone density 
(or bone mass) that is at least 2.5 standard deviations below peak 
bone mass (defined as, the bone mass achieved by healthy adults 
aged 18-30 years). There is yet no agreed definition for children as 
the bone density is difficult to quantify in children. Despite this, it has 
been shown that children with Crohn’s disease have reduced bone 
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density 20 compared to normal controls 157 and children with 
ulcerative colitis 158. The reported prevalence is variable ranging 
from as low as 11% to as high as 50% 20,158,159. This variability may 
partly be explained by the inherent difficulty in interpreting DEXA 
scans. It is easy to over read using adult reference systems. These 
standard measures do not take regard of variability in stature, size, 
sex and race. Gafni et al have described over-reporting in more 
than 50% of the 34 cases referred to them with osteoporosis. 
Amongst other causes the most frequent error (62%) was use of T-
score (SD score compared with young adults) to diagnose 
osteoporosis. After correction for body size, only 26% retained the 
diagnosis of low bone mineral density with 53% considered to be 
normal. Herzog 159 and Ahmed et al 160 have reported similar 
‘reporting’ problems in paediatric Crohn’s disease.  
Several factors seem to be responsible for reduced bone mineral 
density. These include corticosteroid usage, release of cytokines 
such as IL-6, reduced calcium and vitamin D intake and relative 
immobility; all contributing to development of paenic bones. 
Sentongo found hypovitaminosis D in 16% of the 112 paediatric 
Crohn’s patients. This was however, unrelated to bone mineral 
density or average dietary intake of vitamin D in this particular study 
161. 
 
Identifying and treating osteoporosis in children may produce 
dramatic results even when they have suffered vertebral fractures, 
as demonstrated by Thearle whilst treating a 12 year old boy with 
vertebral fractures at the time of first presentation of his Crohn’s 
disease 162.  
 
1.4.2.7    Other 
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Other rare complications include pancreatitis which can result 
secondary to inflammatory bowel disease or treatments like 
azathioprine and 6- mercaptopurine 163,164. Renal complications of 
obstruction and stones 141, hypercoaguable states including DVT 
(deep venous thrombosis) 165, pulmonary emboli and 
cerebrovascular disease  are well described complications 159,166. 
 
1.4.3    Psychological issues 
 
Crohn’s disease is a complex chronic disease, affecting the psyche 
of the patient. There is no cure for the disease and it relapses without 
warning, with onset of undesirable symptoms. These symptoms may 
not only impair daily activities but also be socially unacceptable. 
These include, frequent diarrhoea and unexpected passage of gas 
and stool; usually difficult to control which may result in anxiety and 
depression. Lack of energy, a common symptom of active disease, 
makes it more difficult to cope. Diagnosis is made by painful blood 
tests and endoscopies, and the preparation for the performance of 
the latter can be particularly embarrassing. Treatments may be 
poorly tolerated as for instance enteral nutrition may need to be 
administered via a nasogastric tube.  Medicines such as 
corticosteroids give a moon face, short stature and acne, 
unacceptable for teenagers. Uncertainty of the disease makes 
simple chores like planning holidays really difficult. 
In a study of psychological issues affecting children with Crohn’s 
disease from Leicester, 95% of the patients thought that their families 
were understanding and sympathetic 18. However, there were some 
worrying findings in this study. Nearly 70% were unable to participate 
in sports on a regular basis, 60% unable to leave the house at all, 
50% unable to play outside with their friends with 40% reporting 
concerns about going on holidays, 53% percent thought that their 
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teachers were ignorant of Crohn’s disease and were treated 
unsympathetically. 80% felt that they had underachieved because 
of ill health. Children were worried about their future, and 
specifically about its effect on their schooling and prospects of 
getting a job. Akobeng et al from Manchester reported similar 
findings in their cohort 19. In a previous study it has been shown that 
parents are concerned for their children in issues regarding future 
relationships, particularly marriage 167. 
This is a brief description of Crohn’s disease, and as we endeavour 
to learn about the disease and its treatments, it is obvious that 
quality of life issues are important in children with Crohn’s disease. 
These concepts with tools used for assessment are discussed in detail 
in sub-chapter 1.7. 
 
1.4.4    Tools used for assessment of clinical paediatric Crohn’s 
disease 
 
Several tools have been used and devised to assess disease severity 
in Crohn’s disease 168. In the 1970s Crohn’s disease activity index 
(CDAI) was devised particularly aimed for adults. It included eight 
variables and involved maintenance of a 7 day diary, to reflect 
disease activity in that particular time frame, not easy to use in a 
single sitting. Lloyd-Still’s scoring system evolved during this period. 
This not only included growth but also sigmoidoscopic and 
radiological evaluation 169. Although CDAI has been extensively 
used as a research tool, difficulty in usage meant that these indices 
never became popular enough to be used in a clinic setting. 
In the early eighties Harvey-Bradshaw devised a scoring system 
dependent on symptoms reported by the patients. It is short, simple 
and easy to score. Its completion does not require any laboratory 
data either. Although it has been incorporated in a few studies, it 
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perhaps is not applicable to paediatric practice for two reasons. 
First, the total score heavily depends upon correct symptom 
reporting, which may not be accurate particularly in the younger 
age group. Second, growth an important feature of paediatric 
Crohn’s disease, is not represented by this scale 170,171. Two further 
scales (OMGE, Index of the Organisation Mondiale de Gastro-
Enterologié; The Cape Town index) were introduced; none ever 
became popular 172,173. The CDAI, although cumbersome, remained 
the gold standard for majority of clinical trials conducted in 
paediatric Crohn’s disease. A need for an easily usable, paediatric 
scoring system for assessment of Crohn’s disease was desired. 
In the 1990’s Hyams working in conjunction with twelve paediatric 
gastroenterology centres, devised the PCDAI (paediatric Crohn’s 
disease activity index) 174. The PCDAI index was validated against 
the modified Harvey-Bradshaw scoring index with good correlation 
175. It comprises of clinical markers, laboratory tests and growth 
markers for assessment of disease and consists of 10 questions. This 
can be used and completed in a clinic sitting and has been 
incorporated in many paediatric studies. On the downside, filling a 
PCDAI form can be time consuming and requires a blood test to 
complete an assessment (see table 1.4.4.1). 
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Table 1.4.4.1    The paediatric Crohn’s disease activity index (PCDAI) 
 
 
History (Recall, 1 week) 
 
Abdominal pain  
None          0 
Mild- brief, does not interfere with activities     5 
Mod/severe- daily, longer lasting, effects activities, nocturnal  10 
 
Stools (per day) 
0 – 1 liquid stools, no blood       0 
up to 2 semi-formed with small blood, or 2-5 liquid    5 
gross bleeding, or ≥ 6 liquid, or nocturnal diarrhoea    10 
 
Patient functioning, general well being (recall 1 week) 
no limitation of activites, well       0 
occ difficulty in maintaining age appropriate activities below par 5 
frequent limitation of activity, very poor     10 
 
Laboratory 
 
Hct (%) 
< 10 years (males and females)   11-19 (Females only) 
33    0   ≥ 34   0 
28-32   2.5   29-33   2.5 
< 28   5   < 29   5 
 
11-14 (Males only)    15-19 (Males only) 
≥ 35   0   ≥ 37   0 
30-34   2.5   32-36   2.5 
< 30   5   < 32   5 
 
ESR (mm/hr) 
<20    0 
20-50    2.5 
50     5 
 
Albumin (g/dl) 
≥ 3.5    0   
3.1-3.4    5 
≤ 3.0    10 
 
 
Examination 
 
Weight* 
Weight gain or voluntary weight stable/loss    0 
Involuntary weight stable, weight loss 1-9%    5 
Weight loss ≥ 10%       10 
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Height 
At diagnosis 
< 1 channel** decrease      0 
≥ 1, <2 channel** decrease      5 
> 2 channel** decrease      10 
 
Follow up  
Height velocity *** ≥ -1SD      0 
Height velocity*** < -1SD, >-2SD     5 
Height velocity*** ≤ -2SD      10 
 
Abdomen 
No tenderness, no mass       0 
Tenderness, or mass without tenderness    5 
Tenderness involuntary guarding, definite mass   10  
 
Perirectal disease 
None, asymptomatic tags      0 
1-2 indolent fistulae, scant drainage, no tenderness  5 
Active fistula, drainage, tenderness or abscess   10 
 
Extraintestinal manifestations (fever ≥ 38.5 for 3 days over past week, definite 
arthritis, uveitis, erythema nodosum, pyoderma gangrenosum) 
None        0 
One        5 
≥ two         10 
 
TOTAL SCORE: ___________ 
 
 
* Change in weight was based on a comparison of the patients current visit 
weight with one determined a minimum of 4-6 months previously.  
**Channel decrease. For newly diagnosed patients a historical search was 
made of the patients past records to establish the premorbid height 
percentile. This value was then compared with the current height and a 
decrease in channels calculated. A decrease from 50th to 10th percentile 
would represent a 2 channel decrease. 
***Height velocity was calculated as cm per year, based on patient’s height 
on current visit compared with a height 6m - 1 year ago. 
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1.4.5    Prognosis  
 
Unfortunately there is no known cure for the disease. With focused 
management the majority of children with Crohn’s disease will lead 
an active life, being regularly followed up in a clinic, maintaining 
remission with medications. Anne Griffiths has reported a 5 year 
follow up in Toronto relating to the ‘rule of thirds’. In her study 
approximately 1/3rd had a mild course, 1/3rd troublesome 
exacerbations but achieving remission and the remainder faced a 
difficult disease course, half of this last group eventually benefiting 
from surgery 176. 
Despite use of timely, intensive medical treatments surgery is 
unavoidable in a majority of children. In 1984 Puntis reported 83% of 
children with Crohn’s disease, requiring surgical intervention within 4 
years of diagnosis 177. These figures are high and in 2004 Freeman in 
his cohort, reported that, 56.3% required surgery within a mean time 
of 4.2 years; still a high proportion. More, newer studies are needed, 
as with availability of immunosuppressants like azathioprine and 
infliximab this figure may be lower. Whether genes will in the future 
predict the need for surgery it remains unknown; the three NOD2 
mutations, associated with ileal disease, have not been linked with a 
greater need for surgery 178. 
Crohn’s disease presents with two peaks first in teens and then 
around fifties. Polito, retrospectively studied records of 552 adult 
patients and found greater small bowel involvement (88.7% vs. 
57.5%), more stricturing disease (45.8% vs. 28.8%), and higher 
frequency of surgery (70.6% vs. 55.3%) associated with a younger 
age of diagnosis 179. Freeman more recently reviewed 224 patients 
and has put down increased complications in the younger group 
simply to the fact that the disease has been there for a longer 
duration. His analyses showed that strictures (28.6%) and penetrating 
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complications (46.4%) in the younger group were similar to adults 
especially when both groups were followed up for a similar period of 
time 180.  
Cancer is a rare complication in the paediatric population. Walker-
Smith JA has reported 2 children developing cancer from his years in 
Queen Elizabeth children’s hospital, London (Personal 
communication). Mortality has been described, as a complication 
of drug treatment or a post-surgical septic complication following 
surgery/resection 180. 
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1.5   Treatments for Crohn’s disease 
 
1.5.1    Introduction 
 
Treatments for Crohn’s disease may be grouped into two main 
categories; first, medicines used for acute active disease and 
second those used for maintenance of remission. Corticosteroids, 
enteral nutrition and infliximab are used for acute active treatment. 
5 aminosalicylates, azathioprine and methotrexate in comparison 
are used to maintain remission. There may be some overlap and 
therapies like enteral nutrition (supplemental) and infliximab may fall 
into both categories. 
 
1.5.2    Drugs used for inducing remission 
 
1.5.1.1    Corticosteroids 
 
Corticosteroids are the main stay treatment for acute active Crohn’s 
disease in adults 181 and children 182. A Cochrane review by 
Benchimol in 2008, shows corticosteroids to be superior to placebo 
or 5 ASA for inducing remission in all ages 183. There remains little 
doubt about their effectiveness; though the side effects are 
universally accepted to be a major disadvantage. Steroid 
associated growth retardation is a concern to clinicians, parents 
and the child 184. In addition, teenagers dislike development of 
acne, moon facies, striae and hirsutism, all well recognised side 
effects of steroids. Side effects such as steroid psychosis and 
pseudotumour cerebri have also been reported. In comparison 
enteral nutrition has a safer side effect profile an attractive option 
for children and parents and as a result has replaced corticosteroids 
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as an effective first line treatment in many paediatric 
gastroenterology centres. 
Use of corticosteroids as a maintenance agent is unjustified. The 
long-term consequences with effects on growth and bones would 
be unacceptable. The risks for osteopenia are higher in paediatric 
Crohn’s disease when compared with ulcerative colitis, even after 
adjustment for cumulative dose of prednisolone 158. 
As an alternative to Prednisolone, gastroenterologists have 
attempted to use budesonide 185-187. A special controlled ileal 
release formulation, allows budesonide delivery in the ileum and 
right side of the colon. Adult trials show it to be almost as efficacious 
as oral prednisolone with an added advantage of having a lesser 
side effect profile 188. Recently, a paediatric trial of budesonide, 
which despite failure to recruit full numbers for the study, has 
echoed the adult trials results with significantly fewer side effects 
and comparatively lesser adrenal suppression in children. Although 
remission rates were not significantly different in the two groups (55% 
vs. 71%, p=ns), there was a clear trend for prednisolone to be more 
effective for inducing remission 189. Unfortunately, oral budesonide 
like prednisolone affects growth. In another paediatric study 
reporting its use in a cohort of 32 children, 6 pre-pubertal children 
continued to receive 6 mg budesonide for 6 to 13 months. Although 
5 of the 6 experienced only mild or no gastrointestinal symptoms 
and gained weight, their mean height velocity was only 2.3 +/- 1.0 
cm/year, and none grew at a rate of more than 4cm/year whilst 
receiving budesonide 190. A Cochrane review by Seow of use of 
Budesonide for induction of remission in all ages shows it to be 
superior to placebo and mesalamine but not to corticosteroids 191. In 
a randomised double blind controlled study in children a better 
response was obtained in inducing remission with a dose of 12 mg in 
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comparison to a conventional dose of 9 mg without any reported 
increase in side effects 192. 
Astegiona has reported use of another new steroid 
Beclomethasone, in Crohn’s disease in a cohort of 34 patients with 
66.7% achieving remission at 24 weeks 193. Tursi reported Budesonide 
to be superior to Beclomethasone in inducing remission in patients 
diagnosed with Crohn’s disease for the first time 194.  
 
1.5.1.2    Enteral nutrition 
 
Role of enteral nutrition in treatment of Crohn’s disease is discussed 
in sub-chapter 1.6. 
 
1.5.1.3    Antibiotics 
 
Metronidazole was first reported in 1975, to be effective in treatment 
of Crohn’s disease 195. Studies have shown it be efficacious in 
Crohn’s colitis but not for treatment of small bowel Crohn’s disease 
196-199. Its long term use may result in peripheral neuropathy, with 
reported incidence as high as 50-75% 200. 
Ciprofloxacin, a quinolone, is commonly used in conjunction with 
metronidazole. Where metronidazole is effective against 
Bacteroides, ciprofloxacin is efficacious against enterobacteriaciae 
and E Coli. Prantera et al in a retrospective review of 233 patients 
demonstrated use of combination of antibiotics for treatment of 
acute flare ups 201. Interestingly, in this study combination therapy 
(remission in 70.6%) was found to be as efficacious as metronidazole 
(remission in 72.8%) and ciprofloxacin (remission in 69%) used 
individually. 
Antibiotics are also commonly used for treatment for perianal 
Crohn’s fistulae. Limited uncontrolled studies report success in adult 
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Crohn’s disease. Bernstein in a study of 21 patients reported healing 
in 48% and advanced healing in 21% 202. Similarly, Jacobovits 
reported a 50% success with treatment of 8 patients with 
metronidazole 203. More recently, Dejaco et al have reported similar 
success in a prospective open label study using combination 
antibiotics (ciprofloxacin and metronidazole) and azathioprine in 52 
patients 204. 50% success was reported at week 8 (25% complete 
healing) with patients receiving azathioprine being more likely to 
achieve a response.  
To date there are no randomised controlled trials published on use 
of antibiotics in acute inflammatory bowel disease in children. 
However in clinical practice i.e., treatment of children with active 
Crohn’s disease, both metronidazole and ciprofloxacin tend to be 
used in tandem. 
Recently, topical use of metronidazole has been reported for use in 
perianal Crohn’s disease. In a randomised controlled study of 74 
patients compared to placebo, although the perianal discharge 
and pain was reduced significantly there was no significant change 
in the CDAI (Crohns’ disease activity index) scores 205. 
 
1.5.1.4    Infliximab 
 
Infliximab is an anti-chimeric anti TNF∝ monoclonal antibody. In 1995 
Van Delleman, in an uncontrolled study showed infliximab to be 
effective in treatment of active Crohn’s disease refractory to steroids 
206. Since then several studies have been undertaken and the 
ACCENT 1 trial is the largest to date. 573 adult patients were 
recruited in this trial. They received 3 infusion courses with 8 weekly 
infliximab used as maintenance treatment. At the end of 30 weeks 
the remission rates were 45% in patients receiving regular 8 weekly 
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courses, 39% who received a single 3 dose infusion course and 19% 
in patients receiving a single infusion 207. 
Infliximab is contraindicated in patients suffering with infections such 
as general sepsis, pneumonia and tuberculosis as suppression of 
immunity results in rampant infection, associated with morbidity and 
mortality. Disseminated histoplasmosis and pneumocystis has been 
reported with use of infliximab 208. In the ACCENT I study 5% had 
acute infusion reactions and 1% serious infusion reactions. These 
were more common in patients receiving more than one infusion 
and in those who had developed antibodies to infliximab. Localised 
tuberculosis may spread systemically and patients should be 
screened for the disease before its use 209. 
Infliximab has been used in children and data suggest that it is as 
effective in children as in adults 210-213. There is some suggestion that 
early use of Infliximab may be superior to late use in paediatric 
Crohn’s disease, with children in early stages of their disease 
maintaining longer periods of remission (n=3) 214,215. Numbers in these 
studies are small (total n=15) and these results should be interpreted 
with caution.  In the UK, national guidelines are now in place with 
indications of use limited to severe active Crohn’s disease refractory 
or intolerant to steroids, not treatable by surgery 216. I, in another 
study have shown that 3 dose Infliximab infusion treatment in 
children may delay but not avoid need for surgery in severe resistant 
Crohn’s disease 217. 
More recently, Hyams and group have reported the REACH study 218 
a large 112 children based RCT, demonstrating that paediatric 
patients responding to induction regimen of infliximab were more 
likely to be in clinical response and remission at week 54 when their 
maintenance therapy was given every 8 weeks rather than every 12 
weeks. In another publication, in a post hoc analysis of the REACH 
study, Infliximab was found to be effective in reducing signs and 
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symptoms of concurrent perianal disease 219. I have recently 
reported success with treatment of paediatric urogenital crohn’s 
disease 220. 
Till 2006, 8 cases of the rare and almost always fatal T cell 
hepatosplenic T-cell lymphoma were reported with use of Infliximab 
and concomitant Azathioprine and Prednisolone 221,222.  
Infiliximab is one of the best known monoclonal antibodies used in 
treatment of Crohns disease and has been around for the longest. 
Infliximab is clearly effective but certainly this calls for caution in 
usage and prescription. 
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1.5.2   Drugs/ therapies used for maintaining remission 
 
1.5.2.1    5-Aminosalicylates  
 
5-Aminosalicylates have two components. 5-ASA is the active 
moiety of the drug and acting topically on the gut mucosa to 
prevent inflammation. It’s absorbed rapidly from small intestine and 
excreted in the urine. The second part is a carrier used to deliver the 
5-ASA at the desired place in the intestine, the ileum or the colon. In 
sulphasalazine (Salazopyrine®) the 5-ASA is joined to sulphapyridine 
by an azo bond which is cleaved by colonic bacteria. In Asacol®, 
there is a pH dependent coat around the 5-ASA whereas Pentasa® 
has a timed release mechanism helped by the individual coating of 
the microgranules. 
Sulphasalazine compared to other 5ASAs is believed to have the 
most side effects mainly comprising of renal complications, liver 
toxicity, agranulocytosis or toxic epidermal necrolysis 223,224. 
In a double blind randomised placebo controlled trial, mesalazine 
used at 50 mg/kg/day failed to prove to be an effective 
maintenance treatment 225. A recent Cochrane review of use of 
sulphasalazine (meta-analysis of 6 trials), as maintenance agent for 
treatment of paediatric Crohn’s disease, has not found any 
evidence in favour of its superiority over placebo 226.  
 
1.5.2.2    Thiopurines 
 
Azathioprine (AZA) is a purine metabolite and a pro-drug of 6-
mercaptopurine (6-MP). AZA is converted to 6-MP during the first 
pass of this drug through the liver. 6-MP is further metabolized to 6-
thioguanine (6-TG), the active metabolite that can be measured in 
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blood. 6-MP is eventually inactivated by 2 enzyme pathways: 
xanthine oxidase and thiopurine methyltransferase (TPMT). 
A Cochrane review from 2000 shows an odds ratio of 2.04 for 
inducing remission with azathioprine in comparison to placebo. 
Treatment for more than 17 weeks increased this to 2.51 227. A more 
recent Cochrane review, 2009 continues to show superiority of 
thiopurine use over placebo in maintaining remission in 6 adult 
based trials 228. Fuentes D et al have reported their retrospective 
experience of azathioprine use in Royal Free hospital in UK. They 
reported bone marrow toxicity in 8.6% of cases, leading to 
treatment stoppage, whilst using doses of 3 mg/kg/day 229. Fraser 
has reported well-sustained efficacy over five years and a good 
safety record with use of azathioprine in a retrospective review of 30 
years of practice 230. More recently a meta-analysis of six studies 
showed an approximate fourfold increased risk of lymphoma in IBD 
patients treated with azathioprine/6-MP. The authors attributed this 
increased risk of lymphoma to be multi-causal; result of medications, 
severity of underlying disease, or combination of the two 231. It is 
generally agreed that the overall benefits of use of azathioprine far 
outweigh any possible risks of developing lymphoma. 
Markowitz has reported a placebo controlled multicentre RCT 
evaluating combination of 6 MP and Prednisolone in children with 
moderate to severe CD 232. 55 children were randomised to 6MP or 
placebo within 8 weeks of diagnosis. Although remission was 
induced in 89% of children in both groups, over an 18 month period, 
only 9% of the remitters in the 6MP group relapsed compared to 47% 
of controls. 
A meta-analysis of four placebo controlled trials demonstrates 
thiopurines to be superior to placebo in preventing post operative 
recurrence in adults 233. 
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1.5.2.3    Cyclosporin 
 
Cyclosporin has no proven therapeutic value in treatment of 
Crohn’s disease 234. In a study on newly diagnosed children with 
Crohn’s disease cyclosporin was not found to be as effective as 
corticosteroids 235. In fact, Stange in a multicentre one year follow 
up study of 182 patients did not find cyclosporin to be significantly 
different from placebo 236. Similar results were achieved by Feagan 
in an eighteen month randomized double blind placebo controlled 
trial of more than 300 patients and found cyclosporin similar in effect 
to placebo 237. 
 
1.5.2.4    Methotrexate 
 
Methotrexate has been shown to be effective in treatment of active 
Crohn’s disease 238. In a meta-analysis of 3 trials high dose 
intramuscular methotrexate was shown to be effective in steroid 
dependent patients. In another study 141 steroid dependent 
patients were randomized to intramuscular treatment and placebo 
for 16 weeks. 39% compared to 19% were able to come off steroids 
238-242. An adult based Cochrane review in 2009 shows intramuscular 
methotrexate to be comparable to mercaptopurine, but superior to 
placebo for maintaining remission in Crohn’s disease. One study in 
the meta-analysis found the oral ‘Methotrexate’ formulation to be 
ineffective 243.  
Methotrexate has been rarely used in paediatric Crohn’s disease. 
Mack et al showed that 11/14 children and adolescents previously 
intolerant or refractory to azathioprine or 6-MP improved with 
methotrexate 244. 
In 2000 a French study looked at use of Methotrexate in 41 adults 
with Crohn’s disease. Methotrexate may adversely affect the liver 
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and in this study, 11/41 had a liver biopsy with mild steatosis found in 
5. There was one patient each, with mild sinusoid dilatation, 
granulomatous hepatitis with mild portal fibrosis and slight periportal 
fibrosis 245. 
Uhlen S and group retrospectively looked at 61 children in a 3 year 
multicentre study 246. Indications to use Methotrexate included a 
non response to or relapse under azathioprine or azathioprine 
intolerance/toxicity. Methotrexate improved or induced complete 
remission in 80% of whom 29.5% relapsed after 13 +/- 10 months of 
treatment. It was possible to discontinue corticosteroids in 35 
patients. Prospective studies are needed, however this study with 
others supports and suggests Methotrexate to be a viable second 
line alternative to thiopurines.   
 
1.5.2.5 Thalidomide 
 
Thalidomide lost popularity in the sixties because of its teratogenic 
affects (major limb deformities) found during treatment of morning 
sickness in pregnancy. After the initial fall out, it has now been found 
to have a suppressive activity on TNF production and used for 
treatment of Crohn’s disease. Two open label adult trials with 
refractory Crohn’s disease have been published 247,248. At week 12 a 
response was achieved in about 70% of the patients in both studies 
showing thalidomide to be effective for treatment of acute and 
chronic active disease. It was also shown that lower doses are as 
effective, and, better tolerated than higher doses. Recently it has 
been used as maintenance treatment with 83% remission rate at the 
end of 12 months 249. 
There are very few reports of use of thalidomide in paediatric 
Crohn’s disease in the literature. Sensory neuropathy remains a 
major concern 250-254. In a 2009 Cochrane review no randomised 
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controlled trials were identified to make any recommendation 
regarding usage of thalidomide or the newer lenalidomide for 
maintenance therapy in Crohn’s disease 255. 
 
1.5.2.6 Infliximab 
 
Rutgeerts 256 in 1999 first showed in a double blind placebo 
controlled randomised trial that Infliximab was effective as 
maintenance therapy. At week 44, 62% patients receiving 2 monthly 
Infliximab (10 mg/kg) maintained remission compared to 37% 
receiving placebo. Following this study, Hanauer in 2002 207 in a 
large double blind RCT, recruited 573 patients from 55 European 
centres showed remission rates were higher in the infliximab groups 
(receiving 5mg/kg and 10mg/kg) compared to placebo. Success 
was reported with use of infliximab in another placebo controlled 
RCT for treatement of fistulising Crohn’s disease by Sands in 2004 257. 
Hyams and group have reported the REACH study 218 a 112 children 
based RCT, demonstrating that paediatric patients responding to 
induction regimen of infliximab were more likely to be in clinical 
response and remission at week 54 when their maintenance therapy 
was given every 8 weeks rather than 12 weeks. More recently Hyams 
258 reported a larger multicentre study on maintenance treatment 
with Infliximab in children. A total of 158 infliximab treated children 
received maintenance therapy. Following maintenance therapy 
initiation, 26%, 44%, and 33% of patients continuing on maintenance 
infliximab over 0-1, 1-2, and 2-3 years, respectively, had clinically 
inactive disease not requiring corticosteroids or surgery. The recently 
published NICE guidance in 2010 also describes role of Infliximab as 
a maintenance agent particularly when it has been effective in 
inducing remission 259. 
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In the recent Cochrane review, Infliximab was found to be superior 
to placebo for maintenance of remission (RR 2.50) and clinical 
response (RR 2.19) in Crohn’s disease 260. In addition it was also 
superior in complete healing of perianal and enterocutaneous 
fistulas (RR 1.87). 
 
1.5.3    New therapies 
 
1.5.3.1    CDP571 
 
CDP 571 is a genetically engineered human antibody to TNF∝, with 
the advantage it being less immunogenic than chimeric antibodies. 
In a recent placebo controlled trial in 169 patients with moderate to 
severe Crohn’s disease, the rate of clinical response at 2 weeks was 
significantly higher compared to the placebo group (45% vs. 27%). 
Week 4 response rates similarly favoured the drug – 36.9% to 24.2% 
(p=0.014). However, at week 28, CDP571’s 30.4% to 23.5% response 
rate advantage failed to reach statistical significance.  Though, 
these results are disappointing, it was generally well tolerated with 
anti CDP 571 antibodies developing in 7% of the patients 261. 
Sandborn in a larger study from 2004 of 396 patients 262, and Feagan 
263 in a study of 269 patients in 2006 did not find CDP571 different to 
placebo for use in maintaining remission in Crohns’ disease.  
There is one published study on use of CDP 571 in paediatric Crohn’s 
disease. 13/20 children with Crohn’s disease responded to the 
treatment with a fall of > 10 in the PCDAI score. Mild to moderate 
side effects were documented in 14 patients with development of 
antibodies in 6 patients 264. 
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1.5.3.2    Etanercept 
 
Etanercept is a TNF ∝ binding protein made by fusing the P75 TNF 
receptor tail to immunoglobulin G1. A recent trial of its use in an 
uncontrolled pilot study in 43 patients with moderate to severe 
Crohn’s disease shows no efficacy 265. 
Etanercept has been sporadically used in paediatric Crohn’s 
disease but there are no published trials regarding its use. Early 
reports show it to be a disappointment and is certainly not as 
effective as its in other inflammatory conditions 266. 
 
1.5.3.3    Natalizumab 
 
Natalizumab is a recombinant humanized anticlonal antibody 
(IgG4) to ∝4 integrin. ∝4 integrin is an important mediator for 
leukocyte migration across vascular endothelial cells in the intestine 
and is up-regulated in acute inflammation. The multi-centre ENACT-1 
and ENACT-2 trials are the largest studies on use of Natalizumab. In 
the ENACT-1 study, 905 patients were randomized to natalizumab (3 
infusions timed at week 0, 4 and 8) or placebo. There was no 
difference in efficacy on comparison of the two groups at 10 weeks. 
The ENACT-2 study was a longer term study in which Natalizumab 
responders from ENACT-1 were enrolled. 339 patients were 
randomized to receiving Natalizumab (administered every 4 weeks 
through week 56) or placebo. Patients receiving Natalizumab 
showed a better response to treatment at week 36 compared to 
placebo (remission 44% vs. 26%) 267.  
Two UK based placebo controlled trials of use of Natalizumab one in 
a group of 30 patients with mild to moderate active Crohn’s disease 
showed it to be effective in 7 patients (39%) remission compared to 
one receiving placebo. The study’s primary end point was CDAI at 
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week 2 268. In another placebo controlled study in 248 patients with 
moderate to severe Crohn’s disease a 44% remission was achieved 
and shown to be superior to placebo. A dose of 6 mg/kg was found 
to have a similar efficacy to a dose of 3 mg/kg 269. A recent 
Cochrane review taking the three, to date trials into account 
concluded that, Natalizumab may be effective for induction of 
clinical response. A greater response was seen in those with 
elevated CRP, active disease despite use of immunosuppressants, 
prior to use of anti TNFα therapy 270. 
In a multicentre single arm study, Natalizumab has been used in 38 
adolescent patients and assessed for safety, tolerability and 
efficacy 271. Although remission was achieved in only 29% of the 
patients (PCDAI ≤ 10) a clinical response was seen in 55% (≥ 15 point 
decrease in PCDAI from baseline). 5 patients suffered from acute 
infusion reactions consisting of pyrexia and abdominal pain 
commonly. Serious adverse effects were noticed in 8 patients and 
considered to be unrelated to the drug. The planned study follow up 
was for a period of 32 weeks. 
Natalizumab was withdrawn from the market on February the 28th 
2005. The FDA issued a public health advisory to inform patients and 
health-care providers about the suspended marketing of 
Natalizumab while the agency and the manufacturer evaluated 
two serious adverse events reported with its use in patients. The FDA 
received a report of one death and one possible case of 
progressive multifocal leukoencephalopathy in Crohn’s disease. In 
addition two cases were reported after treatment, their underlying 
diagnosis being multiple sclerosis 272. Progressive multifocal 
leukoencephalopathy is a rare and serious progressive neurological 
disease with no known effective treatment. 
The patient with Crohn’s disease was 60 years old and had long 
standing Crohn's disease, presented with confusion and 
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disorientation in July 2003. He had been treated with natalizumab 
(eight infusions) since March 2002 in ENACT-1 and ENACT-2 trials 
(phase III trials of natalizumab in Crohn's disease). A brain biopsy was 
interpreted as astrocytoma. He died in December 2003, three 
months after treatment with corticosteroids. An autopsy was not 
performed. The brain biopsy was re-examined and the diagnosis 
revised to progressive multifocal leucoencephalopathy (PML). 
Retrospective analysis of serum samples detected JC virus in May 
2003; the viral load increased by a factor of 10 after two further 
injections of natalizumab, confirming a temporal relation between 
PML and natalizumab 272. 
 
1.5.4.4    Certolizumab (CDP870) 
 
Certolizumab is a humanized IgG4 monoclonal antibody against 
TNFα. In a placebo-controlled study, 292 patients with moderate to 
severe Crohn's disease received subcutaneous certolizumab 100, 
200, or 400 mg or placebo at weeks 0, 4, and 8. At all time points, 
the clinical response rates were highest for certolizumab 400 mg, the 
greatest response was at week 10 (certolizumab 400 mg, 52.8%; 
placebo, 30.1%; P = .006) but not significant at week 12 
(certolizumab 400 mg, 44.4%; placebo, 35.6%; P = .278) 273. In a 
larger multicentre study (PRECISE) in 2007 Schreiber reported a large 
multicentre placebo controlled RCT in 668 patients. The patients 
received Certolizumab every 4 weeks through to week 26 at which 
point a higher proportion of patients were in clinical remission 
compared to placebo (48% v 29%) 274. To date, there are no 
paediatric studies of its use. 
 
1.5.4.5    Adalimumab 
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Adalimumab is a fully human IgG1 monoclonal antibody to TNF that 
is administered subcutaneously. In 2004, Sandborn conducted an 
uncontrolled trial in 24 patients with Crohn's disease who had lost 
responsiveness or developed intolerance (acute or delayed infusion 
reactions) to infliximab. Patients were enrolled in a 12 week 
uncontrolled trial and treated with subcutaneous adalimumab 80 
mg at week 0 and then 40 mg every other week starting at week 2. 
None of the patients experienced acute or delayed hypersensitivity 
reactions during treatment. Of the 17 patients, those with baseline 
CDAI scores > or =220: clinical remission occurred at weeks 4 and 12 
in 2 (12%) and 5 (29%), respectively; and clinical response occurred 
in 7 (41%) and 10 (59%), respectively 275. 
The results of the CLASSIC 1 trial on 299 patients (naïve to anti-TNF 
therapy) have been published in 2006. It is a randomized, double-
blind, placebo-controlled, dose-ranging trial was performed to 
evaluate the efficacy of adalimumab induction therapy in patients 
with CD. The rates of remission at week 4 in the adalimumab 40 
mg/20 mg, 80 mg/40 mg, and 160 mg/80 mg groups were 18% (P = 
.36), 24% (P = .06), and 36% (P = .001), respectively, and 12% in the 
placebo group. Adverse events occurred at similar frequencies in all 
4 treatment groups except injection site reactions, which were more 
common in adalimumab-treated patients. Adalimumab was 
superior to placebo in this group of adults with moderate to severe 
Crohn’s disease 276. The CLASSIC II study (the study of maintenance 
Adalumimab) 44% in the placebo group were in remission at week 
56. In comparison 79%, were in remission when receiving 2 weekly 
therapy and 83% when receiving weekly therapy at week 56 277. 
Colombel, in a large multicentre study (CHARM) of 854 patients, 
reported superiority of Adalumimab over placebo for maintenance 
therapy of Crohn’s disease. In week 56 of maintenance treatment 
phase 29% were in remission while receiving 2 weekly treatments, 
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23% when receiving weekly and only 6% in the placebo arm were in 
remission 278.  
Mian has reported a case of a 15 year old girl with Crohn’s disease 
diagnosed at the age of 4. She was steroid dependent, had 
pancolonic involvement with the duodenum and stomach and 
although infliximab was initially successful (at the age of 10 years) 
subsequent usage had resulted in a reaction. Adalimumab was 
successfully used (3 doses over 4 weeks) with symptomatic and 
macroscopic improvement 279. 
The RESEAT study 280 in States reported a retrospective paediatric 
experience in 115 patients from 12 centres. The most popular 
maintenance dose was 40mg alternate weeks (88% of patients). 
Treatment with Infliximab preceded Adalimumab use in 95% of the 
patients. The commonest reasons for discontinuation were loss of 
response (47%) and reactions to the infusion (Infliximab) (45%). 
Clinical response reported by physician global assessment was 65% 
at 3 months, 71% at 6 months and 70% at 12 months. Overall 
Adalimumab was found to be well tolerated and an effective 
resuce therapy for moderate to severe paediatric CD. 
These initial results show promise and suggest that adalimumab may 
be an alternative option to infliximab especially if the patient has 
shown resistance to treatment. Viola reported effective use of 
Adalimumab in 23 children as maintenance therapy with remission 
rate of 65.2% at week 48 281. 
 
1.5.4.6    Miscellaneous 
 
Anti-interleukin 12, interleukin 11, interleukin 10, anti-interleukin 6, CNI-
1493, BIRB-796, RDP-58, Asis 2302, MLN-02, Onercept and MRA (anti-
interleukin 6 receptor antibody) are currently at experimental stages 
282-289. Of these, initial studies on Fontolizumab (anti-interferon γ) 290, 
                                                        
 
 
82
Etanercept 291, Onercept 292, MLN-02(LDP-02), Isis 2302 (Alicaforsen) 
293, interleukin 11 287,288, BIRB-796 and RDP-58 have been a 
disappointment. 
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1.6   Enteral nutrition in treatment of Crohn’s disease 
 
1.6.1    Introduction 
 
The first enteral feed used in treatment for Crohn’s disease was an 
elemental feed 22. Feeds may be elemental, semi-elemental or 
polymeric depending on state of hydrolysation of protein in the feed 
explained further in section 1.6.2.  
The first elemental feeds were developed as part of the US space 
exploration programme and were not intended for any treatment. 
The idea was to produce a highly absorbable feed which would 
result in a low faecal residue in space. When it was first chosen to be 
used in a child with Crohn’s disease it again was never intended to 
be used as treatment but to correct the state of malnutrition. 
Giorgini in February 1973, for the first time reported success with 
treatment of an Italian boy who had anorexia, weight loss, perianal 
fistulae, 3-5 loose bowel movements, erythema nodosum and 
regional enteritis seen on a barium enema. The boy diagnosed a 
couple of years earlier had relapsed on 15 mg alternate days of 
prednisolone. As an inpatient Conded 72H®, a sucrose based liquid 
elemental diet, was used concurrently with corticosteroids and 
salicylazosulfapyridine (an aminosalicylate) for a period of 42 days. 
This was preferred over high dose steroids due to the child’s short 
stature and Cushingoid appearance. The purpose of the liquid diet 
was to provide nutrition by medically ‘by-passing’ the diseased 
intestinal loops. The patient gained 24 pounds, the fistula healed 
and the nitrogen balance became positive during this period 22. 
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1.6.2 Different types of enteral feeds 
 
Enteral feeds are classified on the basis of the hydrolysation of the 
protein in the feed and may be elemental, semi-elemental or 
polymeric. Elemental feeds are amino acid based feeds, semi-
elemental oligopeptides and polypeptides and polymeric feeds are 
based on whole protein. Any of these feeds can be a specialised 
feed, for eg: ACD004 with the added TGF beta (and higher n-3 
ratio) used in Crohn’s disease is a specialised polymeric feed. Feeds 
used in renal disease will also fall in the same category.  
Elemental formulas contain individual amino acids and are usually 
low in LCTs and are thought to be minimally stressful for the intestine 
and exocrine pancreatic function. MCT is the predominant fat 
souce in many products which can be absorbed directly into the 
portal vein in the absence of lipase or bile salts. There are 
considered to be useful for malabsorptive states. 
Semi-elemental feeds comprise of proteins that have been 
hydrolysed into oligopeptides of varying lengths, dipeptides and 
tripeptides. The di- and tri- peptides have a specific uptake transport 
mechanism considered to be more efficient than amino acids or 
whole proteins 294.  
Polymeric formulas contain intact proteins, complex carbohydrates 
and larger proportion of LCT fats in majority of cases. Whole protein 
‘polymeric’ feeds taste better than amino acid based feeds. Sudies 
have shown that these feeds are as effective as elemental feeds for 
treatment of Crohn’s disease in children 295-297. In a randomised 
controlled trial comparing use of a peptide based enteral formula v 
a standard formula, in patients with hypoalbuminaemia, no 
differences were found with regards to tolerance/side effects and 
effectiveness 298. Rodrigues in a randomised controlled trial 
demonstrated similar (p=ns) remission rates for elemental (64%) and 
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polymeric (51%) enteral feeds. Nasogastric feeding was more 
frequently required for administration of elemental feeds 299.  
The opinion regarding choice continues to remain divided as 
paediatric gastroenterologists prescribe both elemental feeds (eg: 
EO28 ®) and polymeric feeds for treatment of acute active Crohn’s 
disease. 
 
1.6.3    Enternal nutrition in paediatric Crohn disease 
 
Since Giorgini, enteral nutrition use has gained popularity as a first 
line treatment for paediatric Crohn’s disease in many centres of the 
world. 
Morin in Quebec in 1980 used elemental diet to treat 4 growth 
retarded children with Crohn’s disease who showed acceleration of 
growth post treatment. All patients achieved clinical remission and 3 
out of the 4 continued to grow during the 67 weeks of supplemental 
treatment and follow up; the fourth required surgery 300. Morin in 
1982, used continuous elemental feeding (via pump) in 10 children 
for 3 weeks. All of them achieved remission with a drop in disease 
activity index from a mean of 307 to 69.2. 8/10 children were still in 
remission 3 months after cessation of treatment with Vivonex® 301. 
This was re-demonstrated by O’Morain in 1983 whilst using Vivonex® 
302. Navarro (1982) in France opted to use a feed based on 
oligopeptides; because of its comparatively lower osmolality. Again, 
the feed was administered via a nasogastric tube constantly 
(continuously) over a period of 2 to 7 months in 17 children. This was 
termed as ‘constant rate enteral nutrition’. Remission was 
successfully introduced with an increase in growth rate, never 
before possible on a child taking continual corticosteroids 303. 
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Sanderson et al (1987), in the first ever randomized controlled trial of 
enteral nutrition and corticosteroids in paediatric Crohn’s disease, 
showed that a semi-elemental feed (Flexical®, Mead Johnson) was 
as efficacious as corticosteroids in inducing remission in small 
intestinal Crohn’s disease. The authors as before once again 
demonstrated improved growth using this form of treatment; a clear 
edge over use of corticosteroids 304. 
 
Undesirable taste of these elemental feeds necessitated insertion of 
a nasogastric tube. Later a better tasting, polymeric feed AL110® 
was used by Beattie et al in a cohort of 6 children 305. This study was 
duplicated by Fell et al (1997) using Modulen IBD®. During treatment 
a mucosal cytokine assessment demonstrated a fall in the pro-
inflammatory cytokines IL-1β, IL-8 and IFN-γ at completion of 8 weeks 
of treatment 24. Over recent years development of polymeric feeds 
have included improvement in taste with further acceptance of this 
mode of treatment in children 305-308. Rodriques and colleagues 
showed that although polymeric nutrition did not affect adherence 
to the dietary treatment, its use was associated with a significantly 
less use of nasogastric tube compared to the elemental formula 309. 
Over the past two decades the superiority of enteral nutrition and 
corticosteroids over each other has been disputed. In 1995, a meta-
analysis performed by Griffiths et al showed corticosteroids to be 
superior to enteral nutrition 310. These findings were further re-
affirmed by Zachos in a Cochrane review in 2001 311. An update of 
this Cochrane review was made in 2007 312. Meta-analysis of ten 
trials comprising 334 patients demonstrated no difference in the 
efficacy of elemental versus non-elemental formulas (OR 1.10; 95% 
CI 0.69 to 1.75). Further analysis of seven trials including 209 patients 
treated with EN formulas of differing fat content (low fat: < 20 g/1000 
kCal versus high fat: > 20 g/1000 kCal) demonstrated no statistically 
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significant difference in efficacy (OR 1.13; 95% CI 0.63 to 2.01). 
Similarly, no differences were found regarding the effect of very low 
fat content (< 3 g/1000 kCal) or type of fat (long chain triglycerides). 
However corticosteorids were found to be superior to enteral 
nutrition for treatment of Crohn’s disease. Importantly, these meta-
analyses included adult patients to increase the yield of these 
analyses. A paediatric IBD oriented meta-analysis was performed by 
Heuschkel et al in 2000 to compare corticosteroid treatments with 
enteral nutrition. A total of 194 children formed the basis of this 
analysis and the authors failed to show corticosteroids to be superior 
to enteral nutritional treatment 182. A more recent meta-analysis by 
Dziechciarz in 2007 showed no difference in the remission rates 
between enteral nutrion and steroids groups in paediatric Crohn’s 
disease 313. 
Management of Crohn’s disease in the paediatric population 
involves issues besides treatment of disease; most important being to 
maintain remission through puberty with a view to maximise growth. 
Even though the superiority of either treatment (enteral nutrition vs. 
corticosteroids) remains in dispute, enteral nutrition has a superior 
side effect profile as it is growth sparing.  In addition investigators 
have demonstrated that corticosteroids, in comparison to enteral 
nutrition, do not achieve mucosal healing of the inflamed intestine 
314. The mucosal (intestinal) healing in children using exclusive 
enteral nutrition is associated with a fall in mucosal pro-inflammatory 
cytokines 24. Additionally Buchanan and colleagues have reported 
remission with use of exclusive enteral nutrition irrespective of the 
Crohn’s disease site 315. 
 
1.6.4    Enteral nutrition in adult Crohn’s disease 
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O’Morain in 1984 reported a randomized controlled trial of use of 
elemental feed Vivonex ® and corticosteroids in 21 patients. After 4 
weeks of treatment, 8/10 in the steroid and 9/11 in the enteral 
feeding group achieved remission. At three months, a single patient 
in each group was considered to be a treatment failure. 
Interestingly one patient in the steroid group was treated with 
enteral feeding and responded very well to the treatment. One 
patient in the feeding group had a perforation once returning to 
free food. In this study O’Morain has clearly outlined poor 
palatability of the feed. Also, these feeds were expensive costing £9-
12 per day. 
Since O’Morains work there are now three published meta-analyses 
and a Cochrane database review comparing use of enteral 
nutrition with corticosteroids 310,311,316,317. 
The Cochrane meta-analyses of Griffiths and Zachos reported in 
2001 310  and then more recently updated in 2007 311 show clear 
advantage of use of corticosteroids over enteral nutrition. These 
results are contrary to O’Morain’s small successful study and the 
paediatric experience in centres skilled in administering enteral 
nutrition, and use enteral nutrition as primary therapy. It is important 
to realize that O’Morain’s group too were highly motivated and 
aimed at administering enteral feeding. The above mentioned 
meta-analyses are based on trials administering treatments 
(corticosteroids and enteral feeds) on an intention to treat basis. 
Patients unable to complete the treatment (enteral nutrition) course 
were considered to have failed the treatment even if in remission. It 
is notable that analyses limiting to patients successfully completing 
the enteral feed treatment achieved comparable remission rates to 
corticosteroids. There is little doubt that motivation of the clinician 
and the patient is essential to ensure successful enteral nutritional 
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treatment. This is a key factor to consider in any trial using enteral 
nutrition. 
Motivation is important from a patient perspective as no one likes a 
radical change in their diet, particularly adults. Despite personal 
preferences, it is now being recognized that adults ‘at risk’ should still 
be strongly considered for treatment with enteral nutrition rather 
than corticosteroids.  
 
The ‘at risk’ group includes:  
 Adults who are particularly going to stay on corticosteroids for 
a long time 
 Adults who are steroid refractory or dependent 
 
Additionally it should be offered to: 
 Patients requesting treatment with a safer profile 
 Patients seeking alternative treatments 
 
A view is now emerging that patients with active Crohn’s disease 
should be encouraged to make decisions regarding their 
treatments, based on full awareness of pros and cons of 
medications used. 
 
1.6.5   Use of supplemental enteral nutrition as maintenance therapy 
 
There is some evidence that enteral nutrition works when used as a 
maintenance therapy. This involves patients who once in remission 
continue to take enteral nutrition alongside normal diet which 
accounts for 1/3rd to ½ of their total RDA. 
Two adult studies report use of supplemental enteral nutrition as 
maintenance therapy in Crohn’s disease.  
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Verma 318 reported use of supplemental nutrition in a series of 39 
adult patients with Crohn's disease in clinical remission. Of these, 21 
patients (Group 1) received oral nutritional supplementation, taken 
in addition to their normal diet. Their outcome (relapse rate, Crohn's 
disease activity index, inflammatory markers) was compared with 
that of 18 patients (Group 2), who were maintained on a normal 
unrestricted diet over an observation period of 12 months. On an 
intention-to-treat basis, 10 patients (48%) in the supplement group 
remained in remission for 12 months, compared to 4/18 (22%) 
patients in the non-supplemented group. Seven patients in Group 1 
and 14 in Group 2 relapsed at a mean of 7.4+/-0.9 and 6.2+/-0.4 
months, respectively. 
Takagi 319 has also reported their experience of use of enteral 
nutrition (elemental) as as a supplement in adults. Supplement 
consisted of half of total daily intake and 51 patients were 
randomised to supplemental/non-supplemental groups. The primary 
outcome was relapse over 2 years. The relapse rate in the half 
elemental diet group was significantly lower [34.6% vs. 64.0%; 
multivariate hazard ratio 0.40 (95% CI: 0.16-0.98)] than that in the 
free diet group after a mean follow-up of 11.9 months. 
There are published studies in children as well.  
Belli has demonstrated significant height and weight gain in a small 
prospective study of 8 children with growth failure. The elemental 
feed was administered for one month out of four via continuous 
nasogastric infusion at home 320. Aiges used a year long nocturnal 
supplementatal nutrition via nosogastric tube and demonstrated 
significant growth spurt in a group of 16 children receiving enteral 
nutrition via gastrostomy 321. Wilschanski in his retrospective study 
compared relapse rate at 1 year in two groups of children (28 on 
supplement and 19 no supplement), found 12/28 relapsing in the 
supplemented group compared to 15/19 in the non-supplmentened 
                                                        
 
 
91
group 26. The study was biased as the choice to type of feeds was 
made by patients (non-randomised study). 
Akobeng has included the two adult studies in the recently 
published Cochrane review in 2007, concluding that despite a small 
number of studies there may be an advantage in using 
supplemental enteral nutrition 322. 
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1.7   Quality of life (QOL) in paediatric Crohn’s disease – 
background and basic concepts 
 
1.7.1   Background 
 
A physician endeavours to achieve health, for instance in Crohn’s 
disease, by maintaining remission, a desirable end point for all 
treatments. Importantly, for patients, mucosal healing and a fall of 
paediatric Crohn’s disease activity index score all indicative of 
remission, though momentarily reassuring, is of little consequence. 
Patients are concerned about their health and more importantly 
what it means to them i.e., their personal feelings. 
Health status, functional status, and quality of life are three concepts 
often used interchangeably to refer to the same domain of "health". 
Quality of life is a broader concept and will encompass health and 
functional status in it. It is important to explain health status and 
functional status of the patient before discussing quality of life is. 
These concepts are described as follows:  
 
1.7.2   The health and functional status 
 
Health status reflects an individual’s level of wellness and illness. It is 
about the physical well-being of the patient in reference to 
biological or physiological dysfunction (bowel inflammation) and 
symptoms (pain, bloody diarrhoea). Poor health and symptoms may 
in turn cause functional impairment, such as patient’s inability to 
participate in sports or even walk (arthritis). This now leads to us to 
define functional status. 
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Functional status of the patient describes an individual’s ability to 
perform daily duties to meet basic needs, fulfil usual roles and 
maintain health and well-being 323. Assessment of functional status 
would be based on two fundamental concepts. One is functional 
capacity, which is an individual’s maximum capacity to perform 
daily activities in the physical, psychological and social domains of 
life. The other concept is of functional performance, which 
comprises of activities people actually do, during the course of their 
daily life 324. Both variables can be affected by biological or 
physiological impairment, symptoms, mood, and specific health 
perceptions of the individual. These factors are intertwined and 
quite often a change in one variable would affect another, causing 
a change in balance of the whole equation.  
Importantly, tools assessing functional and health status, focus on 
assessment of negative health states. It is important that measures of 
well-being that focus on positive aspects of health are also used in 
such assessments. Analysis of positive aspects would give an idea 
about an individuals’ coping mechanism, an important attribute 
which helps to counter events in life. In practice, it is difficult to 
analyse these concepts. 
It is also important to realize that health and functional status are 
often not rated by patients but by physicians or healthcare workers. 
This fundamentally differs from quality of life, which primarily 
encompasses patient’s perceptions about their health status. Good 
health and functional status may simply just not equate to quality of 
life. In a simplistic example, physical functioning may be more 
important for a professional athlete than a novel writer. Limitation of 
physical functioning by disease (say arthralgia of the ankle joints 
reasonably controlled with used of medications) will affect the two 
people differently, certainly their perception about it and hence 
their quality of life. 
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1.7.3   What is quality of life? 
 
With some understanding of the functional and health status 
assessment, it will now be easier to explain the concept of quality of 
life. It is based on the idea that every individual has their own unique 
perspective on quality of life. Quality of life is multi-dimensional and 
encompasses several domains; focusing on both objective and 
subjective perspectives within each domain 325. Objective 
assessment focuses on what an individual can do and defines 
degree of health as explained above. Subjective assessment 
includes what it actually means to the individual. 
Quality of life has been defined as the physical, psychological and 
social domains of health influenced by a person’s experiences, 
beliefs, expectations and perception 325. 
Disease well-being is only one factor which determines quality of life. 
Other factors include characteristics of a person, their coping 
abilities, environmental situation and available social support; all 
important determinants for well-being. It is difficult to develop a tool 
simple enough to use, which would incorporate and accurately 
assess quality of life with due consideration to all of these factors.  
 
Based on the above a good quality of life is said to be present when 
hopes of an individual are matched and fulfilled by experience 326.  
 
Gill and Fenstein lay emphasis on three areas in which quality of life 
may be assessed in the health context 327. 
 Use of objective measures such as clinical indices that 
patients would not necessarily use or be aware of. 
 Functional performance 
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 Patient’s own evaluation of their subjective experience. This 
becomes harder to assess in younger age groups. 
 
In summary, quality of life assessment should encompass the three 
main domains;  
 physical (functional status, disease and treatment related 
symptoms) 
 psychological and 
 social aspects of life 
 
1.7.4   History of paediatric quality of life assessment 
 
Evaluation of quality of life in adults has taken place in many studies 
since the 1960’s. However, the importance of this concept in 
children only gained recognition in the eighties. Until 1998 only 13% 
of the total number of publications concerning quality of life were 
related to children 328. Ditesheim and Templeton performed one of 
the earliest studies on assessment of quality of life in children 
following surgical repair of high imperforate anus 329. This assessment 
was based on school attendance, social relationships and physical 
abilities. In another study, Herndon and co-workers reported quality 
of life in children surviving major burns 330. They demonstrated that 
children have remarkable energy and capabilities to adapt to 
disabilities.  
Other issues were also highlighted during these early years of 
paediatric quality of life assessment. In another study by Henning 
and co-workers, children with renal failure were shown to be 
concerned about their height even though their average height 
was normal 331. This highlights how quality of life can be affected by 
self-perception of children, an integral part of any quality of life 
assessment. 
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1.7.5   Concept of quality of life in children 
 
It is clear that children differ from adults in their views about quality 
of life. For young children quality of life is not about achievement of 
basic functional tasks like in adults 332. More so it is about having lots 
of friends, play football like Wayne Rooney or perhaps have the 
shiniest hair. It is obvious that adults cannot rate a child’s quality of 
life, the thoughts and perceptions are inherently different. 
Second it is important to realize that children may make judgements 
in a manner different to adults. Parents are known to differ in scoring 
their child’s quality of life when compared to the clinician 333. 
Children are likely to differ from their parents in the same regard 334. 
Interestingly in a quality of life study on asthma in children in Ontario, 
Canada 335 children's global rating of change in symptoms 
correlated strongly with changes in quality of life (0.54 to .67) but not 
with measures of airway calibre or asthma control, while parents' 
global ratings did not correlate with children's quality of life but 
showed moderate correlations with airway calibre (0.29 to .48) and 
asthma control (0.50). Differences were more obvious in children 
over the age of 11, correlations with all clinical variables were higher 
for their own than their parents' global ratings.  
Proxy measurements by parents can be strongly influenced by how 
much the subject’s health condition is a burden to the caregivers 
themselves 336. Although it is important to recognise parental burden 
of a child’s illness it still needs to be measured separately to the 
quality of life of the child 337.  
Finally, children’s views about quality of life do change with age 338. 
An adolescent’s perception of quality of life is different from that of 
a younger child. It may be influenced by their cognitive 
development as well as peer group perceptions and a myriad of 
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influences that result from achievement of adolescent 
developmental tasks such as body self integrity and personal 
identity, autonomy and independence and educational and 
vocational goals. 
 
1.7.6   How to assess quality of life in children? Use of generic and 
disease specific questionnaires 
 
Having described the fundamental concepts, there are several 
questions that arise regarding assessment of quality of life in 
children. The first question is who should assess quality of life? 
Majority of previous studies have used parents and then clinic staff 
to make the assessment, which unfortunately undermines the true 
reliability of the assessment (as discussed above). The most common 
problem seen is variability and inconsistency in the parents report 339. 
It has been shown and suggested that children with chronic illnesses 
(a study on children with diabetes) have a more sophisticated and 
mature understanding of their illness compared to well peers and 
are therefore capable of making their own assessments 340. 
There is ample number of available adult quality of life 
questionnaires, which one may be tempted to use in children. It is 
important to emphasize that children are not small adults. They differ 
in their understanding of health, cause of illness and beliefs 
regarding working of medications 341. In addition they have different 
coping mechanisms. From a practical point of view reading age is 
an important pre-requisite to enable the individual to read, 
understand and complete any questionnaire. Furthermore, a 
questionnaire has to be valid for use in the children age group. 
Moreover the questionnaire may contain a difficult response scale, 
use of long questions and finally their item content may include 
questions about sex life, which would be inappropriate 342. 
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It is thus imperative that quality of life questionnaires are designed 
and developed for children. Such questionnaires/ assessment tools 
will fall into two main categories. The first category entails 
assessment of ‘generic measures’ and second assessment of 
‘disease specific measures’. 
 
‘Generic measures’ are designed to be broadly applicable across a 
host of conditions regardless of a particular disease or use of any 
particular treatments. This compares quality of life of a disease in a 
child with another healthy child. It is therefore not specific and is 
based on more general measures. As a result it may not be 
responsive to small changes in children’s conditions and a clinically 
relevant aspect related to a specific condition may be easily 
overlooked. By general principle, these questionnaires tend to be 
longer in length and are more difficult to fill in. 
In contrast ‘disease specific measures’ may be used in a 
questionnaire, which are designed to be valid for a specific 
condition e.g.; PAQLQ (paediatric asthma quality of life 
questionnaire) for asthma in children. The main advantage of 
disease specific measures is that it maximizes ‘content validity’. 
Content validity is a term used to describe the variables used in the 
questionnaire. It is defined as the extent to which a variable 
measures i.e., what it is supposed to measure. Clearly disease 
specific measures would provide greater sensitivity and specificity. 
This gives it an advantage to be used in trials to compare treatments 
of a disease and measure indices in different time frames. 
With all limitations, disease specific instruments cannot be used to 
compare quality of life in children with different conditions/ diseases. 
This will become important when one patient suffers from more than 
one disease/disorder. In these cases a single ‘disease specific 
questionnaire’ would not fulfil the purpose and it may be necessary 
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to use multiple disease specific tools. A simpler/ alternative option 
may be to use ‘generic questionnaires’ in such cases. 
 
1.7.7   Characteristics of an ideal ‘quality of life’ tool 
 
1.7.7.1    Construct validity 
 
In this section, I will discuss two important concepts, validity and 
reliability. An ideal quality of life tool should be ‘valid’. Central to this, 
is the term ‘construct validity’, explained in figure 1.7.7.1 and as 
follows.  
 
The easiest way to understand ‘construct validity’, would be to 
divide it into two imaginary portions or territories (lands); the ‘land of 
theory’ constituting top half of figure 1.7.7.1 and the ‘land of 
observations’ constituting the lower half of figure 1.7.7.1.  
 
The land of theory represents what goes inside the mind and one’s 
attempt to articulate this to others. It constitutes the main idea, the 
theory and hypothesis. In the land of observations one makes/forms 
the actual questionnaire i.e., the actual measures or observational 
procedures. This is constructed and based on the thought processes 
from the ‘land of theory’. The ‘land of observations’ is based on 
ideas from the ‘land of theory’. It is like developing a program to 
reflect the kind of programme one has in mind. 
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Figure 1.7.7.1. The concept of construct validity 
 
Any time one translates (puts into operation) a concept or construct 
into a functioning and operating reality (the operationalisation) one 
needs to be concerned about how well the translation works. 
Hence in terms of quality of life, the concept of quality of life is the 
‘construct’ and the ‘QOL questionnaire’ the operationalisation. 
Construct validity encompasses all these concepts and refers to 
translating any construct into operationalisation.  
A list of ‘validity’ terms encompassed under the broad umbrella of 
construct validity is shown in table 1.7.7.1 and described as follows. 
These terms are used and applied when one talks about quality of 
measurement. 
 
 
 
 
 
 
 
The QOL 
questionnaire 
Observations 
(when tool is used 
by patients) 
Cause construct 
(a mental 
thought) 
 
Effect construct 
The land of theory (what do you think?) 
The land of observations (making of the questionaire & testing it) 
Relationship between theory & observations. Can we generalize to the constructs ? 
Cause effect 
construct 
Tool 
outcome 
relationship 
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Table 1.7.7.1    Components of construct validity 
 
• Construct validity 
 
• Translation validity 
 
• Face validity 
 
• Content validity 
 
• Criterion related validity 
 
• Predictive validity 
 
• Concurrent validity 
 
• Convergent validity 
 
• Discriminant validity 
 
 
In translation validity one focuses on whether the operationalisation 
is a good reflection of the construct. It assumes that one has a good 
detailed definition of the construct and that the operationalisation 
can be checked against it. This approach is definitional in nature. 
However, in criterion related validity one examines whether the 
operationalisation behaves the way it should, given the theory of 
the construct. This is a relational approach to construct validity. It 
assumes that the operationalisation based upon theory of construct 
should function in predictable ways in relation to other 
operationalisations based upon theory of construct. 
 
1.7.7.2    Translation validity 
 
The two types of translation validity are face and content validity. 
In face validity one looks at operationalisation and to see whether 
‘on face’ it seems like a good translation of the construct. This is 
probably the weakest way to demonstrate construct validity as the 
researcher relies on his/her subjective judgement here. 
                                                        
 
 
102
In content validity one checks the operationalisation against the 
relevant content domain (i.e., questions asked to assess quality of 
life contain appropriate content to assess quality of life) for the 
construct. This approach assumes that a good detailed description 
of the content domain is available. This is a direct comparison and 
usually done by experts in the field. The criteria used for comparison 
are the construct definition itself (the formulated theoretical 
concept e.g.; the concept of quality of life in our case). Validity is 
easier to test where a gold standard exists.  
Unfortunately, in real life ‘criterion measures’ (gold standard) often 
do not exist and in such cases criterion related validity tests are best 
regarded in assessment of construct validity. 
 
1.7.7.3    Criterion related validity 
 
In this, one checks performance of operationalisation against some 
criterion. It is different from content validity as it is not a direct 
comparison but the researcher makes a prediction about how the 
operationalisation will perform based on the theory of construct; this 
would particularly apply when a gold standard is not available. 
The differences among the criterion related validity sub-types are in 
the criteria they use as standard for judgement. 
Predictive validity is about the operationalisation’s ability to predict 
something it should theoretically be able to predict. In concurrent 
validity we assess the operationalisation’s ability to distinguish 
between groups that it should theoretically be able to distinguish 
between. Convergent validity relates to the degree to which the 
operationalisation is similar to other operationalisations that it 
theoretically should be similar to. In discriminant validity we examine 
the degree to which the operationalisation is not similar to (diverges 
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from) other operationalisations that it theoretically should not be 
similar to. 
Finally, a quality of life tool needs to be ‘valid’ and ‘reliable’. This 
means that children would respond to the questionnaire similarly on 
different occasions. Reliability may be tested in three different ways: 
  Internal consistency. It is the extent to which the items of a 
domain or scale assess the same dimension and is measured using 
Cronbach’s alpha. This is a statistical assessment of the correlation 
between items within a dimension and tests whether items within a 
scale correlate positively (i.e., they all test the same thing). 
  Test-retest reliability. This is established where individuals 
complete a measure on two separate occasions and those two sets 
of scores are then positively correlated. This may be tested using 
intra-class correlation. 
  Inter-rater reliability. It is an assessment of the consistency 
of an instrument when administered by different interviewers to the 
same patient. 
 
1.7.8    Quality of life assessment in paediatric inflammatory bowel 
disease 
 
A choice of disease specific instruments are available for quality of 
life assessment in adults with IBD (The rating form of IBD patient 
concern 343, UC/CD health status scale 344, Cleveland clinic 
questionnaire 345 and IBDQ 346). Dorssman et al in his studies in 1991 
on adult quality of life in inflammatory bowel disease showed that 
clinical disease activity is unrelated to patients perception of their 
health status 347,348. Unfortunately, the choice for quality of life 
assessment in paediatric IBD is limited. 
Recently IMPACT, a disease specific quality of life questionnaire was 
developed by Anne Griffiths in Toronto Canada for use in children 
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349. It comprises of 33 questions answered using a 7 cm visual 
analogue scale. These questions are organised under six domains: 
IBD symptoms, systemic symptoms, emotional functioning, social 
functioning, body image and feelings towards treatments and 
interventions. The total score can be converted linearly to range 
from 0-100, with higher scores representing a better quality of life.  
The readability statistics and number of unanswered questions were 
assessed among 147 patients (97 CD, 50 UC) with mean age 14.4 +/- 
2.2 years (range 9.2-18.0 years) using the self-administered 
questionnaire. In the absence of a previous ‘gold standard’, 
construct validity was based on, a priori hypotheses.  
IMPACT was further developed into IMPACT II by Loonen et al 350. 
The original in Dutch has been translated into Canadian English, UK 
English and French. The researchers reported difficulty in use of the 
original IMPACT questionnaire, based on a pilot study in Netherlands. 
These difficulties were: 
The questionnaire was found to consist of many long double 
barrelled and multi interpretable questions and answers. Answering 
phrases were simplified and changed to ‘very much’ and ‘not at all’ 
or ‘very often’ ‘never’, where applicable. 
The absence of a specified time frame in the questions was 
considered sub-optimal. 
The format with the answer representing the most impairment on the 
visual analogue scale on the left side was found to be leading and 
upsetting to the children. 
 
Below is an example of how a question from IMPACT I changed to its 
new form in IMPACT II: 
Q: Put a mark on the line to tell how much your stomach has been 
hurting recently 
                             _____________________________ 
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         A               B 
 
 
 
 
(New) Q: How much has your stomach been hurting you during the 
last two weeks? 
                           _____________________________ 
         A            B 
 
 
Hence, evolution into IMPACT II involved simplifying double barrelled 
questions, addition of a 2 weeks time frame to questions specifically 
related to frequency of problems/symptoms and switching of 
answering anchors with the answers representing least impairment, 
to the left side of the visual analogue scale. The IMPACT II comprises 
of 35 questions instead of the original 33 in IMPACT I. The 
questionnaire takes about 5-10 minutes to complete.  
The IMPACT II has also undergone the validation process. Reliability 
coefficient was good for 5/6 domains and measures of test-retest 
stability in clinically stable patients were good for all domains. Good 
discriminant validity was demonstrated between symptom groups 
and disease course severity in all domains 25. 
Another version of the IMPACT tool with a Likert scale has been 
developed in a pilot study in addition to the current visual analogue 
scale 351. Further to its use in the study on enteral nutrition the 
IMPACT tool 307 has been more recently used in the joint 
Natalizumab study 271. 
 
Details of IMPACT II are listed in table 1.7.8.1. 
 
My stomach has been 
hurting so much, the pain is 
as bad as it has ever been, 
and comes all the time; it’s 
really hard to deal with 
I have not had any stomach 
cramps at all recently 
Not at all Very much 
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Table 1.7.8.1    Items and scales of IMPACT II questionnaire 
 
Scale Items 
IBD symptoms Stomach aches 
Not being able to eat what you want because of disease 
Diarrhoea 
Worried about blood with bowel movement 
Being sick 
Afraid to soil pants 
Having to pass gas 
Systemic symptoms How much energy 
How did you feel 
How tired did you feel 
Emotional functioning Worried about having a flare up 
Worried about having a chronic condition 
Worried about health in future 
Thinking it is unfair to have this disease 
Being angry to have this disease 
Being ashamed 
Being happy 
Social functioning The influence of the disease upon the family 
Having to miss out on hobbies 
Having rules imposed because of the disease 
Having fun 
Is it harder to make friends 
Worries not to be able to go out on dates 
Teased or bullied because of the disease or treatment 
Does the disease make it harder to travel or go on holiday 
Try and keep your disease a secret 
Able to talk to anyone about worries 
Able to play sports as much as you would like 
Able to go to school 
Body image How do you feel about height 
How do you feel about weight 
How do you feel about the way you look 
Treatment/ 
interventions 
How do you feel about taking medicines 
How do you feel about investigations 
Worried about ever having an operation 
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1.8   Hypothesis and aims of the thesis 
 
1.8.1   Hypothesis 
 
Enteral nutrition is a well-established treatment for acute Crohn’s 
disease in childhood. This has been previously discussed in section 
1.6. Fell et all demonstrated a clinical remission rate of 79% in 29 
children with active intestinal Crohn's disease using a polymeric feed 
Modulen (CT3211) 24. As, there has been an accumulating evidence 
of beneficial effects with n-3 fats and its anti-inflammatory properties 
27, a new polymeric feed ACD004, with a higher n-3 : n-6 ratio 
compared to the commonly used CT3211 feed (Modulen IBD®), was 
produced with a view to offer better anti-inflammatory profile in an 
enteral feed. With this new feed being used for the first time, the first 
hypothesis to be tested is that use of ACD004 is efficacious in 
children with acute and active Crohn's disease.  
 
Supplemental enteral nutrition has been prescribed and used in 
maintaining remission in children with Crohn's disease. Wilschanski 
and workers, in a retrospective study, showed that a relapse rate of 
70% at one year was halved by enteral supplementation 26. There 
are however no prospective studies of use of supplemental nutrition 
in children with Crohn's disease. The second hypothesis of this thesis 
is that use of daily enteral supplementation (ACD004) helps to 
maintain remission in children with Crohn’s disease.  
 
Physical measures of disease activity and degrees of mucosal 
inflammation, in isolation, are of limited interest to patients with 
inflammatory bowel disease. A successful therapy should ideally 
both improve a patient’s quality of life and reduce the long-term 
consequences of the disease by modifying its course. Some 
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paediatric gastroenterologists believe that enteral nutrition therapies 
and strategies compromise quality of life in children as it affects the 
day to day eating habits. The third hypothesis of this thesis is that 
there is an improvement in quality of life of children receiving enteral 
nutrition not only for treatment of active disease but also when used 
as a supplement for maintenance of remission. 
 
1.8.2   Aims 
 
The aims of this thesis are: 
 
¾ Assess efficacy based on the proportion of full remission at 8 
weeks in children with Crohn’s disease receiving ACD004. 
 
¾ Assess reduction in relapse rate in Crohn’s disease in children on 
long-term continuous oral ACD004 supplementation as part of 
their total daily requirements (TDR) compared to a control group 
receiving the same energy intake, as usually food, over a period 
of 104 weeks. 
 
¾ Assess quality of life in children with Crohn’s treated with enteral 
feed during the acute phase and whilst using the feeding as a 
supplement. 
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Chapter 2. Use of a new enteral feed for 
treatment of paediatric Crohn’s disease 
– Phase A 
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2.1    Background 
 
Enteral nutrition is a preferred first line treatment for acute active 
paediatric Crohn’s disease in many paediatric gastroenterology centres. 
This is due to its beneficial effects on nutritional status and growth, with lack 
of ‘steroid like’ adverse effects. Enteral feeding, down-regulates mucosal 
pro-inflammatory cytokines, resulting in mucosal healing 24,314,352. Use of 
enteral nutrition in children has been discussed in previous sections. 
ACD004 is amongst the newer generation of enteral feeds and is a newly 
developed enteral feed used in this trial. It is produced by Nestle and is a 
whole protein polymeric feed. This feed evolved from the previous CT3211 
(marketed as ‘Modulen IBD®’). The main difference is an altered increased 
n-3 fat ratio. n-3 fats are known for their anti-inflammatory properties 27. The 
n-6: n-3 ratio in ACD004 has been decreased towards the lower 
recommended value with a view to derive maximum benefit from an 
enteral feed. This is discussed in further details in section 2.2. 
Chapter 2 describes the first part of this study looking at induction of full 
remission with ACD004. This is a prospective and open study of use of 
enteral nutrition for a period of 8 weeks in children with acute and active 
Crohn’s disease. This treatment period is followed by food reintroduction 
over 4-6 weeks. We have called this ‘phase A’ of the treatment trial. 
 
2.2    What is ACD004 ? 
 
As mentioned before ACD004 was developed as a next step up to the 
currently used Modulen IBD® feed produce by Nestle, Switzerland. There 
are considerable similarities to Modulen feed, particularly from the protein, 
carbohydrates, calorific value and electrolytes point of view. Both feeds 
provide 1 Kcal/ml of energy and are casein based. The carbohydrate 
source is glucose.  
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There is however a considerable difference in the fat blend of the feeds. 
The fat source in ACD004 is vegetable oil comprising of high oleic sunflower 
and low erucic rapeseed oil. In comparison Modulen IBD® (CT3211) derives 
its fats from vegetables particularly corn oil. This results in a shift in the n-6:n-
3 ratio, decreasing it to 5.2: 1 (10.8: 1 in Modulen IBD ®). This also results in a 
decrease in the saturated fat ratio providing a saturated fat to 
unsaturated fat ration of 0.50:1. As a result there is an increase in 
monounsaturated fats to 50% and MCT (medium chain triglycerides) to 
5.75 g/100 mls. This is within the recommended daily allowance (RDA) of 
saturated fats.  
The constituents of the feed are enlisted in table 2.2.1. 
 
Table 2.2.1   Major constituents in the polymeric feed ACD004 
 
Energy density (Kcal/L)  1000 
Protein (g/L)   40 
Carbohydrates (g/L)  110 
Na (mg/L)   600 
K (mg/L)    1400 
Cl (mg/L)    930 
Ca (mg/L)   800 
P (mg/L)    550 
Ca/P    1.5 
Mg (mg/L)   250 
Mn (µg/L)    1000 
 
 
2.3    Aims 
 
The primary object of this phase was to assess efficacy based on 
proportion of full remission at 8 weeks. Secondary objectives were to 
demonstrate short-term safety with tolerance of the feed. Other secondary 
measures included assessment of growth, development and quality of life. 
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2.4    Methods 
 
2.4.1    Description 
 
Patients were recruited prospectively and consecutively over a 2 year 
period. Children with symptoms suggestive of inflammatory bowel disease 
seen in the ‘inflammatory bowel disease’ paediatric gastroenterology 
outpatient clinic were admitted for further investigations. On admission, all 
had a detailed clinical assessment which included a detailed history, 
informed consent for the study and examination with measurement of 
heights and weights. This was followed by blood tests to check for blood 
count, liver function, and inflammatory markers with serology for Yersinia 
and Amoebiasis. Suspected cases were screened for tuberculosis and 
were further investigated with a Mantoux test and a chest radiograph. All 
children had a diagnostic upper gastrointestinal endoscopy, 
ileocolonoscopy and a barium meal and follow through. Once the results 
of investigations were available PCDAI with mucosal disease scores (as 
seen on endoscopy) were recorded. Finally children on admission 
completed the quality of life questionnaire form in presence of the 
investigators (see chapter 3).  
The admission checklist is given in table 2.4.1.1 and figure 2.4.1.2. 
A diagnosis of Crohn’s disease was made using previously described 
criteria (see chapter 1.2).  
A multi-disciplinary team comprising of paediatric gastroenterologists, 
nurses, dieticians and child psychiatrists were responsible for care of the 
children. The paediatric dieticians assessed each child, calculated and 
prescribed ACD004 (enteral feed) at the rate of 110-120% of the 
recommended daily allowance (RDA). The calculation of RDA is based on 
FAO/WHO/UNU values (1985). 110-120% of RDA would approximate to the 
increased daily calorific requirement in a child unwell with Crohn’s disease 
353 307. The children were given a minimum volume to drink each day and 
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asked to keep a daily diary record of their intake. The daily intake was 
supervised by the nursing and dietetic team. Standard feed preparation 
instructions (followed by staff members and given to parents) are given in 
table 2.4.1.3. 
Children were followed up at week 4 when they were assessed clinically, 
had a PCDAI score and blood tests (please see figure 2.4.1.2 for details) 
with a weight check. Patients were called telephonically by the dieticians, 
in between, to ensure compliance and troubleshoot any problems which 
children and parents may encounter at home. This was also to adjust the 
ACD004 dosage according to the children’s demand and wellbeing. 
After 8 weeks of exclusive enteral feeding children were re-assessed 
(PCDAI score and ileocolonoscopy). Remission was defined as a fall in 
PCDAI to less than 20. Children treated with antibiotics, 
immunosuppressants or needing surgery at or before 8 weeks irrespective 
of the PCDAI score were considered to have failed the treatment (see 
table 2.4.1.2 for inclusion and exclusion criteria of the study).  
At week 8 children were readmitted for assessments as on week 0. These 
included history, examination, blood tests, endoscopy (mucosal disease 
assessment), dietary assessment, quality of life assessment and PCDAI 
scores. Food reintroduction was planned on discharge with each food 
group introduced over three days. Those in remission continued with the 
study and were given a date for review in paediatric outpatients for 
recruitment into phase B. 
The investigations and clinical assessment details are listed in figure 2.4.1.2.  
This period of 8 weeks intensive treatment is termed as ‘phase A’ (see flow 
diagram 2.4.1.1).  
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Table 2.4.1.1    Admission checklist (week 0) for a child entering phase A of the 
ACD004 study 
 
• Written informed consent 
• Inclusion/ exclusion criteria 
 
• Demography (sex, age, race) 
• Clinical and dietary assessment 
• Medical and surgical history 
• Concomitant medication 
 
• Height and body weight 
• Pubertal status 
 
• PCDAI to assess disease activity 
• Quality of life 
 
• Biochemical assessment 
• Hb & Hct, Platelet count 
• CRP, ESR 
• Albumin, Electrolytes 
 
• Radiographic assessment of disease site using barium meal and follow through 
 
• Histology and colonoscopy (microscopic and macroscopic assessment)  
 
Figure 2.4.1.1    Design of study (Phase A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wk8 
End of this part of study 
Ileo-colonoscopy + gastroscopy 
(endoscopic + histologic scores) 
PCDAI 
 
Bloods 
Wk0 
Recruitment 
Ileo-colonoscopy + gastroscopy 
(endoscopic + histologic scores) 
PCDAI 
 
Exclusive Enteral 
Nutrition for 8 weeks 
PHASE A 
Children in remission  
proceed to food  
re-introduction + phase B  
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PHASE A 
 
PHASE B (randomized controlled study) 
  
Diagnosis 
 
 
3 weeks 
 
 
9 weeks 
 
13 weeks 
 
0 month 
 
2 
months 
 
4 
months 
 
 
8 
months 
 
12 months 
 
16 
months 
 
 
20 
months 
 
 
24 
months 
Inclusion Criteria X            
Informed Consent X            
Randomisation    X         
             
Hb X X X X   X X X X X X 
Hct  X X X X   X X X X X X 
Platelet count X X X X   X X X X X X 
ESR X X X X   X X X X X X 
CRP X X X X   X X X X X X 
Albumin X X X X   X X X X X X 
Urea X X X X   X X X X X X 
             
Height (cm) X  X    X X X X X X 
Weight (kg) X X X X   X X X X X X 
             
PCDAI X X X X   X X X X X X 
Quality of Life X X X X   X X X X X X 
             
Barium Meal & 
Follow Through 
X            
             
Colonoscopy X  X          
Histology X  X          
             
Dietetic 
Assessment 
X X X X   X X X X X X 
Weighed food 
intake 
     X       
Figure 2.4.1.2    Investigations flow chart for phase A and B 
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Table 2.4.1.2    Inclusion and exclusion criteria for the study 
 
 
Inclusion Criteria 
 
• Age: 5 to 19 years  
• Males or females 
• Diagnosis of Crohn’s disease as confirmed by: 
o histology  
o colonoscopy  
o barium follow-through 
o PCDAI  ≥ 20 in the acute phase 
o All subjects with a new diagnosis or known patients of Crohn’s 
disease who have just been treated with 5-ASAs, not taking part in 
any other study and been in remission for at least 4 months, are 
included. 
• All subjects will take enteral nutrition as their sole source of nutrition during the first 
8 weeks of the initial phase of the study 
• All subjects recruited will be attending their respective paediatric inflammatory 
bowel disease clinic and available for follow-up 
• Written informed consent obtained from subject or legal guardian 
 
 
Exclusion Criteria 
 
Subjects will be considered ineligible for enrolment in the study if any of the following 
are met: 
 
• Immunosuppressive drugs and steroids 
• Exclusive oral disease 
• Exclusive perianal disease 
• Subjects already included in other clinical trials or who have taken part in a 
clinical trial within the previous 4 weeks 
• Subjects who are unable to comply fully with study requirements  
 
 
Early end of study 
 
• Subjects will be prematurely discharged from the study if any of the following 
circumstances occur: 
• Not in full remission at the end of Week 8 (end of exclusive feeding) 
• Relapse of the disease (PCDAI > 20) 
• Non compliance (defined as a reduction or interruption of prescribed enteral 
product to 20% or more over the 8-week exclusive feeding phase 
• Onset of life threatening adverse event 
• Death of the patient 
• Is life threatening 
• Requires hospitalization or prolongation of current hospitalization 
• Results in persistent or significant disability/incapacity 
• Subject’s request 
• Enrolment in another investigational study 
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Table 2.4.1.3    Preparation of the polymeric enteral feed for administration 
 
a. Instructions for use of polymeric feed 
 
• Wash hands thoroughly.  Follow instructions carefully and select volume of 
feed required. 
• Measure boiled and cooled water and pour into a clean jug, bowl or shaker. 
• Measure corresponding amount of powder, either use scoop or weigh 
powder in grams.  Level off scoop with the back of a knife. 
• Add powder to the water.  Immediately stir or shake until well mixed. 
• Use immediately or cover and refrigerate and use within 24 hours. 
 
  
b. Mixing table 
 
 
Volume of feed  
required 
 
Water 
 
Powder 
 
 
 2 litres 
 
1800 mls 
 
Whole tin 
 
 
1 litre 
 
 
900 mls 
 
207 grams (or 41 scoops) 
 
750 mls 
 
 
675 mls 
 
153 grams (or 31 scoops) 
 
500 mls 
 
450 mls 
 
103 grams (or 21 scoops) 
 
 
1 scoop = 5 grams 
(Once reconstituted, 100 mls = 100 kcal) 
 
 
 
 
2.4.2    Clinical disease scoring using PCDAI 
 
This clinical tool has been previously described in sub-chapter 1.4 and I also 
used PCDAI to assess severity of disease 174. There are 11 items in the index 
with each question carrying an individual score (see table 1.4.4.1). At 
completion, the scores are totalled and net value gives an indication of 
the severity of disease. In the original article Hyams et al defined a score of 
greater than 10 to be representative of active disease, 11-30 as mild 
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disease and 31 or more representative of severe disease. In this thesis a cut 
off score of 20 was used to define active disease out of a possible 
allowable score of 110. 
We have often observed, in clinical practice, that a PCDAI score of 10 or 
15 may inappropriately include children who are in clinical remission. An 
illustrative example would be of a child presenting with abdominal pain 
secondary to viral infection which results in a raised ESR. This child would 
score at least 10 on the PCDAI scale and hence by definition would fall in 
the category of active disease. This would result in increased number of 
false positives in the study. Viral infections are common in children and 
inappropriate diagnoses may compromise this long term study as relapse is 
the end point of this prospective trial. Recently Otley et al have addressed 
the issue of re-validation of the PCDAI scores for definition of active disease 
354. This group used similar methodology as employed in paper by Hyams 
et al and also correlated the PCDAI scores with the physician’s global 
score. They concluded that a cut-off of 10 was too low. They arrived at the 
minimum figure of 18.7 ± 7.3 as definition for active disease. Therefore, we 
defined relapse as a PCDAI of 20 or more. 
 
2.4.3    Endoscopic (macroscopic) scoring 355 (table 2.4.4.1) 
 
For endoscopic scoring (mucosal inflammation visualised by endoscope) 
in this thesis, I have used a previously used scoring system. This system 
described by Williams CB is not validated but has been used in local 
research methodology. This method was originally chosen due to absence 
of a robust endoscopic scoring system suitable for use in children. 
Reasonings for this chioice have been discussed in detail in the ‘discussion’ 
section (section 2.8). 
This endoscopic scoring system is a simple system based on inflammation 
visualized endoscopically, scored on a scale ranging from 0-3; with a score 
of 0 representing no inflammation and 3 active inflammation with 
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ulceration (see table 2.4.4.1) 355. Therefore, each segment of the large and 
small bowel can be scored individually for inflammation. The worst colonic 
score from any segment was considered to be representative of the total 
colonic score. This scoring technique is discussed in more detail in the 
‘discussion’ section. 
 
2.4.4    Histology (microscopic) scoring 352 (table 2.4.4.1) 
 
This system, similar to the endoscopic scoring system, is unvalidated. This 
was devised and used in previous investigations in the paediatric 
gastroenterology departments of St Bartholomew’s and Royal Free 
hospital. As this method uses a similar scoring method (and scale) to 
endoscopic inflammation scoring, it was adopted to maintain conistency 
and comparibility. The histological scoring scale also ranges from 0-3. The 
ileum and each area of the colon receiving a score described in table 
2.3.4.1 352. Again, each segment of the large and small bowel can be 
scored individually for inflammation. The worst colonic score from any 
segment was considered to be representative of the total colonic score.  
The specimens were all examined and scored by the same technique for 
inflammation by paediatric gastroenterology histopathologists in Royal 
Free and Chelsea Westminster Hospitals. Histopathologists at both centres 
were blinded to the identity, clinical/endoscopic details and timing of 
biopsy.  
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Table 2.4.4.1    Endoscopic and histologic grades for scoring intestinal inflammation in 
Crohn’s disease in children 
  
ENDOSCOPIC SCORING 355 
 
0 – No inflammation 
1 – Mild inflammation, with erythema and/or occasional aphthoid ulcers 
2 – Moderate inflammation, with extensive superficial ulceration and/or 
occasional deep ulcers 
3 – Severe inflammation, with extensive deep ulceration 
 
HISTOLOGY SCORING 352 
 
0 - Normal or minor chronic inflammation 
1 - Prominent chronic inflammation (not lymphoid follicles) and / or focal cryptitis/ 
surface inflammation 
2 - Prominent active inflammation with crypt abscess or crypt destruction 
3 – Inflammation with ulceration 
 
 
2.4.5 Adverse Event and adverse event reporting 
 
2.4.5.1 Adverse event (or adverse experience) 
An adverse event is defined as any untoward occurrence in a subject or 
clinical investigation subject administered as investigational product and 
which does not necessarily have to have a causal relationship with this 
treatment. 
An adverse event can therefore be any unfavourable and unintended 
sign (including an abnormal laboratory finding) symptom or disease 
temporarily associated with the use of an investigational product whether 
or not considered related to the investigational product. It may or may not 
lead to withdrawal of the subject from the study. 
 
2.4.5.2 Adverse reaction 
Adverse reaction is an unintended response to an investigational product 
related to any dose. The phrase ‘response to an investigational product’ 
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means that a causal relationship between the product and the adverse 
event cannot be ruled out. 
 
2.4.5.3 Serious adverse event 
Serious adverse event is defined as any untoward medical occurrence 
that at any dose: 
 
• Results in death 
• Is life threatening 
• Requires in-subject hospitalisation or prolongation of existing 
hospitalisation 
• Results in persistent or significant disability/incapacity or 
• Is a congenital anomaly/birth defect 
 
2.4.5.4 Non-serious adverse events 
All other adverse events not included within the serious adverse event 
definition are considered as non-serious. They can be mild, moderate or 
severe.  
Mild events are usually transient require no special treatment and do not 
interfere with the subject’s clinical conditions. 
Moderate events usually introduce a low level of inconvenience or 
concern to the subject and may interefere with clinical conditions, but are 
usually improved by simple therapeutic measures. 
Severe events deteriorate subjects clinical condition and generally require 
systemic drug therapy or other treatment. 
 
 
2.5    Funding, study site/dates and ethics 
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2.5.1  Funding sources 
 
The phase A was fully funded by Nestle, Switzerland. 
 
2.5.2  Dates and site of the study 
 
The study for Phase A was conducted between, March 2000 to September 
2002. 
The study was carried out at Royal Free and Chelsea Westminster Hospitals, 
London. I managed all appointments at the two centres and conducted 
these studies in person. 
 
2.5.3  Data collection 
 
Data was collected in CRFs (case report forms) provided by Nestle. The 
data was cross checked by the supervisor, in relation to clinical notes and 
laboratory results on the computer systems. Carbon copies of these 
records were retrived after cross checking. I retained the original CRFs in 
the hospital and transferred information to patient secured database to 
Excel and SPSS for analyses. 
 
2.5.4  Ethics 
 
Patient information sheet and patient consent forms given in appendix A 
and B, were devised using previously described guidelines used in the 
hospital. These, along with the complete study protocol, were reviewed 
and approved by the ethical committee. The phase A and B studies were 
approved by LREC, the local research ethics and research committees of 
Royal Free and Chelsea and Westminster hospitals. 
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2.6    Statistics 
 
2.6.1   Power calculation 
The power calculation was done a priori. 
 
The criterion used for null and alternative hypotheses were: 
Ho: the proportion of subjects with complete remission is 0.85 
Ha: the proportion of subjects with complete remission is < 0.85 
In the previously conducted study CT3211, the observed proportion of total 
remission was 0.85. A proportion of 0.60 is defined by the investigators as 
the clinically meaningful proportion. In the current study a minimum total of 
27 subjects is needed in the 2 year recruitment period to complete phase 
A to obtain alpha = 5% and 90% power in the ability to detect a difference 
between the proportion of remission with ACD004 as compared to 0.85 
(CT3211). 
 
The investigators agreed that although a minimum total of 27 subjects 
were needed for phase A, recruitment would continue throughout the two 
year period, thus enabling us to collect more information about the feed. 
 
2.6.2 Description of statistics analyses 
 
All analyses were done on an intention to treat basis. Statistical software, 
SPSS v 11.01 was used for all statistical tests. The data was rechecked with 
SPSS v 16.0.0 for the repeat submission following the MD thesis examination 
interview (viva). 
All power calculations were done by statisticians based at Nestec, 
Luassane. Statistcal analyses were carried out by me, as guided by Dr 
Corrine Hager (statistician in Nestec) and Dr Richard Morris, Reader in 
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Medical Statistics and Epidemiology, based at University College of 
London. 
Databases were maintained in Microsoft® Excel 2000 and 2003 and SPSS v 
11.0.0 and 16.0.0. Normally distributed continuous data has been 
described using mean and standard deviation whereas non-normally 
distributed continuous data as median (range or interquartile range-IQR). 
All categorical results are a number (%). ‘t test’ and ‘ANOVA’ were used to 
assess parametric data; ‘Kruskall Wallis’ and ‘Wilcoxon Rank’ test to 
analyse non parametric data.  
Significance was defined as p < 0.05.  
 
2.7    Results 
 
2.7.1    Demographics 
 
Forty two children were recruited over a 2 year period in Royal Free and 
Chelsea Westminster Hospitals, London (March 2000 – February 2002). Thirty 
nine were newly diagnosed and three had been previously diagnosed 
having now presented with relapsed disease but had been in remission for 
a mean period of 1.2 yrs (0.6-2 yrs) – see inclusion criteria, table 2.4.1.2. 
They were not on any concomitant immunosuppressants. 
The median age of children in the study was 13.6 years (IQR = 11.4 - 15.1 
yrs). 28 males and 14 females were recruited. 18 were pre-pubertal, 9 in 
mid puberty and 15 at end of their pubertal development. 34 (81%) had 
severe disease (PCDAI > 30) and 8 (19%) mild to moderate disease 
(defined by PCDAI < 30). Table 2.7.1.1 gives details of children recruited in 
the study with date of births, decimal age at presentation and gender. 
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Table 2.7.1.1    Details of children recruited in phase A of the study with coded serial 
for the study, date of births, gender and decimal age at presentation (years) 
 
Serial DOB Sex Decimal age at presentation (yrs) 
SJ 01 3/7/89 m 10.866 
BK 02 26/9/86 f 13.644 
MB 03 7/9/84 m 15.707 
LR 04 25/7/90 m 9.901 
SM 05 17/10/86 m 13.879 
CO 06 10/9/84 m 15.819 
CO 07 17/12/85 m 14.660 
PB 08 10/12/84 m 15.693 
DT 09 1/9/86 f 13.986 
AW 10 2/9/89 m 10.986 
CM 11 22/9/86 m 13.934 
AW 12 18/12/91 m 8.764 
SH 13 19/8/85 m 15.115 
KC 14 11/3/86 f 14.597 
LH 15 5/3/87 m 13.647 
VS 16 9/3/92 f 8.655 
WS 17 26/12/90 m 9.890 
GD 18 29/4/90 f 10.592 
KH 19 28/1/85 f 15.890 
VR 20 31/1/87 f 13.934 
AE 21 23/10/90 m 10.211 
GK 22 2/2/88 m 12.948 
PD 23 25/8/87 m 13.403 
LS 24 28/1/85 f 15.997 
AH 25 9/1/87 m 14.066 
SO 26 4/7/88 m 12.581 
SN 27 22/3/91 f 9.871 
GL 28 23/12/86 f 14.173 
JR 29 24/8/88 m 12.510 
EE 30 24/1/89 m 12.110 
JW 31 10/1/89 f 12.178 
DC 32 26/2/88 m 13.060 
OS 33 7/12/85 m 15.359 
MY 34 23/2/87 m 14.290 
SW 35 16/12/89 m 11.482 
LH 36 2/4/86 f 15.225 
RK 37 29/6/85 f 16.005 
BH 38 5/1/86 m 15.518 
BB 39 14/6/89 f 12.077 
PG 40 5/10/84 m 16.805 
AE 41 22/02/90 m 11.970 
FS 42 18/12/87 m 14.112 
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2.7.2    Response to treatment 
 
2.7.2.1    Follow up at 4 weeks 
 
All patients were followed up at 4 weeks into treatment. There was a 
significant fall in ESR, CRP and PCDAI at this stage (p < 0.0001) with a 
significant increase in weight (WAZ) and albumin (p < 0.0001). 
 
Table 2.7.2.1    PCDAI, WAZ and blood marker changes at week 4 of commencing 
enteral nutrition. 
 
 
 
 
 
 
 
 
There was a significant change in all paramenters with drop in PCDAI and 
inflammatory markers, and increase in albumin at week 4. 
 
 
Table 2.7.2.2    PCDAI, WAZ and blood marker changes at week 8 after commencing 
enteral nutrition. 
 
 
 
 
 
 
 
 
There was no change in in PCDAI, inflammatory markers, or albumin at week 8 
(compared to week 4). Although there was significant fall in weight (WAZ) at week 8 
(from week 4), there was an overall significant improvement in weight when 
compared to week 0 (p < 0.0001). 
 
 
 
 Week 0 Week 4 p 
PCDAI 43.8 (32.5-50.6) 7.5 (5-15) p < 0.0001 
ESR 32 (16.3-67.3) 10 (7-16) p < 0.0001 
CRP 27 (5.3-71.3) 2 (0-8) p < 0.0001 
WAZ -1.08 (-1.82 - -0.24) -0.66 (-1.6 – +0.1) p < 0.0001 
Albumin 32 (29-36.3) 41 (38-42) p < 0.0001 
 Week 4 Week 8 p 
PCDAI 7.5 (5-15) 7.5 (5 - 10.6) ns 
ESR 10 (7-16) 10 (4 - 20) ns 
CRP 2 (0-8) 1 (0 - 9.5) ns 
WAZ -0.66 (-1.6 – +0.1) -0.81 (-1.49 - 0.1) p = 0.023 
Albumin 41 (38-42) 40.5 (37.3 - 43) ns 
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2.7.2.2 Follow up at 8 weeks 
 
At completion of 8 weeks of enteral nutrition treatment, 33/42 children 
were in remission (78.6%).  
 
There was no significant change in PCDAI, ESR, CRP and albumin between 
week 4 and week 8 (see table 2.7.2.2 and figures 2.7.2.1, 2.7.2.2 and 
2.7.2.3). However, in the latter 4 weeks, there was a significant decrease in 
weight (p=0.023) from a median z score of -0.66 (IQR= -1.6 - +0.1) to -0.81 (-
1.49 - +0.1) - See table 2.7.2.2. Despite the drop in WAZ scores in the latter 4 
weeks there was an overall increase in weight from week 0 to week 8 (p < 
0.0001) 
 
There was an overall endoscopic and histologic healing in the ileum and 
colon of children. The scores significantly improved at completion of 8 
weeks of treatment (WR, p < 0.01) – see table 2.7.2.3.  
 
Table 2.7.2.3    Mucosal inflammation assessment at completion of treatment. 
Comparative scores pre and post treatment. Median scores are given with 
interquartile ranges in brackets. Wilcoxon Rank test was used for analysis. 
 
 
 Pre - treatment Post treatment p 
Ileum endoscopy  2 (0.5 – 2.5) 0 (0 – 1) 0.000 
Ileum histology 1 (1 - 3) 1 (0 – 1) 0.002 
Colon endoscopy 2 (1 – 3) 1 (0.25 – 1) 0.000 
Colon histology 2 (1 – 3) 1 (1 – 1) 0.001 
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Figure 2.7.2.1    Significant fall in PCDAI in the first 4 weeks of treatment which then 
does not change over the subsequent 4 weeks 
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Figure 2.7.2.2    Significant drops in ESR and CRP in the first 4 weeks of treatment whith no 
further change in the subsequent 4 weeks through to week 8 
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Figure 2.7.2.3    Significant increase in albumin in the first 4 weeks of treatment which 
then remains constant till completion of treatment 
 
 
2.7.3    Response according to disease phenotype 
 
2.7.3.1 Clinical response 
The majority of the children had ileocolonic Crohn’s disease (n=22, 52.4%). 
Of the remainder, 11 had ileal (26.2%) and 9 colonic disease (21.4%). The 
disease subclassification is based on the Vienna classification discussed in 
detail in subsection 1.2.2 and table 1.2.2.1. 
There was no significant difference between PCDAI, ESR, CRP, WAZ and 
albumin at presentation in the three groups (Kruskall Wallis, p=ns). Colonic 
Crohn’s disease was signicantly commoner in boys (88.9%, p=0.02) with 
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54.5% boys in the ileal subgroup and 63.5% boys in the ileocolonic disease 
subgroup. 
At completion of 8 weeks of treatment there was a significant difference 
between the remission rates of the colonic, ileal and ileo-colonic 
subgroups (see table 2.7.3.3). Only 44.1% children in the colonic group 
were in remission compared to 81.8% in the ileal and 90.9% in the 
ileocolonic sub-groups. 
Table 2.7.3.2 shows change in PCDAI, blood and weight parameters in 
each Crohn’s disease subgroup.  Although only 44% of children with 
colonic Crohn’s disease achieved remission, all had a significant drop in 
PCDAI although not low enough to qualify as remission. The change in ESR 
and albumin in this disease group was insignificant. 
In comparison, the ileal and ileocolonic groups showed significant 
improvement in all disease parameters at completion of enteral nutrition. 
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Table 2.7.3.1    Demographics and disease severity in the three phenotypes, at 
diagnosis. 
 
  Ileum Ileo-colon Colon Test p 
1. 
 
n 11(26.2%) 22 (52.4%) 9 (21.4%)   
2. 
 
 
Age (median) 13.4  
(9.9-14.6) 
14 
(11.8-15.4) 
12.5 
(8.8-16.8) 
KW 0.40 
3. 
 
M:F 6:5 14:8 8:1 χ2 0.02 
(colon) 
4. Pubertal status    χ2 0.72 
 - Pre-pubertal 5 18 9   
 - Early puberty 3 9 3   
 - Late puberty 4 12 2   
5. 
 
Weight (z score) -1.6 (1.7) -1.1 (1.1)  -1.4 (1.1) KW 0.45 
6. 
 
CRP at dx 23.4 (23.5) 48.1 (48.3) 28.5 (28.8) KW 0.14 
7. 
 
ESR at dx 26.3 (21.7) 41 (31) 40.6 (35.3) KW 0.32 
8. 
 
Albumin at dx 38.1 (8.4) 33.6 (5.1) 35.5 (6.5) KW 0.08 
9. 
 
PCDAI at week 0 34.2 (10.6) 40.5 (12.2) 40.7 (14) KW 0.05 
10 
 
Remission at end  
of treatment (%) 
 
9 (81.8%) 20 (90.9%) 4 (44.4%) χ 2 0.016 
KW – Kruskall Wallis test, χ2 - Chi squared. 
 
Table 2.7.3.2    Change in PCDAI, weight, albumin, ESR and CRP in ileal, colonic 
and ileocolonic Crohns treatment after treatment with ACD004 
 
                                                        
 
 
133 
a. Ileal Crohns disease group 
 
 
Pre treatment Post treatment p 
PCDAI 
 
40 (25 - 50) 6.25 (1.9 – 11.3) 0.005 
WAZ 
 
-1.05 (-1.92 – 0.07) -0.81 (-1.62 – 0.22) 0.04 
Albumin 
 
32 (27 – 39) 41.50 (38.3 – 44.5) 0.008 
ESR 
 
20 ( 12 – 42) 9 (5.8 – 12.3) 0.008 
CRP 
 
24 (3 – 75) 0 (0 – 1) 0.011 
 
b. Ileo-colonic disease group 
 
 
Pre treatment Post treatment p 
PCDAI 
 
45 (32.5 – 52.5) 7.5 (5 – 10) 0.0 
WAZ 
 
-1.26 (-1.87 – 0.08) -0.9 (-1.5 – 0.38) 0.0 
Albumin 
 
32 (29 – 35) 39.5 (37.8 – 42.3) 0.001 
ESR 
 
43 (21 – 85) 8 (2 – 22.5) 0.001 
CRP 
 
39.5 (20 – 85.3) 1 (0.3 – 13.5) 0.0 
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c. Colonic disease group 
 
 
WAZ = weight Z score 
All values are ‘medians with IQR (inter-quartile range) in brackets. 
 
Table 2.7.3.3   Remission rates of three phenotypes at completion of 
treatment 
  Ileum Ileo-colon Colon Test p 
1. 
 
n 11(26.2%) 22 (52.4%) 9 (21.4%)   
2. 
 
PCDAI at week 0 40 (25-50) 45 (32.5-
52.5) 
42.5 (33.8-
43.8) 
KW 0.05 
3. PCDAI at week 8 
 
6.3 (1.9- 
11.3) 
7.5 (5-10) 12.5 (5-25) KW 0.16 
4. 
 
Remission at end  
of treatment (%) 
 
9 (81.8%) 20 (90.9%) 4 (44.4%) χ 2 0.016 
 
 
Pre treatment Post treatment p 
PCDAI 
 
42.5 (34.4 – 45) 16.3 (5 – 23.8) 0.012 
WAZ 
 
-1.02 (-1.7 - -0.31) -0.64 (-1.4 - -0.22) 0.012 
Albumin 
 
31 (28.5 – 36.5) 40.5 (36.3 – 42.5) 0.161 
ESR 
 
31 (17.5 – 50) 17 (7.8 – 42.5) 0.612 
CRP 
 
23 (3 – 30) 2 (0 – 8.3) 0.018 
                                                        
 
 
135 
2.7.3.2  Mucosal response 
 
There was no histologic improvement in colonic inflammation in the 
colonic Crohns disease subgroup. However, an improvement was noted in 
the endoscopic scores. See table 2.7.3.4. 
The ileo-colonic Crohns’ disease group showed a significant improvement 
in the colonic healing, at both endoscopic and histologic levels in 
response to treatment with enteral feeding. See table 2.7.3.4. 
 
Table 2.7.3.4    Comparison of the colonic histologic and endoscopic scores in the 
ileocolon and colon groups. * A comparison of the endoscopic and histologic mean 
scores of the colonic and ileocolonic groups show no significant difference at 
commencement of treatment. (p=0.51 and p=0.67 respectively) 
 
 
 Median scores at 
enrolment* 
Median scores at  
end of treatment 
p Test 
Ileocolon group 
(Endoscopic score) 
2 (2 - 3) 1 (0 - 1) 0.000 WR 
Colonic group 
(Endoscopic score) 
2 (2 – 2.5) 1 (1 - 2) 0.023 WR 
Ileocolon group    
(Histologic score) 
2 (2 - 3) 1 (0 - 1) 0.000 WR 
Colonic group 
(Histologic score) 
3 (3 – 3) 1 (1 - 2) 0.083 WR 
 
WR- Wilcoxon Rank Sum test 
 
 
2.7.4    Compliance, tolerance, treatment failures and adverse effects 
 
2.7.4.1 Compliance 
 
Compliance was monitored by dieticians at recruitment and intitaiting 
enteral nutrition. Children stayed were inpatients admitted to paediatric 
gastroenterology ward for a median 3 days and discharged only when 
they were making full volumes with parental training for making feeds. 
Compliance during the trial was monitored by the tins/feeds used by 
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patients and by phone calls in between appointments. There were no 
compliance issues reported in the study. 
 
2.7.4.2    Use of nasogastric tube 
 
Three children (3/42) required nasogastric tube feeding during the eight 
week treatment period. Another required nasogastric tube only for the first 
week of treatment, which was removed at discharge from hospital.  
 
2.7.4.3    Details of study failures/early dropouts 
 
4 treatment failures dropped out early and did not complete the 8 weeks 
therapy, due to worsening of their disease. These children additionally 
commenced on corticosteroids for their treatment and as a result were 
excluded from the study. One of the four treatment failures developed 
refeeding syndrome; this is discussed below (sub-section 2.7.4.4). 
 
2.7.4.4    Refeeding syndrome 
 
A 14-year-old girl (Case number 20, Phase A – see table 2.7.1.1) with 
Crohn’s disease developed refeeding syndrome. She, since onset of 
symptoms, before commencing treatment, over a period of eight weeks 
had lost 7 kg in weight 41.6 kg (weight for age = 14.8th centile, z = -1.05). At 
recruitment, she was 168.2 cms tall (height for age = 88.6 centile, z = +1.2) 
and her BMI was 14.70 (BMI SDS = -1.58). She was pale, afebrile but had no 
oral ulcers. By the time enteral nutrition was commenced 7 days later 
(patient’s/parental choice in delay in treatment), the patient had lost a 
further 2.7 kg. She had a pulse rate of 120/min. She was prescribed 2500 
kcal/day of ACD004. Within 72 hours the patient had lost a further 1.8 kg. 
As the patient was unable to take the prescribed amount (RDA), full 
enteral feeds were administered by a nasogastric tube. With the increase 
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of feeds there was a precipitous drop in phosphate levels to 0.23 mmol/l, 
despite a standard daily phosphate supplementation of 1.25 mmol/kg/day 
in the feed (Nestlé, Clinical Nutrition). A diagnosis of refeeding syndrome 
was made. Her weight had increased by 2.9 kg to 41 kg. An ECG was 
done with a normal corrected QT interval of 0.44 seconds (normal range: 
0.35 - 0.45s). An echocardiogram showed normal cardiac function. Her 
enteral intake was reduced by 25% to 1800 ml (1800 calories/day), and 
phosphate supplements were increased to 5 mmol/kg/day. Within 48 hours 
her phosphate rose to 1.19 mmol/l followed by gradual improvement and 
recovery over the subsequent week. 
 
 
Figure 2.7.4.1    Flow chart of investigations from the day of admission through to final 
follow up. Refeeding syndrome was diagnosed on day 5 
 
 
 Admission D2 D4 D5  D7 D12 D21(F Up) 
Hb 8.3 7.4 10.3 9.0  10.1 11.8 
Plat 646 579 404 351  788 331 
CRP 193 156 145 166 43 10 1 
ESR    9  12 7 
Albumin 21 21 18 16 18 22 41 
        
Phosphate 0.98 0.84 0.63 0.23 1.19 1.48 1.36 
Ca 2.43 2.34 2.3 2.28 2.33 2.49 2.48 
Na 134  132 125 133 137  
K 3.6  3.9 5.0 4.1 4.7  
Mg 0.81     0.93 0.85 
Urea 3.0  3.5 2.5  3.1  
        
Selenium 28.8     46.4  
Zinc 5.8     11.3  
 
 
2.7.5    Food reintroduction – After phase A 
 
4 children left the study (described in section 2.7.4.1) before completion of 
phase A. 5 more children dropped at completion of phase A due to 
disease relapse, 1 required surgery for persistent right sided disease. All 33 
children in remission entered the food re-introduction phase.  
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During this phase, food was gradually introduced whilst the enteral feed 
was reduced to 30% of RDA at the end of this phase. Unfortunately, there 
was a high drop out during the food re-introduction stage (24.2%). Children 
in this group have been termed as ‘early relapsers’. 
 3/8 dropped out of the study although still being in remission.  This was 
because one was lost to follow up, one moved area and the last once in 
remission did not return for any further follow ups until two years late for 
treatment of another relapse.  
Of the remaining 5, two relapsed in the 3rd and another two in the 4th week 
of food re-introduction. The paediatric gastroenterology team chose to 
use Azathioprine in one child with a PCDAI < 20 as she had marginally 
raised inflammatory markers following food re-introduction and was seen 
to be following her brother’s disease pattern. In the drop-out group, 5 
children had ileocolonic, 2 ileal and 1 colonic Crohn’s disease. 
 
2.8    Discussion 
 
ACD004 is an effective enteral feed and its remission rate is comparable to 
Modulen IBD® (CT3211), a similar whole protein based polymeric enteral 
feed. Results of the CT3211 study have been previously published and 
reported 24. Comparing disease severity in children recruited in both 
studies, those treated with ACD004 had relatively more severe (81% vs. 
41.4%) disease (as defined by PCDAI > 30).  
These remission rates (both ACD004 and CT3211 studies) are also 
comparable to a previously published Canadian trial of a comparative 
study of corticosteroids and enteral nutrition 356. In this study children with 
colonic Crohn’s disease were excluded and they achieved a remission 
rate of 75% for enteral nutrition and 89% for corticosteroids. 
ACD004 is a palatable polymeric feed and nasogastric tube feeding was 
only required in 3 children (7%) and in a 4th for a very short while. Previous 
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studies using elemental and semi-elemental diets have used nasogastric 
tube feeding in all children 304. 
ACD004 was used for a period of 8 weeks for treatment of acute Crohn’s 
disease. This study demonstrates resolution of symptoms and fall in 
inflammatory markers by week 4 (see table 2.7.2.1 and 2.7.2.2). Bannerjee 
357 has recently shown a drop in IL-6 and ESR within 3 days of starting 
treatment. There is no definitive period of ideal duration of treatment, as 
the practice is very variable in gastroenterology units with shorter periods 
of 4-6 weeks, also reported.  A decision of using enteral nutrition for 8 
weeks was based on current policy and practice of our unit. 
ACD004 has a higher ratio of n-3: n-6 fats (the constituents and ratios in 
these feeds have been discussed in section 2.2). Several clinical studies 
have suggested a beneficial role of use of fatty acids in the 
pathophysiology of intestinal inflammation. High dietary intake of n-6 
polyunsaturated fatty acids (PUFA) with low intake of n-3 PUFAs has been 
associated with development of Crohn’s disease 358. This was a 
retrospective and correlational study in a genetically stable homogenous 
Japanese population. Andoh and co-workers have recently demonstrated 
that n-6 fatty acid-rich diet in comparison to n-3 fatty acid rich diet 
enhanced initial mucosal damage in TBNS enteritis 359. It is suggested that 
intake of n-3 fatty acids leads to PGE3 and LTB5 production which have 
1/30 potency of PGE2 and LTB4 360. The latter is a chemotatic factor that 
facilitates accumulation of neutrophils in the mucosa. Ingestion of n-6 fats 
in the TBNS enteritis mouse model also results in a significant increase in 
serum IL-6 levels 359. IL-6 is derived from several sources including 
macrophages/monocytes and endothelial cells which may possibly be 
modulated by intake of n-3 fats through less understood mechanisms. 
Belluzi et al assessed the role of a fish oil preparation for maintenance of 
remission in Crohn’s disease. 11/39 compared to 27/39 relapsed in the fish 
oil group when compared to placebo 27. 
In this study we used PCDAI to assess clinical disease score. PCDAI was 
developed by Hyams and involves scoring for questions about symptoms, 
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signs and blood tests (see table 1.4.4.1). At completion, the scores are 
totalled and net value gives an indication of the severity of disease. In the 
original article Hyams et al defined a score of greater than 10 to be 
representative of active disease, 11-30 as mild disease and 31 or more 
representative of severe disease. In this thesis a cut off score of 20 was 
used to define active disease out of a possible allowable score of 110. This 
was determined by peers developing the study trial. One of the main 
concerns regarding a cut off value of 10, in a study conducted over more 
than 2 years was to have inappropriate dropouts. We have often 
observed, in clinical practice, that a PCDAI score of 10 or 15 may 
inappropriately include children who are in clinical remission. An illustrative 
example would be of a child presenting with abdominal pain secondary 
to viral infection which results in a raised ESR. This child would score at least 
10 on the PCDAI scale and hence by definition would fall in the category 
of active disease. Viral infections are common in children and 
inappropriate diagnoses may compromise this long term study as relapse is 
the end point of this prospective trial. Hyams and co-workers in a PCDAI re-
evaluation study debated the point of remission/mild disease cut off at 
considerable length (this study/report was not available at the time of 
study trial). They raised the same concerns as discussed above. They 
demonstrated a lower PCDAI cut off value (for remission/mild disease) had 
greater specificity but lower sensitivity in relation to physician’s global 
assessment of mild disease vs inactive disease. Although the group stayed 
on the original definition of disease cut off it was accepted that with a 
lower cut off, it would be impossible for a child with slow linear growth to 
acheive remission even with the most effective therapy (poor growth 
scores 10 on PCDAI scale). 
I used a new endoscopic mucosal scoring system for inflammation. This 
system although described and used before remains unvalidated. An 
alternative is, the Crohn’s disease endoscopic index of severity (CDEIS) 
which is a validated research tool used in adults developed by French 
group GETAID (Groupe d’Etude Therapeutique des Affections 
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Inflammatories Digestive) 361. It is the gold standard for adult research 
studies and has been used in many trials. There are however, no reported 
trials of its use in paediatrics as it is not validated for paediatric usage. 
CDEIS contains four questions; two of them are about length of colon 
affected by disease. A 4 year old’s colon will be shorter than that of a 16 
year old adolescent and as children of varying ages are recruited in this 
study, such a scoring system would be difficult to use. I, in agreement with 
co-investigators, therefore, did not adopt this system. 
Whilst using the endoscopy scoring system described by Williams CB, the 
greater difficulty was to devise a meaningful formula which would give a 
figure representing the best global score for bowel inflammation in the 
ileum and colon. There were three possible ways to do so, each with its 
pros and cons, discussed as follows: 
One is to add up all the numbers (0-3 in each individual colon segment). 
This will make the ileocolonic ‘total’ scores falsely high when compared to 
‘ileal’ or ‘colonic’ disease sub-groups. This is easily explained. The colon will 
score ‘0’ in the ileal disease group and the ileum ‘0’ in the colonic disease 
group. Different totals in different disease phenotypes would make it 
impossible to analyse, quantify and compare degree of inflammation 
amongst the phenotypes of Crohn’s disease. 
A second option is to take a mean of all the colonic and ileal scores from 
the three disease phenotype groups. This technique would give ileum a 
very small representation in the total. In a child with severe ileal disease the 
ileum will underscore as its score will dilute when averaged amongst 
several ‘normal’ (each segment scoring zero) colonic biopsies. Mild 
widespread disease would score the same or even more compared to 
severe localized disease. 
The third way is to take the worst possible inflammation score as 
representative of the bowel. This technique would result in a child with 
severe localized colonic disease scoring the same as another with severe 
widespread disease. However, severe disease would be correctly 
represented in addition severe ileal disease would also be correctly 
                                                        
 
 
142 
represented and could be compared to colonic score if it were necessary. 
I adopted this technique for these reasons (least compromise) and was 
uniformly agreed by all co-investigators before commencement of study. 
This study also looks at the response of different Crohn’s disease subgroups 
(as per Vienna classification) to treatment with enteral nutrition. The results 
are interesting. Although there is a clear overall improvement in disease 
after treatment with enteral nutrition, isolated colonic Crohn’s disease in 
children responds poorly (systemic and mucosal) to treatment with 
exclusive enteral nutrition. It is important to emphasize that the colonic 
disease subgroup did not have associated ileal or small bowel 
involvement. Previously, Furukuwa and colleagues have shown severe 
colonic cobblestoning to be poorly responsive to treatment with enteral 
nutrition in adults 362. Interestingly, this was not significant when patients 
were treated with total parenteral nutrition. 
The understanding of mechanisms of effects of enteral nutrition is limited 
and why this should work less well in colonic disease is difficult to explain. 
There is now increasing evidence that inflammation in Crohn’s disease is 
propagated due to contribution of both genetic and environmental 
factors 363-367.  
NOD2/CARD15 is associated with ileal disease 368 and is composed of two 
caspase recruitment domains; a nucleotide-binding domain (NBD) and a 
leucin-rich-repeat (LRR) region. Truncation of the LRR domain of 
NOD2/CARD15 impairs recognition and binding activity for bacterial 
peptidoglycans therefore stimulating the pro-inflammatory NFκB pathway 
369-371. In addition increased populations of both E Coli and B Fragilis have 
been demonstrated in Crohn’s disease 372 and particularly bacteroides 
have been shown to induce colitis in HLA B27 transgenic mice 373. In this 
regard, increased bacterial contact in the ileum, caecum and rectum, 
due to relative stasis of food in these areas, may be significant, particularly 
in ileo-colonic Crohn’s disease. Analyses of faecal flora shows that enteral 
nutrition (fibre free) results in an increase in total aerobes in the gut flora in 
humans 374. Thus it may be that enteral nutrition is effective in off setting this 
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balance therefore making it effective in ileo-colonic Crohn’s disease. It is 
also possible that differing genetic mechanisms may be operable in 
colonic disease responsible for the differential response. This is a 
speculation and remains unproven to date. 
Last, a child developed refeeding syndrome at commencement of enteral 
feeding. Refeeding syndrome may develop on feeding malnourished 
children and is defined as “the occurrence of severe fluid and electrolyte 
shifts (especially, but not exclusively, of phosphate) and their associated 
complications in malnourished patients undergoing enteral / parenteral 
refeeding” 375. Marik defined refeeding syndrome as a fall in phosphate 
levels by more than 0.16 mmol/l, to below 0.65 mmol/l 376. Refeeding 
syndrome is not uncommon and severe hypophosphataemia (< 0.35 
mmol/l) has been reported in 0.8% of all hospitalised adult patients 377. 
Starvation for as little as 48 hours may predispose to refeeding syndrome, 
with a low serum pre-albumin level (<110 g/l) predicting 
hypophosphataemia 376. Marik showed that 81% (17/21) of patients 
developing refeeding syndrome had a pre-albumin level of less than 110 
g/l; yet similar levels were also found in 30% of patients who did not 
develop refeeding syndrome. Not all malnourished patients without 
mineral supplementation develop the classic electrolyte and fluid shifts, or 
their consequences, during refeeding 375. The reasons for this are not clear. 
The child who developed refeeding syndrome had dramatic weight loss, 
although not unusual per se at first presentation, which, had occurred over 
a matter of weeks, and not months. As a result of this severe disease, 
nutritional stores had been depleted more rapidly than normal. The 
constellation of active inflammation, malabsorption and profound 
anorexia thus led to this episode of refeeding syndrome during 
conventional treatment with enteral nutrition. She had a persistent 
tachycardia during the early stages of her refeeding. While this may partly 
have been due to active inflammation and/or bacteraemia, several other 
factors may have contributed. The patient may have mounted a 
compensatory tachycardia in view of early fluid overload, and this may 
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have been exacerbated by her low serum albumin. Despite this fluid 
overload, clinical oedema was not documented. Significant 
hypophosphataemia may also have had a direct effect on cardiac 
contractility and output, although a normal cardiac echo was performed 
after the diagnosis was made. There have been very few reports of 
children with refeeding syndrome, and no reports of it occurring during the 
management of Crohn’s disease with enteral nutrition. This case highlights 
the need for continued caution especially whilst using enteral nutrition in 
malnourished children. This instance of refeeding syndrome is very unlikely 
to be related to the type of formula or directly related to underlying 
Crohn’s disease. 
In summary, this pilot study demonstrates that ACD004 is not only effective 
in treatment of active paediatric Crohn’s disease but is comparable to its 
predecessor enteral feed CT3211 (Remission rates: 78.6% vs. 79%).
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Chapter 3. Randomised controlled trial for 
use of supplemental enteral nutrition to 
maintain remission – Phase B 
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3.1    Background 
 
There is a constant search for an ideal maintenance agent in paediatric 
Crohn’s disease; one which is effective and has the least side effect profile. 
Enteral nutrition is a recommended standard first line treatment for acute 
active paediatric Crohn’s disease in many centres across the world. It is 
only logical that, with its excellent safety profile, paediatric 
gastroenterologists have considered it for maintenance treatment as well. 
Therefore, despite little evidence, paediatric gastroenterologists have also 
advised patients to use enteral feeds as a regular supplement alongside 
with their food intake in the hope this will help maintain remission. 
Retrospective studies 26 suggest a possible beneficial role of supplemental 
enteral nutrition, however to date there are no prospective studies. As a 
result this prospective trial was designed, looking at use of enteral 
supplementation for maintenance of remission in children with Crohn’s 
disease.  This is the phase B of the study. 
 
3.2    Aims 
 
The primary objective of this study is to assess reduction in relapse rate in 
Crohn's disease in children on long-term continuous enteral nutrition 
supplementation using it as part of their total daily requirements compared 
to a control unsupplemented group, over a period of 104 weeks (2 years). 
 
3.3    Methods 
 
All subjects recruited in phase A (newly diagnosed Crohn’s disease or 
relapsed subjects) were treated for an 8-week period of exclusive enteral 
nutrition (chapter 2, see table 2.2.1 for feed composition). Those failing to 
respond to treatment, deteriorating or relapsing at any stage dropped out 
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of the study at that point and were counted as a relapse. All analyses 
were done on intention to treat basis. 
Children in remission at eight weeks (end of phase A, chapter 2) entered a 
4 to 6 week food reintroduction phase. Food items were re-introduced at 
the rate of one food item every two days over a period of 4 to 6 weeks 
(See sub-section 2.7.5).  During this transition period the enteral feeds were 
reduced to 30% of the children’s recommended daily allowance under 
guidance by the dieticians. All subjects in full remission (defined by PCDAI 
< 20) at completion of food re-introduction were enrolled in Phase B, which 
marked the start of the randomized controlled trial. 
Once subjects reduced their enteral feeds to 30% of the daily requirement 
allowance (500-750 mls/day), they were randomized into two groups 
highlighting start of Phase B, the randomised controlled trial. One group 
continued to supplement their diet with 30% of recommended daily 
allowance with the enteral feed while the other group continued 
decreasing the oral enteral feed until a full ad libitum diet was taken.  Their 
enteral nutrition was then stopped and a normal diet continued. The 
summary of these two groups is given as follows (see study design flow 
chart - figure 3.3.1): 
 
Group 1: Full diet supplemented with about 30% of total daily requirement 
of the enteral feed (500-750 mls/day) to start at the beginning of Week 13-
15 (end of food reintroduction) to Week 112-114 (2 years). 
Group 2: This is the un-supplemented group. Normal diet to start at the 
beginning of Week 13-15 (end of food reintroduction) to Week 112-114. 
 
The phase B was planned to be a multi-centre study involving 6 paediatric 
gastroenterology units (3 centres from UK, and 1 each from France, 
Netherlands and Switzerland). This was to be carried over a 2 year period 
till adequate numbers were recruited to meet the desired power of the 
study (n=72) determined at priori. 
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Children are followed 4 monthly after recruitment into phase B. Families 
were given access to the investigators phones so that an earlier 
appointment could be made if necessary eg; developing symptoms of 
Crohn’s disease or discuss any dietary issues. On each visit the children had 
a clinical assessment which included a history of symptoms, a clinical 
examination and blood tests. Following this, children had a PCDAI score, 
and were asked to complete the quality of life questionnaire. The study 
design flow chart is given in table 3.3.1and the flow chart for clinical 
assessments and investigations is given in table 3.3.1. 
All children filled a consecutive 3 days food diary for dietary assessment by 
the dietician at month 2 of recruitment into phase B. This involved 
documentation of all fluids and food taken by the child over three days. 
This information was completed on forms given to parents by the dietician 
and then posted or dropped by the parents to the hospital. The 
information was then fed into a software programme (Caveat V 5.0) for 
calorific as well as macro- and micro-nutrient assessment. The purpose is to 
check intake of children participating in the study. This was completed by 
children participating in both arms of the study, the supplemented as well 
as the non-supplemented groups. The supplemented groups took dietary 
supplements (ACD004) orally (nasogastric tubes were not used in phase B). 
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Figure 3.3.1    Study design flow chart 
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PHASE B (randomized controlled study) 
  
 
0 month 
 
2 
months 
 
4 
months 
 
 
8 
months 
 
12 months 
 
16 
months 
 
 
20 
months 
 
 
24 
months 
Randomisation X        
         
Hb X  X X X X X X 
Hct  X  X X X X X X 
Platelet count X  X X X X X X 
ESR X  X X X X X X 
CRP X  X X X X X X 
Albumin X  X X X X X X 
Urea X  X X X X X X 
         
Height (cm) X  X X X X X X 
Weight (kg) X  X X X X X X 
         
PCDAI X  X X X X X X 
Quality of Life X  X X X X X X 
         
Dietetic 
Assessment 
  X X X X X X 
Weighed food 
intake 
 X       
 
Table 3.3.1 Flow chart for clinical assessment and investigations at 4 monthly follow up from the time of 
recruitment.
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3.4    Randomisation and Statistics 
 
3.4.1    Randomisation sequence generation and randomisation allocation 
concealment & randomisation implementation 
 
A computer programme was used to produce the randomization list 
based on computer-generated sequence of random numbers. This person 
was blinded to the details of the study. The list was transferred to a 
sequence of sealed envelopes each containing the name of the next 
treatment on a card. The person placing the cards in the envelope was 
also blinded and unaware of details of this particular study. This was 
conducted in Nestle, Switzerland. The envelopes were delivered by the 
Nestle study monitor to me in London. At recruitment, I opened the next 
envelope in the sequence and assigned treatment. 
 
 
3.4.2    Blinding (masking) 
 
This is a dietary intervention study. Due to its nature it was not possible to 
blind the investigators or the patients regarding supplementation. 
 
 
3.4.3    Power calculation 
 
Since no equivalent long-term follow study of nutritional intervention in 
Crohn’s disease has been performed, historical relapse data was used by 
the investigators for power calculation.  The estimate of the proportion of 
subjects who relapse without nutritional supplement is 0.65 and 0.40 for 
those on supplement 26. The number of subjects needed in a one 
proportion power analysis (alpha = 5%, power = 90%) was 36 per group. 
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3.4.4 Description of statistics analyses 
 
All analyses were done on an intention to treat basis. Statistical software, 
SPSS v 11.01 was used for all statistical tests. The data was rechecked with 
SPSS v 16.0.0 for the repeat submission after the MD thesis examination 
interview (viva). 
All power calculations were done by statisticians based at Nestec, 
Luassane. Statistcal analyses were carried out by me as guided by Dr 
Corrine Hager (statistician in Nestec) and Dr Richard Morris, Reader in 
Medical Statistics and Epidemiology, based at University College of 
London. 
Databases were maintained in Microsoft® Excel 2000 and 2003 and SPSS v 
11.0.0 and 16.0.0. All statistical analyses were performed in SPSS v 11.0.0, 
Standard Version. Normally distributed continuous data has been 
described using mean and standard deviation whereas non-normally 
distributed continuous data as median (range or interquartile range-IQR). 
All categorical results are a number (%). ‘t test’ and ‘ANOVA’ were used to 
assess parametric data; ‘Kruskall Wallis’ and ‘Wilcoxon Rank’ test to 
analyse non parametric data. The relapse time was graphically 
demonstrated using Kaplan Meier Survival Curves. Regression analysis was 
used to assess factors predicting relapse. 
Significance was defined as p < 0.05. 
 
 
3.5    Funding, study site/dates and ethics 
 
3.5.1  Funding sources 
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The phase B (as phase A) was funded by Nestle, Switzerland. However, no 
further moneys were provided to continue the study, once phase A (n=42) 
was completed through to phase B (see details in the results section – 
subsection 3.6). Continuation of the trial with expansion of phase B 
involving multicentre recruitment depended upon approval of further 
moneys by Nestle, Switzerland. 
 
 
3.5.2  Dates and site of the study 
 
The study for Phase B was conducted between, March 2000 to September 
2002. 
The study was carried out at Royal Free and Chelsea Westminster Hospitals, 
London. I managed all appointments at the two centres and conducted 
these studies in person. 
 
 
3.5.3  Data collection 
 
Data was collected in CRFs (case report forms provided by Nestle). The 
data was cross checked by the supervisor, in relation to clinical notes and 
laboratory results on the computer systems. Carbon copies of these 
records were retrived after cross checking. I retained the original CRFs in 
the hospital and transferred information to patient secured database to 
Excel and SPSS for analyses. 
 
 
3.5.4  Ethics 
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Patient information sheet and patient consent forms given in appendix A 
and B, were devised using previously described guidelines used in the 
hospital. These along with the complete study protocol, were reviewed 
and approved by the ethical committee. The phase A and B studies were 
approved by the local research ethics and research committees (LREC) of 
the Royal Free and Chelsea and Westminster hospitals. 
 
 
3.6   Results (see figure 3.6.2) 
 
3.6.1    Phase A 
 
See chapter 2 for details. In summary at completion of 8 weeks of enteral 
nutrition treatment, 33/42 children were in remission (78.6%) 
  
 
3.6.2    Food re-introduction 
 
Food re-introduction has been discussed in section 2.7.5 in detail. To re-
summarize, all 33 children in remission at completion of phase A entered 
the food re-introduction phase. 8 children dropped out of the study during 
this phase. In the drop-out group, 5 children had ileocolonic, 2 ileal and 1 
colonic Crohn’s disease. 
 
 
3.6.3    Phase B (Randomised controlled study of supplemental enteral 
nutrition) 
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3.6.3.1    Demographics 
 
25 children proceeded on to be recruited in phase B of the study 
(randomized controlled supplemental study). Unfortunately, this RCT came 
to a premature end due to withdrawal of funding and failed to progress 
into a multi-centre trial. 34.7% of the study power was achieved (25/72). 
Of the total 25 children recruited in phase B, 2 had ileal disease, 20 
ileocolonic and 3 colonic disease. 15/25 (60%) were males. 
 
 
3.6.3.2    Comparison of the supplemented with unsupplemented group 
 
The process of randomization has been previously described in the statistics 
section. There were 12 children in the supplemented and 13 in the 
unsupplemented group with no baseline differences between the two 
groups (age, Wt SDS, CRP, ESR, albumin, puberty, disease phenotype, sex 
and PCDAI). See table 3.6.1.  
The supplemented group received 30% of their recommended daily 
allowance as a daily supplement of enteral feed. 
 
 
3.6.3.3    Phase B results 
 
At 6 months into phase B, 12 had relapsed which accounts for 48% of the 
group. 6 of them received supplemental nutrition and the other 6 were 
non-supplemented. One girl had a right hemicolectomy for stenosing ileal 
disease. A further 6 relapsed by one year (remaining 7); and at completion 
of the 2 year study 6/25 (24%) were in remission. 4 of these children were 
originally randomized to be supplemented and 2 non-supplemented. One 
teenage girl admitted patchy compliance with the supplement as she was 
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self conscious of her image and was keen to remain slim. 2 of them had 
colonic inflammation and 4 ileocolonic disease. 
 
There was no significant difference in the remission period between the 
supplemented and non-supplemented groups (Supplemented (median 
0.5 yrs, IQR 0.27–2 yrs) vs. non-supplemented (median 0.67 years, IQR 0.17-
0.92 yrs) p = ns, MWU test (p=0.650). See figure and table 3.6.1. 
 
A six centre meeting was held one year after commencement of Phase B 
at the two UK centres. Although plans were made for continuation of the 
study, funding was withdrawn by the company at the last moment which 
resulted in collapse of the randomised controlled trial. The 6 centre 
recruitment failed and I continued to monitor the original recruitees 
through to completion of their phase B. 
The local research and ethics committee were informed re: collapse of 
trial. The subjects were informed verbally but not in writing. 
 
 
3.6.4    Differences in food intake between the supplemented and non- 
supplemented groups 
 
10 children (5 supplemented and 5 non-supplemented) completed a 
three day food diary under supervision of the dieticians; the information 
was processed using software, Caveat v 5. This assessment took place at 
month 2 into phase B (see flow chart – table 3.3.1). 15 children failed to 
complete the food intake diary. 7/15 relapsed during the 2-3 month period 
and dropped out of the study. A total of 8 children/families (4 from the 
supplemented arm and the other 4 from the non-supplemented arm) 
failed to hand in the forms despite several reminders. 
No difference was found in the calorific (total calories/kg), macro 
(carbohydrates, protein and fats) and micro-nutrient (calcium, iron, zinc, 
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phosphate, selenium, folate, thiamine, riboflavin, vitamin B6 and nicotinic 
acid) intake of the two groups (WR, p=ns). 
 
 
3.6.5    Predictors of relapse 
 
On univariate regaression analysis of children in phase B high PCDAI at first 
presentation was found to be predictive of early relapse (r = 0.416, p = 
0.039). However no variables were found to be significant on multivariate 
regression analysis (p=ns). The other plotted factors alongside PCDAI were 
supplement status, age at presentation, sex, disease phenotype, weight 
SDS, PCDAI, Albumin, ESR and CRP at presentation.  
Interestingly, only one child relapsed between year 1 (n=7 in remission) and 
year 2 (n=6 in remission). 
 
 
3.6.6    Adverse events 
 
No adverse events were reported in this RCT.
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Figure 3.6.1    Kaplain Meier Survival curve reflecting maintenance of remission in the 
supplemented and non supplemented sub-groups, for the full duration of the study 
(2.23 years).  
 
There was no difference in duration of remission achieved in between the two 
groups (Mann Whitney U test, p=ns) 
   
 
 
 
 
 
 
 
 
 
 
 
 
0 1 2 3 
0 
25 
50 
75 
100 
125 
Non Supp 
Supp 
Duration of Remission (years) 
Percent of patients 
                                                        
 
 
159
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.2    Flowchart for the randomised controlled study of supplemental 
enteral nutrition (Phase B) 
 
Phase A (n=42) 
33 in remission at end of Rx at Wk 8 
Early relapses during food reintroduction (n = 8) 
Patients entering RCT ‘Phase B’ (n=25) 
 
ENROLLMENT 
Randomised blindly by computer generated 
envelopes into supplemented and non-
supplemented groups 
Excluded n=0 
Not meeting inclusion criteria = 0 
Refused to participate = 0 
 
SUPPLEMENTED 
Allocation to intervention (n=12) 
Received allocated intervention (n=12) 
Did not receive allocated intervention (n=0) 
NON SUPPLEMENTED 
Allocation to intervention (n=13) 
Received allocated intervention (n=13) 
Did not receive allocated intervention (n=0) 
ALLOCATION 
FOLLOW UP 
Lost to follow up = 0 
 
6 relapsed at 6 months (6 remaining) 
2 relapsed in between 6-12m (4 remaining) 
4 in remission at end of 2 years 
 
Lost to follow up = 0 
 
6 relapsed at 6 months (7 remaining) 
4 relapsed in between 6-12m (3 remaining) 
Another 1 relapsed at 13m 
2 in remission at end of 2 years 
 
ANALYSIS 
This study came to a premature end and 
did not achieve power of the study of 36 
in each group. This was due to funding 
withdrawal by the sponsoring company 
 
Analysed (n=12) 
 
Excluded from analysis (n=0) 
 
Analysed (n=13) 
 
Excluded from analysis (n=0) 
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 Supplemented Non-supplemented Test p 
 
Demographics 
    
n 12 13   
Sex (males) 7 8 MWU 0.894 
PCDAI 5 (0-7.5) 10 (1.25-10) MWU 0.207 
WAZ -0.48 (-1.4-0.36) -0.89 (-1.5–0.26) MWU 0.611 
Albumin 42 (38-44) 41 (34-45) MWU 0.797 
ESR 12.5 (7.3-19.3) 12.5 (6.5-34) MWU 0.912 
CRP 4 (2-9) 7 (1-21) MWU 0.365 
 
Outcome 
Remission at 
2 years (n) 
4 2 χ2 0.294 
Median time  
to relapse 
from enrolm. 
(IQR) 
0.5 years 
 
 
(0.27-2) 
0.67 years 
 
 
(0.17-0.92) 
MWU 0.650 
 
Table 3.6.1    A comparison of supplemented and non-supplemented groups 
 
 
3.7    Discussion 
 
Supplemental enteral nutrition is an attractive option as it is without 
side effects and is believed to maintain remission and promote 
growth an important issue in paediatric IBD management. Belli has 
demonstrated significant height and weight gain in a small 
prospective study of 8 children with growth failure. The elemental 
feed was administered for one month out of four via continuous 
nasogastric infusion at home 320. Aiges used a year long nocturnal 
supplemental nutrition via nasogastric tube, and demonstrated 
significant growth (weight and height) in 8 children who were 
feeding less than normal daily intake 321. Israel reported growth spurt 
in a group of 16 children receiving enteral nutrition via gastrostomy 
378. Cautious interpretation is needed, as these methods administer 
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much more than 1/3rd or 1/4th of total daily requirement, as aimed or 
described in this study. 
In this limited RCT, no difference has been demonstrated in the 
remission rates of the two groups (with or without supplementation). 
Previously, Wilschanski retrospectively reported a 43% relapse rate 
within 6 months of presentation after first treatment with exclusive 
enteral nutrition 26. 60% of them had relapsed by completion of 1 
year. In this study 32 children were in remission at end of Phase A. At 
end of food reintroduction 7 had early relapse and a further 12 in 
the first 6 months. This accounts for about 60% of the children 
relapsing within 6 months and more than 80% by year one; these 
results are not comparable to Wilschanski’s study. This may be due 
to biased randomisation in Wilchanski’s report, always a pitfall in 
retrospective studies.  
On the contrary, Hirakawa has reported a better remission prognosis 
in adults when treated with 30 Kcal/kg IBW/day of enteral feed at 
home 379. They achieved a remission rate of 94%, 63% and 63% after 
1, 2 and 4 years. This was significantly higher than adults not 
receiving any maintenance treatment who had a remission of 50%, 
33% and 0%. There is however a major reservations about this study. 
From all practical purposes daily use of 30 Kcal/kg is extremely hard. 
This regimen of nutrition usage continuously over 1-4 years is 
impractical and cumbersome; difficult for children to follow. In 
another study, Teahon reported a retrospective study on a cohort of 
113 adult patients (mean=32 years (1SD=15)) treated with elemental 
diet. 85% of the patients (n=96) achieved remission after 4 weeks 
(average figure, range 2-12 weeks) of acute treatment with an 
elemental feed, Vivonex®.  22% patients relapsed within 6 months of 
treatment with an annual relapse rate of 8-10%. Patients with 
disease complicated by fistula or perianal involvement had early 
relapse, approaching 100% for the latter 380. There is however, 
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considerable patient selection bias using enteral nutrition in this 
study. Most recently, in 2007 Akobeng has reported a Cochrane 
review of role of supplemental enteral nutrition for maintaing 
remission 322. The review includes two adult trials using enteral 
nutrition as a supplement positively supporting its role in maintaining 
remission. In one study 319, patients who received half of their total 
daily calorie requirements as elemental diet and the remaining half 
by normal diet had a significantly lower relapse rate compared to 
patients who received unrestricted normal diet (9 of 26 versus 16 of 
25; OR 0.3, 95% CI 0.09 to 0.94). In the other study 318, elemental and 
polymeric feeds (providing between 35 and 50% of patients' pretrial 
calorie intake in addition to unrestricted normal food) were equally 
effective for maintenance of remission and allowing withdrawal of 
steroid therapy (8 of 19 versus 6 of 14; OR 0.97, 95% CI 0.24 to 3.92). 
 
A review of the long term follow up reveals interesting information. 
Children doing well at the end of 1st year of diagnosis, regardless of 
receiving/not receiving supplemental nutrition; seem to do well by 2 
years as well. In this study 7/42 (16.7%) were in remission by end of 
year 1 and only 1 relapsed between years 1 and 2; 6/42 children 
(14.3%) in remission at end of second year. Early relapse is predicted 
by high PCDAI at first presentation. Children with mild disease 
(defined by PCDAI) seem to fare better. 
The mechanism, by which supplemental enteral nutrition may work, 
if it were to work, is unclear. Johnson 296 has recently reported a 
prospective randomized controlled trial of using partial enteral 
nutrition (enteral nutrition + diet) compared to sole enteral nutrition 
in children with active acute Crohn’s disease. Although by principle 
this study is different from the idea of using supplemental enteral 
nutrition, some features of it are certainly relevant to the discussion 
here. First the response to enteral feeds is much worse than 
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previously reported literature. Based on intention to treat analysis, 
remission (PCDAI <10) was achieved in only 15% (4/26) of the partial 
enteral nutrition group compared with 42% (10/24) of the total 
enteral nutrition group (p = 0.035). Withdrawal from the allocated 
treatment before completion of the intended six week period was 
necessary in 10/26 (39%) in the partial enteral nutrition group and 
8/24 (33%) in the total nutrition group. Importantly, there is no 
mention of compliance in this study. Poor compliance always results 
in failure of enteral nutrition; a common problem encountered in its 
usage in the adult population (chapter 1.6). Despite these faults 
partial enteral nutrition does not seem to work as well as total 
enteral nutrition, to achieve remission in children with active Crohn’s 
disease. Applying the same argument to supplemental nutrition, if a 
child on supplemental enteral nutrition were to have a relapse, it 
perhaps will fail to treat it. 
 
In view of the currently available data, there seems to be little 
evidence to support a case in favour of supplemental enteral 
nutrition being an effective treatment; a larger study may be 
needed to answer the question. In light of availability of a wide 
range of immunosuppressants and monoclonal antibodies, some 
would recommend use of 6MP or azathioprine early at disease 
onset. Markowitz has demonstrated a lower remission rate at 18 
month follow up using 6MP as maintenance treatment when 
compared to placebo in a multicentre placebo controlled 
prospective study of 55 children 232. It is however, hard to justify a 
blanket use of immunosuppressants particularly in children who may 
not need it. In view that severe disease (high PCDAI) at presentation 
predicts early relapse, it may be that immunosuppressants should be 
considered in this group of children. The “step-up vs top-down” 
study, by D’Haens and colleagues 381 suggests that introducing the 
                                                        
 
 
164
most efficacious IBD drugs early in disease course has a significant 
impact on outcome in adults with Crohn’s disease. This randomized 
study compared the conventional therapeutic approach (“step-
up”) with a newer, more aggressive strategy (“top-down”). In the 
“step-up group” patients were treated first with steroids and, in case 
of steroid dependency or resistance, immunosuppressants and 
infliximab were used. In the “top-down group” patients received 
upfront a combined treatment of immunossupressants and 
infliximab. This study demonstrate the superiority of the “top-down” 
over the “step-up” approach, as demonstrated by a significantly 
higher proportion of patients in remission and showing MH in the 
“top-down”, as compared to the “step-up” group. Markowitz 232 
reported in children on 6-MP group (compared to 
immunosuppressive maintenance treatment), the duration of steroid 
use on first relapse was shorter (observed-to-expected ratio of days 
with prednisone of 0.73 versus 1.34 in the control group, P < 0.001). 
Kugathasan 215 has suggested early use of Infliximab in children with 
Crohn’s disease. Further studies are needed regarding these options. 
Such decisions are not easy as one always has to weigh the side 
effects of these treatments. Please see discussion on side effects of 
monoclonal anitbodes such as T cell lymphoma in section 1.5.1.4. 
This RCT came to a premature end due to withdrawal of funding 
and failure to progress into a six centre multi-centre trial. The total 
recruited number for the study is under-powered (34.7% 
recruitment). The study was originally funded for a period of two 
years, with a verbal promise of extending it to a 6 centre study in 
future; the money accounted for payment was for the project, a 
research fellow (myself selected in an interview, following 
advertisement of the post in the BMJ) and the overhead university 
fees (100%). Research contract income (overhead university fees) is 
important in all drug company funded trials 382. If a university 
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researcher seeks financial support for research from industry (for 
example a pharmaceutical company), the university requires that 
the industry source pays them an additional overhead charge, 
which ranges from 50 to 150% of the research support. Income from 
industry is classed as research contract income, and universities are 
penalised if they fail fully to recover research contract overhead 
money. 
The two year project involved a phase A of the study which was use 
of ACD004 a new enteral feed, the recruitment to continue with 
launching of phase B as each child finished phase A. This was to 
develop into a multicentre study after two years with recruitment by 
centres in Europe. As the payment for the two years had been 
made, the ethics committee accepted this proposal. In hindsight it 
was an error and a full contract down to the last detail and penny 
should have been negotiated and agreed before commencement 
of study. The initial agreement also involved recruitment of a 
research fellow for a period of two years. Though it was agreed that 
a further research fellow will be recruited, if necessary, this never 
happened. 
Research sponsored by pharmaceutical companies may be fraught 
with problems. People may have differing agendas and the control 
group selection may be poor. Moreover, there is little doubt that 
long term studies are difficult to conduct and maintain. It needs 
continued motivation of the investor and the investee. Personnel in 
either group may change after a year or two; the new personnel 
may not be as interested in the project. In the study described in this 
thesis, Professor John Walker-Smith retired after a year of starting the 
project. He was the principal investigator in this project and had 
negotiated the original funding. In addition it is also likely to be 
related to the company’s disappointment in finding the results 
comparable to Modulen IBD ®, the already used feed. ACD004 did 
                                                        
 
 
166
not prove to be vastly superior (comparing remission 
percents/numbers) feed. In addition, there were problems in 
manufacture and supply of the product closer to the end of the 
study. I suspect the company did not wish to invest further in this and 
pulled out at the earliest opportunity. 
 
There are several lessons to be learnt from this study. Randomized 
controlled trials should not be over-ambitious, be realistic, involve a 
strict legal contract and binding for both the investor and the 
investee encompassed in a well defined time frame. Any deviation 
should be penalised. The current research governance practice has 
changed and it would have strengthened this study if input had 
been made at the start. Recently the Department of Health 
(England) has commissioned a research network on medicines for 
children. This is based at University of Liverpool in partnership with 
Alder Hey children’s hospital. The collaborators include Imperial 
College, London, the Liverpool Women’s Hospital, the National 
Perinatal Epidemiology Unit at the University of Oxford and the 
National Children’s Bureau. The aims of this network are to facilitate 
the conduct of randomized controlled trials and other well designed 
studies of medicines for children including those for prevention, 
diagnosis and treatment. This should enable to maintain uniform 
quality in paediatric medical trials and particularly foresee and 
prevent mishaps like these. The ACD004 study was well designed 
and uniform quality not being an issue in this case, but may be drug 
companies would be perhaps less likely to pull out of studies, as they 
will have a strict binding and the worry of developing bad publicity 
when a central organisation is involved. Another advantage is that 
these organisations can contribution towards the trial costs as well. 
In summary, this was the first ever randomized controlled on use of 
supplemental enteral nutrition in paediatric Crohn’s disease and 
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despite its early end, it illustrates some important management 
points. Children with mild disease sustain a longer remission; this has 
not been shown before. Children well (in remission) at the end of the 
first year are likely to continue doing so at end of second year. 
Further studies are required to assess benefits of treating the severe 
disease group early with immunosuppressants such as azathioprine. 
Though limited recruitment, this prospective study fails to duplicate 
the results of Wilschanski’s biased retrospective study. Also, contrary 
to common belief, enteral feed supplementation does not increase 
the calorific intake, macro or micro nutrient intake of the child.
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Chapter 4. Prospective assessment of 
quality of life (QOL) in children with 
Crohn’s disease after treatment with 
exclusive enteral nutrition 
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4.1   Introduction 
 
Over the last decade, increasing emphasis has been placed on 
formal documentation of improvement in quality of life during and 
after any medical intervention. Quality of life is a complex term 
referred to as ‘the perception of life with respect to physical, social 
and psychological functioning’ 350 (chapter 1.7). Crohn’s disease is 
characterised by gastrointestinal symptoms, malnutrition & anorexia, 
growth and pubertal delay, and the adverse effects of treatments 
such as corticosteroids and surgery. These factors result in low mood 
and stress, which in turn affects physical, social and psychological 
functioning ultimately resulting in a poor quality of life 383-385 (chapter 
1.4 & 1.7). 
 
IMPACT II is a recently validated questionnaire used in assessment of 
quality of life in children with Crohn’s disease; discussed in chapter 
1.7 25,350. Cross sectional studies show association of active Crohn’s 
disease with a poor quality of life 19. However it remains 
undocumented and unproven whether an individual’s successful 
treatment with exclusive enteral nutrition will result in an improved 
quality of life. Despite the often excellent compliance as 
demonstrated in chapter 2 (subsection - 2.7.4.1) 24,305, enteral 
nutrition is historically considered difficult to administer and use; 
thought by many to adversely effect quality of life in children. We 
undertook this prospective study to document changes in quality of 
life for children with active Crohn’s disease, and assess if they were 
associated with mucosal healing after treatment with exclusive 
enteral nutrition. 
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4.2    Aims 
 
This study addresses the secondary aim of the phase A and B 
studies, which is to assess quality of life in children using ACD004. 
 
4.3    Methods 
 
4.3.1 Description and use of IMPACT II questionnaire 
 
I consecutively enrolled children (age 8-17 years) over a period of 2 
years. Children recruited in this study are a selection from the cohort 
described in chapter 2 (Table 4.7.1.1 shows all the children in the 
ACD004 study with the last column, highlighting the cases able to 
participate in this study. Selection was made on ability of the 
children to self-complete the IMPACT II, quality of life questionnaire 
without any parental assistance. This was to avoid 
advertant/inadvertant parental transference and bias introduced 
by their help.  
At enrolment, children completed the IMPACT II questionnaire 
following standard instructions 25,350. Details of the quality of life 
instruments with history and evolution of IMPACT II questionnaires is 
detailed in sub-chapter 1.7. To recap, the IMPACT questionnaire, 
originally devised and validated in Canada was modified for use in 
the UK.  It consists of 35 questions answered using a 7 cm visual 
analogue scale. These questions are organised into six domains: IBD 
symptoms, systemic symptoms, emotional functioning, social 
functioning, body image and feelings towards treatments and 
interventions. The total score can be converted linearly to range 
from 0-100, with higher scores representing a better quality of life. 
The questionnaire takes 5-10 minutes to complete. In this study all 
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questions were completed in the outpatient department by children 
without help from either parents or the investigator. Children unable 
to understand the questions or scoring system were excluded from 
the study. 
The IMPACT II questionnaire was used for assessment of quality of life 
in this thesis. Details of the questionnaire have been discussed in sub-
chapter 1.7.8. The quality of life concepts and background are 
detailed in chapter 1.7. 
 
In the prospective quality of life study in this thesis, the questionnaire 
was filled in by the children, in the presence of the same investigator 
(Dr N Afzal). This was to ensure that the patients’ feelings were 
represented accurately. If the child could not understand a 
question, they were encouraged to ask the interpretation from 
myself but not their parents. This was because at the start of study, 
when younger children asked their parents for assistance, 
transference of parents’ feelings and answers was obvious resulting 
in a biased answer.  
Children unable to understand the questionnaire or the scoring 
system at all, despite repeated explanations, were excluded to 
avoid bias (from the person explaining the questions) in the study.  
At completion of phase A as children progressed through the food 
reintroduction phase into phase B they continued to have their 
quality of life assessment (See flow chart for investigations and 
quality of life – figure 2.4.1.2).  Exclusion from the study also marked 
the end of ‘quality of life assessment’ part of the study. 
 
4.3.2 Clinical and mucosal disease scoring 
 
As already described in chapter 4, ACD004 was used for a period of 
8 weeks. Endoscopic investigations, quality of life assessment and 
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PCDAI scoring at recruitment were repeated at week 8. Remission 
was defined as a fall in PCDAI to less than 20. The inclusion and 
exclusion criteria for this study are the same as stated in table 2.4.1.2 
with addition of another essential criterion, regarding children ability 
to fill the form themselves. As mentioned, those unable to self 
complete the IMPACT II questionnaire, were excluded from this 
particular study. 
The terminal ileum and each segment of the colon received an 
endoscopic and histologic score ranging from 0-3 as previously 
described 355 – see Table 2.4.4.1 and sections 2.4.3 and 2.4.4 for 
detailed description. The discussion for using the system is detailed in 
section 2.8. The biopsies were scored in a blinded fashion by a 
histopathologist familiar with paediatric gastrointestinal diseases. The 
worst endoscopic and histological score from each ileocolonoscopy 
was then recorded and used to calculate means for comparison of 
pre- and post-treatment values. 
 
 
4.5 Statistics 
 
4.5.1    Description of statistics analyses 
 
Statistical software, SPSS v 11.01 was used for all statistical tests. The 
data was rechecked with SPSS v 16.0.0 for the repeat submission 
after the MD thesis examination interview (viva). 
The quality of life scores (inclusive of individual domains scores) were 
calculated by Dr. Hester Loonen, who designed the original IMPACT 
II. Further statistical analyses were carried out by as guided by Dr 
Loonen and Dr Richard Morris, Reader in Medical Statistics and 
Epidemiology, based at University College of London. 
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Databases were maintained in Microsoft® Excel 2000 and 2003 and 
SPSS v 11.0.0 and 16.0.0. All statistical analyses were performed in 
SPSS v 11.0.0, Standard Version. Normally distributed continuous data 
has been described using mean and standard deviation whereas 
non-normally distributed continuous data as median (range or 
interquartile range-IQR). All categorical results are a number (%). ‘t 
test’ and ‘ANOVA’ were used to assess parametric data; ‘Kruskall 
Wallis’ and ‘Wilcoxon Rank’ test to analyse non parametric data. 
Median and interquartile ranges were used for non-parametric 
data. 
Significance was defined as p < 0.05. 
 
 
4.6    Funding, study site/dates and ethics 
 
4.6.1  Funding sources, data collection, ethics and dates/site of 
study 
 
The funding sources, data collection/recording and ethics have 
been described in chapters 2 and 3. The dates are the same as for 
phase A and B of the study (March 2000 to September 2002). 
 
 
4.7     Results 
 
4.7.1     Demographics 
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42 children were recruited in the pilot study (described in chapter 2). 
Of the 42, 26 children were recruited in the QOL part of the study 
(62% recruitment from the pilot study cohort). The analyses in this 
study are based on results from these 26 children and therefore 
disease assessment figures (for disease remission and deomgraphics) 
given here differ from those in chapter 2 (where analyses is based 
on 42 children).   
 
Regarding details of the 16 dropouts, 2/16 children did not wish to 
take part in the QOL study. 3/16 children in the excluded group, 
although able to complete the IMPACT questionnaire, had 
additional treatment due to worsening of disease and were 
therefore excluded. The remainder 11 were unable to complete the 
IMPACT questionnaire on their own, with median age being 
significantly lower for those who couldn’t complete it (median = 10.6 
years) when compared to the recruited group (median 14.02 
years)(p < 0.01).  
 
See table 4.6.1.1 for demographic details of subjects from the main 
study included in the quality of life study (tickbox in column 5). 
 
16 males (67%) and 10 females were recruited in this study. Eight 
children (30.8%) were pre-pubertal, 5 (19.2%) in early puberty 
(Tanner stage 2-3) and 13 (50%) in late puberty (Tanner stage 4-5). 
The majority of children had ileocolonic disease (n=20) and of the 
remaining, 2 had only ileal, and 4 only colonic involvement. 21/26 
(81%) children had moderate to severe disease (PCDAI > 30). 
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Serial DOB Sex 
Decimal age at 
presentation (yrs) 
QOL study 
enrolment 
SJ 01 3/7/89 m 10.866  
BK 02 26/9/86 f 13.644 ; 
MB 03 7/9/84 m 15.707  
LR 04 25/7/90 m 9.901 ; 
SM 05 17/10/86 m 13.879 ; 
CO 06 10/9/84 m 15.819 ; 
CO 07 17/12/85 m 14.660 ; 
PB 08 10/12/84 m 15.693 ; 
DT 09 1/9/86 f 13.986 ; 
AW 10 2/9/89 m 10.986 ; 
CM 11 22/9/86 m 13.934 ; 
AW 12 18/12/91 m 8.764  
SH 13 19/8/85 m 15.115 ; 
KC 14 11/3/86 f 14.597 ; 
LH 15 5/3/87 m 13.647 ; 
VS 16 9/3/92 f 8.655  
WS 17 26/12/90 m 9.890  
GD 18 29/4/90 f 10.592  
KH 19 28/1/85 f 15.890  
VR 20 31/1/87 f 13.934  
AE 21 23/10/90 m 10.211  
GK 22 2/2/88 m 12.948 ; 
PD 23 25/8/87 m 13.403 ; 
LS 24 28/1/85 f 15.997 ; 
AH 25 9/1/87 m 14.066 ; 
SO 26 4/7/88 m 12.581  
SN 27 22/3/91 f 9.871  
GL 28 23/12/86 f 14.173 ; 
JR 29 24/8/88 m 12.510 ; 
EE 30 24/1/89 m 12.110  
JW 31 10/1/89 f 12.178 ; 
DC 32 26/2/88 m 13.060 ; 
OS 33 7/12/85 m 15.359 ; 
MY 34 23/2/87 m 14.290  
SW 35 16/12/89 m 11.482 ; 
LH 36 2/4/86 f 15.225 ; 
RK 37 29/6/85 f 16.005 ; 
BH 38 5/1/86 m 15.518 ; 
BB 39 14/6/89 f 12.077  
PG 40 5/10/84 m 16.805 ; 
AE 41 22/02/90 m 11.970  
FS 42 18/12/87 m 14.112  
 
Table 4.7.1.1 Children were recruited in the quality of life study 
(marked ; in last column) on the basis of their ability to 
independently fill and complete the QOL questionnaires. The 
children recruited in this study were significantly older (p=0.008) with 
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a median age = 14.02 years (IQR – 13.02 – 15.4 yrs) compared to 
those excluded from the study (n = 16) – median age 12.07 years 
(IQR – 10.04 – 14.01). In the excluded sub-group, the median age of 
children who were excluded as they did not understand the QOL 
questionnaire (11/16) was significantly younger at 10.6 years. 
 
 
4.7.2    QOL in phase A during response to exclusive enteral nutrition 
 
All children received exclusive enteral nutrition for eight weeks. The 
feeds were well tolerated orally, with only 3 children needing 
overnight nasogastric feeds to meet their daily requirements. These 
children were taught to themselves pass the nasogastric tube, 
check its placement and administer feeds (with parental help) 
overnight via a pump 304.  
Of the total children who could complete the questionnaire enrolled 
in this study, 23/26 children (88.5%) achieved clinical remission 
(PCDAI < 20) after 8 weeks of treatment with exclusive enteral 
nutrition. Of the non-responders in the study, 1 had colonic, 1 
ileocolonic, and one severe ileocaecal disease. Additional 3 
patients who could also complete the questionnaire but dropped 
out of the study due to worsening of disease and commencement 
of additional treatment; 2 had ileocolonic and one ileal 
involvement.  
There was a significant fall in the PCDAI scores (Median = 35, IQR 25 
– 40.6) at completion of treatment (p<0.01). See table 4.7.2.1. 
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Table 4.7.2.1    Comparative scores before and after treatment with 
enteral nutrition 
A. Clinical parameters (Wt, PCDAI, CRP, ESR, Albumin) 
 
Parameter Pre 
Treatment 
Post 
Treatment 
Test P 
PCDAI 43.8(31.9-50.6) 7.5(0-10) WR <0.0001 
WAZ -1.3(-2 - -0.2) -0.98(-1.6 –0.21) WR <0.0001 
Albumin 32 (29-37.3) 41(37.3 - 43) WR <0.0001 
ESR  35 (14-61) 8 (2.5 – 19.8) WR <0.0001 
CRP 27(15.5 - 56) 1(0-8.3) WR <0.0001 
 
WAZ = weight for age Z scores 
 
 
B. the 6 individual domains comprising the IMPACT QOL questionnaire 
 
 Pre treatment Post treatment p (WR) 
IBD symptoms 0.49 (0.37 – 0.74) 0.79 (0.55 – 0.85) < 0.01 
Systemic symptoms 0.29 (0.13 – 0.49) 0.90 (0.63 – 0.98) < 0.01 
Emotional functioning 0.47 (0.35 – 0.68) 0.79 (0.53 – 0.87) < 0.01 
Social functioning 0.65 (0.53 – 0.84) 0.87 (0.74 – 0.92) < 0.01 
Body image 0.52 (0.30 – 0.84) 0.74 (0.58 – 0.91) < 0.01 
Treatment/ interventions 0.53 (0.22 – 0.74) 0.66 (0.41 – 0.87) 0.04 
Total QOL scores 0.58 (0.44 – 0.72) 0.81 (0.61 – 0.84) < 0.01 
 
Numericals in the table represent median quality of life scores (The figures in 
brackets represent IQR – interquartile range). Higher QOL scores represent 
better quality of life. 
WR = Wilcoxon Rank 
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Figure 4.7.2.1   Relationship of QOL (IMPACT II) with the PCDAI scores (x axis). 
There is a significant negative correlation between the two variables. (r=-0.67, 
p<0.05) 
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Figure 4.7.2.2. Change in total quality of life scores in each individual case 
before and after treatment with enteral nutrition. The two dotted lines 
represent two children one with the same quality of life score at completion 
of treatment and another showing considerable deterioriation in the QOL 
scores (see text section 4.7.3 for further details). Higher values represent better 
quality of life 
0
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4.7.3    Quality of life after 8 weeks of treatment 
 
There was an overall improvement in QOL scores of children with 
Crohn’s disease following treatment with exclusive enteral nutrition.  
Assessment of each of the six individual domains showed a 
significant improvement in all categories, including the domain 
“feelings towards treatments and interventions” (p=0.04). (See table 
4.7.2.1) 
One out of 26 showed deterioration in QOL. This child had isolated 
colonic disease and failed to achieve remission, eventually requiring 
bowel resection. Another child showed no change in QOL scores 
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before and after treatment, despite achieving a clinical and 
histological remission. Interestingly this patient underwent a small 
bowel resection 3 months later due to an ileal stricture. On the 
contrary, two children who failed to achieve a clinical remission, 
nonetheless showed an improvement in their quality of life after 
treatment.  
 
4.7.4    Quality of life in children requiring nasogastric feeding 
 
3/26 children (two girls and one boy) required nasogastric feeding 
to help them complete their 8 week course of enteral nutrition. 
Although the overall quality of life scores improved in all three of 
them, the individual domain scores for ‘feelings towards treatments 
and interventions’ deteriorated. 
  
4.7.5    Mucosal healing 
 
Endoscopic assessment of the terminal ileum (in 21/26 patients) and 
each colonic segment was carried out prospectively. Scoring was 
as previously reported, with the worst affected segment from each 
procedure being used for analysis, where 0=normal and 3=severe 
ulceration (see chapter 2, table 2.4.4.1 for scores and details in 
sections 2.4.3, 2.4.4 and 2.8). The median endoscopic score at 
diagnosis was 2 (IQR 2-3), and after treatment was 1 (IQR 0-1) 
(p<0.01).  
 
Similar to macroscopic healing, there was a significant improvement 
in the mean histology scores before and after treatment with enteral 
nutrition (pretreatment: 2 (IQR 1-3), posttreatment: 1 (IQR 1-1) (p < 
0.01). None of the 23 paired samples showed a histological 
deterioration after treatment. Six children showed no improvement 
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in histology, whilst the remaining 17 children had an improved score 
on blinded analysis. 
I performed regression analysis to determine if changes in QOL 
scores predicted degree of change in mucosal histology scores. 
Items (questions in the questionnaires) assessed in both the PCDAI 
and the IMPACT II questionnaire overlap and this is demonstrated by 
their close correlation (r=-0.67) before and after treatment (Figure 
4.3.1). Regression analysis failed to demonstrate a significant 
correlation between the change in IMPACT II score and histology 
scores (p=0.113). In addition there was no correlation between 
endoscopic improvement and change in either IMPACT II scores. 
Furthermore, none of the other predictors identified a priori as 
perhaps influencing mucosal healing were found to be statistically 
significant (data not shown). These included age at diagnosis, 
weight gain during treatment and change in ESR, CRP and albumin.  
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Figure 4.7.5 There is no correlation between change in quality of life 
and histology scores after treatment with enteral nutrition (r = 0.071, p = 
0.113) 
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4.7.6    Quality of life assessment at completion of Phase A and 
commencement of phase B, during the 4-5 weeks food 
reintroduction stage 
 
The food reintroduction took place over 4 weeks – see sections 2.8.5 
and 3.6.2 for a detailed description. During this period, children 
underwent a gradual food reintroduction programme. At end of 
phase ‘A’ all children were on a complete enteral nutrition diet. 
Of the total 26 children participating in the phase A QOL study, 9/26 
children from end of Phase A dropped out. 6 of the children 
completing questionnaires relapsed before reaching Phase B and 
therefore had dropped from the study (see exclusion criteria – table 
2.4.1.2). It was not possible to complete the questionnaire in the 
remaining 3, due to the strict rules of the author’s presence during 
completion of these questionnaires. These children dropped out of 
the quality of life study and did not participate any further in this part 
of the study. QOL life questionnaire was completed by 17 children at 
commencement of Phase B post food reintroduction phase. 
 
Although there was no change in the total quality of life scores at 
commencement of phase B, during the food reintroduction stage, 
significant improvement was seen in the social functioning domain 
and IBD symptoms. There was an insignificant change in the scores 
of the other domains. 
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 End of Phase A Start of Phase B p (WR) 
IBD symptoms 0.79 (0.55 – 0.85) 0.93 (0.81-0.96) 0.002 
Systemic symptoms 0.90 (0.63 – 0.98) 0.96 (0.87 - 0.98) 0.06 
Emotional functioning 0.79 (0.53 – 0.87) 0.85 (0.73 – 0.97) 0.06 
Social functioning 0.87 (0.74 – 0.92) 0.89 (0.81 – 0.93) 0.008 
Body image 0.74 (0.58 – 0.91) 0.72 (0.50 – 0.87) 0.683 
Treatment/ interventions 0.66 (0.41 – 0.87) 0.91 (0.72 – 0.95) 0.28 
Total QOL scores 0.81 (0.61 – 0.84) 0.89 (0.65 – 0.91) 0.084 
 
Table 4.7.6.1    Change in quality of life during food reintroduction phase.  
Higher scores mean better quality of life (values in medians and ranges in IQR) 
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Figure 4.7.6.1 Change in quality of life scores during food re- introduction 
(End of phase A to start of Phase B). Higher values represent better quality 
of life 
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4.7.7    Quality of life in Phase B of the study 
 
17 children had a quality of life assessment at the start of phase B 
(see section 4.7.6 and tables 4.7.6.1 & 4.7.7.1) following which were 
enrolled into randomised controlled trial (see details chapter 3).  
 
8/17 were randomised to receive supplemental enteral nutrition 
(ACD004 – see chapter 3) whereas 9/17 children did not receive a 
supplement. 
 
2 children each in the supplemented and non-supplemented group 
completed 2 years of the study in remission. The remaining 13/17 
children relapsed before completion of 2 years. The median time to 
relapse was 0.67 years (IQR 0.25 – 1.54 years). There was no 
significant difference (p = 0.696) in the time to relapse between the 
supplemented (median 0.33 years, IQR = 0.25 – 1.34) and non-
supplemented groups (median 0.67 years, IQR = 0.17 – 1.77). 
 
Despite only 4 children in remission at termination of phase B (13/17 
relapsing at end of study period), a comparison of quality of life 
scores shows no difference at completion of study (all children, 
including those in remission were included in this analysis). On 
comparison of individual quality of life domains deterioration is seen 
in the IBD and systemic systems QOL scores. However, there was 
neither an improvement nor deterioration in emotional functioning, 
social functioning, body image and attitudes towards to treatments 
and interventions.  
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 Start of Phase B End of Phase B p (WR) 
IBD symptoms 0.93 (0.81-0.96) 0.69 (0.51-0.95) 0.028 
Systemic symptoms 0.96 (0.87 - 0.98) 0.64 (0.26 - 0.94) 0.015 
Emotional functioning 0.85 (0.73 – 0.97) 0.64 (0.30 – 0.91) 0.161 
Social functioning 0.89 (0.81 – 0.93) 0.89 (0.81 – 0.93) 0.074 
Body image 0.72 (0.50 – 0.87) 0.78 (0.67 – 0.91) 0.813 
Treatment/ interventions 0.91 (0.72 – 0.95) 0.67 (0.51 – 0.83) 0.89 
Total QOL scores 0.89 (0.65 – 0.91) 0.80 (0.53 – 0.92) 0.09 
 
Table 4.7.7.1    Change in quality of life in Phase B follow up study. Higher 
values represent better quality of life. (values in medians and ranges in IQR)  
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Figure 4.7.7.1 Change in quality of life scores of children during phase B 
follow up study. Higher values represent better quality of life 
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4.7.8 Comparison of quality of life between supplemented and 
non-supplemented group 
 
There were no differences in the total quality of life scores or 
individual domain scores, between children receiving supplemental 
enteral nutrition and those not receiving any supplements at 
completion of phase B (p=ns). 
 
 
4.7.9  Comparing quality of life from start of disease to time of first 
relapse 
 
Finally, I have compared quality of life of children enrolled at start of 
phase A at the time of diagnosis with their quality of life at the end 
of the study. The median time to end of study is 0.92 years (IQR 0.50 – 
0.90). Only 4/17 maintained remission by end of study. 
 
There was an increasing acceptance to treatments and 
interventions with improvement of quality of life scores in this 
domain. In addition there was a significant improvement in the 
systemic symptoms domain. However the total quality of life scores 
and individual scores in the other domains remained unchanged. 
 
 Start of Phase A End of Phase B p (WR) 
IBD symptoms 0.49 (0.37 – 0.74) 0.69 (0.51-0.95) 0.131 
Systemic symptoms 0.29 (0.13 – 0.49) 0.64 (0.26 - 0.94) 0.05 
Emotional functioning 0.47 (0.35 – 0.68) 0.64 (0.30 – 0.91) 0.328 
Social functioning 0.65 (0.53 – 0.84) 0.89 (0.81 – 0.93) 0.091 
Body image 0.52 (0.30 – 0.84) 0.78 (0.67 – 0.91) 0.424 
Treatment/ interventions 0.53 (0.22 – 0.74) 0.67 (0.51 – 0.83) 0.037 
Total QOL scores 0.58 (0.44 – 0.72) 0.80 (0.53 – 0.92) 0.131 
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Table 4.7.9.1    Change in quality of life over the year from start of phase A to 
end of phase B – Median time = 0.92 years (IQR 0.50 – 0.90). Higher values 
represent better quality of life. (values in medians and IQR)  
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Figure 4.7.9.1 Change in quality of life scores from time of diagnosis (start 
Phase A) to time of first relapse 
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Figure 4.7.9.2  Changes in quality of life scores during different phases of 
the study trial. This is a breakdown of the same graph as shown in figure 
4.7.9.1. 
 
 
4.8   Discussion 
 
This study shows successful use of exclusive enteral nutrition as 
treatment in a cohort of 26 children unwell with active Crohn’s 
disease (part of the same cohort recruited in phase A). Despite 
complete food avoidance for a period of 8 weeks, children showed 
an improvement in their quality of life with clinical remission in 23/26 
children (88.5%). More importantly this study illustrates the point that 
these clear improvements in quality of life and PCDAI scores are not 
mirrored by mucosal healing, as evidenced by using both 
histological and endoscopic criterions. 
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Physical measures of disease activity and degrees of mucosal 
inflammation, in isolation, are of limited interest to patients with 
inflammatory bowel disease. A successful therapy should ideally 
both improve a patient’s quality of life and reduce the long-term 
consequences of the disease by modifying its course. One of the 
limitations of quality of life instruments such as the IMPACT II 
questionnaire is that they assess quality of life over a very short time 
frame (the last 14 days). It is well documented in children that both 
information recall and appreciation of long-term consequences are 
more limited than in adults. In addition the children coping 
mechanisms are different from adults 386-388. As such, we must remain 
aware, of relying too heavily on short-term measures of quality of life 
when making management decisions in children with IBD. We 
assume that these decisions are perhaps also important in 
influencing their long-term well-being. Of course an ideal treatment 
is one that is efficacious and improves short- and long-term quality 
of life, yet data on the latter is simply not yet available, and 
information from single measures of quality of life should not be 
extrapolated to represent long-term quality of life outcomes.  
 
Physical and psychological stressors have been shown to result in an 
increase in cytokine production in humans 387,388. The same has been 
demonstrated in animal models where increased cytokine release 
occurs after injection of epinephrine 389. Stress has also been shown 
to delay wound healing, which may in itself indirectly result in 
increased production of pro-inflammatory cytokines 390,391. Similar 
mechanisms are likely to occur in children with inflammatory bowel 
disease. Therefore perhaps a reduction in anxiety and stress, with an 
improved perception of their quality of life may have a direct effect 
on their disease activity. 
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Quality of life is a complex concept (chapter 1.7). It is known that 
disease activity alone does not determine patient well-being and 
quality of life. QOL is also determined by personal characteristics, 
coping abilities, the environmental situation and social support 392. 
This explains the fact as demonstrated in this study, two children with 
similar PCDAI scores may have very different quality of life scores. 
Generally instruments for measuring quality of life in children are 
scarce 393. Use of adult instruments such as the generic SF36 are not 
appropriate as they measure health status (particularly physical 
functioning), rather than a patient’s perception of their well-being, 
i.e., their health related quality of life (HRQOL) 350 (chapter 1.7). With 
the increasing need for such an instrument in paediatric IBD, 
‘IMPACT II’ evolved from the original paediatric IBD specific 
instrument ‘IMPACT I’ developed in Canada by Griffiths et al 394 
(chapter 1.7). Impact-II has been validated for use in children above 
8 years of age. However, in this study I found it difficult for any child 
less than 11 years of age to understand and answer the questions 
independently. As the instrument is designed for self-administration, 
parental help in responding is likely to bias the results; echoing my 
experience from initial phase of this study. 
 
While histological improvement was documented in 17/26 children 
after treatment, this did not appear to correlate with any QOL 
parameters. This could be due to several factors. The previously 
employed histological scoring system 314 uses a narrow range to  
quantify inflammation on biopsies. Together, the relatively small 
number of patients in the study and the lack of variability in histology 
score may be inadequate to conclude that there is no correlation. 
This may, also, not take into account children with mild disease who 
continue to have mild disease after treatment or those children with 
severe disease who continue to have severe disease. Children in 
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both scenarios will have a minimal difference in their histology 
scores. Quality of life is a complex concept, and disease 
treatment/healing is only one variable of many to affect it. 
 
The good correlation between the PCDAI and IMPACT-II 
questionnaire is likely the result of common questions to both 
instruments, which makes it all the more surprising that improvements 
in histology scores correlate with changes in PCDAI, but not quality 
of life scores. Of course histological healing may in fact only be a 
minor determinant affecting quality of life. Histological healing may 
only be diagnosed by taking appropriate biopsies at an invasive 
procedure. Whilst some practitioners feel that mucosal healing is a 
vital goal in the long-term management of the disease, there is no 
evidence that this improves the long-term outlook for patients 
diagnosed with Crohn’s disease in childhood.  
 
Finally, it is particularly gratifying to see, in such a young population, 
that quality of life is improved with a therapy that has none of the 
side effects of corticosteroids, whilst having clear advantages in 
terms of growth and nutrition.  
 
The phase B study in this chapter remains the only report looking at 
quality of life, prospectively over 2 years when children are treated 
with enteral nutrition. Interestingly the symptom scores improve by 
food reintroduction whilst 8 children drop out of the study. This 
improvement is perhaps likely to be related to presence of more 
well children at start of phase B compared to those at end of phase 
A (hence the high dropout). However the improvement in social 
functioning can be explained by the fact that enteral feeding over 
the day can result in a restrictive life style. 
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There is deterioration in the bowel and systemic symptoms domains 
at the end of phase B. This is likely to be related to the high number 
of relapsing children. Again, the total quality of life scores and those 
of the individual domains do not change. This may represent 
acceptance by the children regarding their chronic disease state 
resulting in a quality of life which is largely unaffected. In the same 
context quality of life scores, at the end of both phase A and B, 
when compared to scores at enrolment remain unchanged. It 
appears that though the disease process and its treatment do 
improve quality of life, children’s first impressions and feelings about 
their disease tend to stay. Otley et al 395 have reported a quality of 
life study in a large cohort of children one year after diagnosis in 
which significant improvement in HRQOL was noted during the year 
from diagnosis. Mean IMPACT scores varied significantly depending 
on the disease severity and also decreased with increasing age. 
These results illustrate that quality of life is a much more complex 
concept which is in turn affected by many variables; disease state 
being only one of those variables in the equation. 
 
In summary, this study demonstrates an improved quality of life after 
treatment with exclusive enteral nutrition in children with active 
Crohn’s disease. Although some may raise the concern that quality 
of life measures may not reflect healing at mucosal level, it is 
extremely important to realize that QOL is integral to patient 
treatment. There is clearly a need for studies regarding long-term 
outcome of children diagnosed with Crohn’s disease. This has to be 
the end point to effectiveness of treatments used in chronic disease. 
Perhaps, when we have good data on predictors of long-term 
quality of life, we may be able to focus even more effectively on 
short-term quality of life measures.  
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Figure 4.8 Cartoon illustration by a child (case SM05 - see table 
2.8.1.1) in Phase A of the study, showing another child on exclusive 
enteral nutrition working in the MacDonald’s serving chips and 
burgers but cannot eat them himself. The spotty face in the picture 
reflects Crohn’s disease. This shows his view of restricted eating by 
enteral feeding and that there could be other children who are 
‘worse off’ as they can’t eat whilst working in food shops.
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Chapter 5. Summary, critical discussion 
and conclusions
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5.1    Summary 
 
This thesis describes use of a new polymeric enteral feed ACD004, 
with a higher n-3 : n-6 ratio for treatment of paediatric Crohn’s 
disease.  
 
Chapter 2 describes effectiveness of the ACD004 feed in treatment 
of acute and active paediatric Crohn’s disease. 78.6% of the 
children achieved complete remission. This was found to be similar 
to CT3211, the previous polymeric feed (with relatively lower n-3 : n-6 
ratio). One child developed refeeding syndrome which is unlikely to 
be related to the feed itself. The colonic Crohn’s sub-group 
responded less well to ACD004. 
 
Chapter 3 decribes the randomised controlled trial, looking at role 
of ACD004 as a supplement compared to no supplement in 
maintenenace of remission. The trial collapsed with only 1/3rd of the 
calculated power being met due to withdrawal of funding. The 
limited study did not show any difference between the two groups. 
 
Chapter 4 describes a longitudinal assessment of quality of life in 
children taking enteral nutrition for treatment and for maintaining 
remission. There is a significant improvement in quality of life scores 
at completion of acute treatment. Although disease and systemic 
symptoms deteriorate on relapse, there is no change in the 
emotional and social functioning domains of quality of life which is 
suggestive of disease acceptance in children. Taking supplements 
does not adversely affect quatliy of life in children. This highlights the 
complex concept of quality of life with disease state being only one 
of the variables amongst many, affecting quality of life. 
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5.2    Critical discussion 
 
Enteral nutrition is an effective treatment for Crohn’s disease. To 
date two paediatric meta-analyses shows it to be as effective as 
corticosteroids 182,396. The Cochranre reviews however, show the 
steroids to be superior to exclusive enteral nutrition in inducing 
remission 311,312. The phase A of this study could have been designed 
as a randomised controlled trial to assess the two forms of treatment 
prospectively. In addition it could have been useful to compare a 
quality of life study in the two groups. This would have, however, 
required a greater number of children for recruitment. It would have 
perhaps made sense to involve the six centres at the outset 
embarking on the randomised controlled trial in phase A, rather 
than at phase B. 
 
Phase B (RCT) came to a premature end due to withdrawal of 
funding and failure to progress into a six centre multi-centre trial. The 
study was originally funded for two years with a verbal promise to of 
extending it to 6 centre study in future. The ethics committee 
accepted the trial proposal with full payment made for research 
fellow, university overhead fees and the project itself. In hindsight it 
was an error and and a full contract down to the last detail and 
penny should have been negotiated and agreed before 
commencement of the study. Long-term projects always require 
continued motivation of the investor and investee. During phase B of 
this study Professor John Walker-Smith retired after a year of starting 
the project. He was the principal investigator and had negotiated 
the original funding. In addition it is also likely to be related to the 
company’s disappointment in finding the results comparable to 
Modulen IBD. Additionally to the end of the study there were 
problems with manufacture and supply of the product adding to 
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frustration and lack of interest. I suspect the company did not wish 
to invest further in this and pulled out at the earliest opportunity. 
There are several lessons to be learnt from this. Randomised 
controlled trials should not be over-ambitious, be realistic and 
involve a strict binding contract for both the investor and investee in 
a well defined time frame. Any deviation should be penalised. The 
research network on medicines for children did not exist at that time 
and a trial gone through the MCRN could have been useful in not 
only contributing to the trial costs but also making it difficult for the 
investors to abandon the trial with a worry of bad publicity. 
 
5.3    Conclusions and future 
 
Enteral nutrition is an effective and safe remission inducing agent in 
paediatric Crohn’s disease. Sanderson 304 and Thomas 397 have 
shown enteral nutrition to be superior over steroids in preserving 
growth with higher height standard deviation scores at 6 months 
after the induction treatment in children with Crohn’s disease. 
Another study evaluated the final adult height in a group of 123 
patients with CD diagnosed prior to 16 years of age. Their mean final 
height was found to be 2.4cms less than the parental or target 
height. Almost one fifth had a final height < 8cms below their target 
height. The two main factors causing reduction of final height were 
presence of jejunal disease and period of symptoms prior to 
diagnosis. Interestingly, corticosteroids and requirement for surgery 
weren’t linked to final height acquisition 398. More longitudinal 
comparable studies are needed to look at long-term growth with 
use of enteral nutrition. A therapeutic intervention in a child with 
inflammatory bowel disease cannot be judged successful unless 
growth is normal and proceeding satisfactorily. Future studies with 
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enteral nutrition and other treatments in children with IBD should also 
incorporate normal growth as a marker of success. 
 
In addition to reducing inflammation, decreasing disease activity, 
and improving nutrition in children with newly diagnosed CD, 
exclusive enteral nutrition normalizes serum markers of bone 
turnover, suggesting an improvement in bone health with its use 399. 
Infliximab has already been shown to have a positive effect on 
bone metabolism in the REACH study 400. Further studies on short- 
and long-term effects of enteral nutrition on bone density and 
overall bone health in children with Crohn’s disease are needed. 
Currently there is little evidence of using enteral nutrition with other 
treatments for induction of remission. One report from Japan, a 
study of 110 adults with Crohn’s disease, showed a greater response 
with infliximab when used in conjunction with enteral nutrition 401. 
Combination therapy may be particularly useful in moderate to 
severe cases where there may be treatment resistance present.  
 
There is a wide variation in practice regarding use of enteral 
nutrition. Exclusive enteral nutrition is less commonly used in USA 
compared to Britian 402. The reasons for these differences are 
unclear and could be related to lack of dietetic and nursing 
support, financial support or lack of understanding. Increased 
understanding should permit more considered decisions. In addition 
hard-boiled lollies 403 and flavouring agents 353,404 in conjunction with 
enteral nutrition is reported. Further studies are required into these 
practices with a view to improving compliance.  
 
There are no prospective studies to show that supplement enteral 
nutrition is an effective form of treatment. Equally, the initial results (in 
the limited ACD004 trial) are discouraging. Although a better trial on 
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use of enteral feed as a supplement needs to be organised, equally, 
it is difficult to stay away from proven effective treatments like 
azathioprine and 6-mercaptopurine which have stood the test of 
time and have been around 1960s 230. The health commissioners also 
see a cost benefit in such treatments. From a children’s point of view 
tablets are easier to swallow in comparison with supplement enteral 
nutrition. A redesign and any re-attempts to conduct Phase B of this 
study, should incoroporate comparative or adjunctive usage of 
immunosuppressants such as thiopurines.  
 
Supplementary enteral nutrition may also have benefits in 
preventing post-operative recurrence of Crohn’s disease. In an adult 
study, those receiving at least 1200 Kcal of an enteral formula 
(polymeric or elemental) for the first 12 months following a resection 
had a lower risk of disease recurrence 405. These benefits are 
particularly seen in patients with penetrating disease and in those 
without colonic disease. Further studies are required evaluating 
maintenance enteral nutrition post-operatively with accurate 
definition of disease phenotype. 
 
Quality of life issues are important in all chronic conditions. In 
treatment of acute paediatric Crohn’s disease, although, the overall 
quality of life scores generally improved there are reservations about 
difficulty in taking the enteral feed. Even though, polymeric feeds 
remain the best tasting feeds to date it still, is far from ideal. Children 
would prefer better tasting flavour options and feed manufacturers 
should incorporate this. A better tasting feed would perhaps make 
enteral feeding a preferable treatement of choice for the adults as 
well. In the same context more studies are needed regarding the 
duration of use of the enteral feed.  
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Crohn’s disease is not a single disease but a heterogeneous group 
of disorders. There is a need for studies which incorporate studies 
taking the phenotype classifications such as the Montreal’s 
classification into consideration. This should enable us to tailor the 
treatments more effectively for individual cases. Our understanding 
of the disease pathogenesis continues to improve. We are now 
beginning to understand that genetic predisoposition, dysregulated 
immune response and environmental influences contribute to 
pathogenesis of the disease 406. 
 
Quality of life questionnaires continue to evolve and since the 
writing of this thesis, IMPACT III is available 271. It uses the Likert scale 
making it easy to be used and measured. Despite this, there is still a 
dearth of quality of life assessment tools in the younger age group. 
Although the IMPACT II is validated to be used by children above 8 
years of age, I failed to administer it successfully to children younger 
than 10 years of age, as they found it difficult to understand. Easily 
reproducible qualityof life assessment tools for young children with 
inflammatory bowel disease need to be developed in future 
research. 
 
Quality of life issues in paediatric Crohn’s disease are complex and 
certainly disease activity forms only one dimension of the 
assessment. We as doctors are good at addressing disease issues 
but poor at diagnosing and addressing other domains (emotional 
and social functioning, body image and attitudes to treatments) 
forming quality of life. We need to do more work to look at ways to 
improve quality of life other than improving it by treating the 
disease. Clearly, a simplistic psychological assessment is not the 
answer either. I have worked with children and families with Crohns 
disease for last many years and I feel that there needs to be a 
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parallel psychological assessment/input (in addition to disease 
assessment) during clinic visits with required tailored to each 
individual child and family. Further studies are required in this regard 
as development of these services would require use of resources 
and already stretched psychiatry services in the NHS, UK. 
 
Last, randomized controlled trials should not be over-ambitious but 
should be realistic. RCTs should involve a strict legal contract and 
binding for both the investor and the investee encompassed in a 
well defined time frame. Any deviation should be penalised. The 
current research governance practice has changed and it would 
have strengthened this study if such steps had been taken at the 
start. Recently the Department of Health (England) has 
commissioned a research network on medicines for children. This is 
based at University of Liverpool in partnership with Alder Hey 
children’s hospital. The collaborators include Imperial College, 
London, the Liverpool Women’s Hospital, the National Perinatal 
Epidemiology Unit at the University of Oxford and the National 
Children’s Bureau. The aims of this network are to facilitate the 
conduct of randomized controlled trials and other well designed 
studies of medicines for children including those for prevention, 
diagnosis and treatment. This should enable to maintain uniform 
quality in paediatric medical trials.
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Chapter 6. Appendix 
6.1    Consent Form 
 
(Form to be on hospital headed paper) 
 
Centre Number: 02-CWH 
 
Study Number: 9916-CLI (final version dated 16.07.1999) 
 
Subject Identification Number for this trial: 
 
 
CONSENT FORM 
 
          Please 
initial box 
 
 
1. I confirm that I have read and understand the information sheet  
  
dated……………….(version………….) for the above study and have   
had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to  
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
 
3. I understand that sections of my medical notes may be looked at by 
 responsible individuals from NESTEC S.A or from regulatory  
 authorities where it is relevant to my taking part in research.  
 I give permission for these individuals to have access to my records. 
 
4. I agree to take part in the above study. 
 
________________________ _________________ ________________________ 
Name of patient/guardian Date   Signature 
 
________________________ _________________ ________________________ 
Name of Person taking consent Date  Signature 
(if different from Researcher) 
 
________________________ _________________ ________________________ 
Researcher   Date   Signature 
 
1 copy for subject; 1 for Researcher (stored in the Study Master File); 1 to be kept 
in hospital notes. 
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6.2    The study information leaflet for children and parents 
consenting to participate – patient informed consent 
 
You are being asked to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with your relatives, friends and your GP if you wish. Ask us if there is anything that 
is not clear or if you would like more information. Take time to decide whether or 
not you wish to take part. 
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical 
Research and You’. This leaflet gives information about medical research and looks 
at some questions you may want to ask. A copy may be obtained from CERES, PO 
Box 1365, London N16 0BW. 
Thank you for reading this. 
 
What is the purpose of the study? 
At the …… hospital most children with active Crohn’s disease are now treated 
initially with a special milk based diet as their sole nutrition (only food) for 2 
months. Most often this can be drunk by mouth, if not it is given intra-gastrically 
via a tube through the nose. Children are able to cope with this because usually 
after 48 hours they feel so much better. A new form of diet, ACD004, is being 
evaluated. It has a different fat composition which is believed may help further to 
reduce bowel inflammation. Otherwise it is very similar to other special feeds for 
the treatment of Crohn’s disease. We think it may offer children a better chance of 
keeping well after its use (i.e., remission). 
 
We would also like to test the idea that continuing supplementation with this diet 
for sometime after your child returns to an otherwise normal diet helps keep your 
child well. We would like your permission to include your child in a random 
allocation of supplement or no supplement. In this way we can find out if oral 
supplements are helpful. This study will last a total of 5 years. 
 
Why has my child been chosen? 
Your child has been chosen because we feel that with his/her Crohn’s disease, 
nutrition along may heal his/her gut. Initially, 27 subjects will be studied from the 
Royal Free and Chelsea and Westminster Hospitals. From about April 2000, other 
patients from France and the Netherlands will also take part in the study, making it 
a total of 72. 
 
What will happen if my child takes part? 
If you and your child decide to take part in the study, during the first part, we will 
ask him/her to take nothing but the special milk diet for 8 weeks, followed by a 
gradual re-introduction of food items over a period of 4-6 weeks. During this time 
he/she will be weaned off the product until the amount of tested feed he/she is 
taking represents only 25-30% of daily nutritional needs. Having reached this 
amount, he/she will be entered into the second part of the study when he/she will 
receive a normal diet with or without ACD004 as a supplement for many months. 
This will be decided by randomization. Sometimes when we do not know which way 
of treating patients is best, we need to make comparisons. Children will be put into 
groups and then compared. A computer that has no information about the 
individual selects the group –i.e., by chance. Subjects in each group then have a 
different treatment and these are compared. 
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Before starting the test milk treatment your child will be investigated in exactly 
the same way as all children with Crohn’s disease at the ….., are at the moment. 
The number of blood tests and special investigations to assess treatment response 
and colonoscopies or Barium meal X rays will be the same. 
 
Your child will initially have to stay in the hospital for 3-5 days to get used to 
having only the tested product instead of food. This may also mean placing a tube 
through the nose into the stomach to feed him/her if she is too ill to take it by 
mouth. 
 
Your child will be attending the paediatric inflammatory bowel disease clinic after 
treatment in the usual way. To assess how well the treatment is working we will 
ask your child to fill in a questionnaire after a few of the visits. 
 
 
What does my child have to do? Are there lifestyle restrictions? 
As mentioned above your child will not be allowed any food apart from the special 
milk drink for the first 8 weeks of your taking part in the study. If your child is 
selected to be in a group to receive long term supplementation he/she will need to 
carry on drinking a small amount of the feed (roughly 1-1½ pints a day) on a 
regular basis even if totally healthy.  
 
What is the product being tested? 
The product is a complete nutritional support feed based on specially treated 
cow’s milk protein and vegetable oils. These vegetable oils are known to 
potentially reduce inflammation. Otherwise the feed is very like other special diets 
we use to treat children with Crohn’s disease. 
 
It looks like milk and fulfils all nutritional needs plus the extras due to the disease. 
Your child will be given a study card, the size of a credit card. Please make sure 
he/she carries the study card at all times. 
 
What are the alternatives for diagnosis or treatment? 
Alternatives to this treatment at this stage of Crohn’s disease are other special 
feeds or corticosteroids, although at our hospital we try to avoid use 
corticosteroids. 
 
What are the side effects of taking part? 
Your child may experience a temporary worsening of any of the following: 
diarrhoea, nausea, vomiting and abdominal cramps. These are more likely to occur 
at beginning of treatment. That is why treatment is started in hospital. If your 
child suffers these or any other symptoms after discharge from your hospital, you 
should report them to the investigator Dr…… or any of his team either straight 
away or if mild, at the next scheduled meeting. 
 
What are the possible disadvantages or risk of taking part? 
The possible disadvantages will be not having any normal food during the first 8 
weeks of the treatment. Secondly, and like all treatments, it might not work on 
your child. 
 
What are the possible benefits of taking part? 
We hope that the treatment will help your child. The inflammation of his/her gut 
can disappear and he/she may catch up on height and weight growth. However, 
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this cannot be guaranteed. The information we get from this study may help us 
treat children with Crohn’s disease better. 
 
Has any other study of this kind been done before? 
A similar product was used in a previous study involving 29 Crohn’s disease patients 
at the Royal Free Hospital, London between 1995 and 1997. 
 
What if new information becomes available? 
Sometimes during the course of the research project, new information becomes 
available about the treatment that is being studied. If this happens, your research 
doctor will tell you about it and discuss with you whether you want to continue in 
the study. If you decide to withdraw your research doctor will make arrangements 
for your care to continue. If you decide to continue in the study, you will be asked 
to sign an update consent form. 
 
What happens when the research study stops? 
Sometimes, the sponsor might decide to stop the study. Should this be the case, a 
similar product is available on the market to help your child. 
 
What if something goes wrong? 
Compensation for any injury caused by taking part in this study will be in 
accordance with guidelines of the Association of British Pharmaceutical Industry 
(ABPI). Broadly speaking, the ABPI guidelines recommend that ‘the sponsor’ 
without legal commitment, should compensate you without you having to prove 
that it is at fault. This applies in cases where it is likely that such injury results 
from giving away any new drug/new treatment or any other new procedure carried 
out in accordance with the protocol for the study. ‘The sponsor’ will not 
compensate you where such injury results from any procedure carried out which is 
not in accordance with the protocol for the study. Your right at law to claim 
compensation for injury where you can prove negligence is not affected. Copies of 
these guidelines are available on request. 
 
Will my taking part in this study be kept confidential? 
Data from this study will be recorded on specially designed forms. Your name will 
not appear on any of those forms, in fact you will be given a number once enrolled 
in the trial. Access to your medical records may be available to doctors, the 
sponsor’s monitors, clinical trials auditors, ethics committees and regulatory 
authorities if required. The study results may be published but your identity will 
not be disclosed.  
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6.3    Declaration of Helsinki 
 
Recommendations Guiding Physicians in Biomedical Research Involving Human 
Subjects 
 
 
Adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964 and amended 
by the 29th World Medical Assembly, Tokyo, Japan, October 1975, the 35th World 
Medical Assembly, Venice, Italy, October 1983, the 41st World Medical Assembly, 
Hong Kong, September 1989 and the 48th General Assembly, Somerset West, 
Republic of South Africa October 1996. 
 
 
INTRODUCTION 
 
It is the mission of the physician to safeguard the health of the people.  His or her 
knowledge and conscience are dedicated to the fulfilment of this mission. 
 
The Declaration of Geneva of the World Medical Association binds the physician 
with the words, "The health of my subject will be my first consideration", and the 
International Code of Medical Ethics declares that, "A physician shall act only in the 
subject's interest when providing medical care which might have the effect of 
weakening the physical and mental condition of the subject". 
 
The purpose of biomedical research involving human subjects must be to improve 
diagnostic, therapeutic and prophylactic procedures and the understanding of the 
aetiology and pathogenesis of disease. 
 
In the current medical practice most diagnostic, therapeutic or prophylactic 
procedures involve hazards.  This applies especially to biomedical research. 
 
Medical progress is based on research which ultimately must rest in part on 
experimentation involving human subjects. 
 
In the field of biomedical research a fundamental distinction must be recognized 
between medical research in which the aim is essentially diagnostic or therapeutic 
for a subject, and medical research, the essential object of which is purely 
scientific and without implying direct diagnostic or therapeutic value to the person 
subjected to the research. 
 
Special caution must be exercised in the conduct of research which may affect the 
environment, and the welfare of animals used for research must be respected. 
 
Because it is essential that the results of laboratory experiments be applied to 
human beings to further scientific knowledge and to help suffering humanity, the 
World Medical Association has prepared the following recommendations as a guide 
to every physician in biomedical research involving human subjects.  They should 
be kept under review in the future.  It must be stressed that the standards as 
drafted are only a guide to physicians all over the world.  Physicians are not 
relieved from criminal, civil and ethical responsibilities under the laws of their own 
countries. 
 
I Basic Principles 
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1. Biomedical research involving human subjects must conform to generally 
accepted scientific principles and should be based on adequately performed 
laboratory and animal experimentation and on a thorough knowledge of the 
scientific literature. 
 
2. The design and performance of each experimental procedure involving 
human subjects should be clearly formulated in an experimental protocol which 
should be transmitted for consideration, comment and guidance to a specially 
appointed committee independent of the investigator and the sponsor provided 
that this independent committee is in conformity with the laws and regulations of 
the country in which the research experiment is performed. 
 
3. Biomedical research involving human subjects should be conducted only by 
scientifically qualified persons and under the supervision of a clinically competent 
medical person.  The responsibility for the human subject must always rest with a 
medically qualified person and never rest on the subject of the research, even 
though the subject has given his or her consent. 
 
4. Biomedical research involving human subjects cannot legitimately be 
carried out unless the importance of the objective is in proportion to the inherent 
risk to the subject. 
 
5. Every biomedical research project involving human subjects should be 
preceded by careful assessment of predictable risks in comparison with foreseeable 
benefits to the subject or to others.  Concern for the interests of the subject must 
always prevail over the interests of science and society. 
 
6. The right of the research subject to safeguard his or her integrity must 
always be respected.  Every precaution should be taken to respect the privacy of 
the subject and to minimize the impact of the study on the subject's physical and 
mental integrity and on the personality of the subject. 
 
7. Physicians should abstain from engaging in research projects involving 
subjects unless they are satisfied that the hazards involved are believed to be 
predictable.  Physicians should cease any investigation if the hazards are found to 
outweigh the potential benefits. 
 
8. In publication of the results of his or her research, the physician is obliged 
to preserve the accuracy of the results.  Reports of experimentation not in 
accordance with the principles laid down in this Declaration should not be 
accepted for publication. 
 
9. In any research on human beings, each potential subject must be 
adequately informed of the aims, methods, anticipated benefits and potential 
hazards of the study and the discomfort it may entail.  He or she should be 
informed that he or she is at liberty to abstain from participation in the study and 
that he or she is free to withdraw his or her consent to participation at any time.  
The physician should then obtain the subject's freely-given informed consent, 
preferably in writing. 
 
10. When obtaining informed consent for the research project the physician 
should be particularly cautious if the subject is in a dependent relationship to him 
or her or may consent under duress.  In that case the informed consent should be 
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obtained by a physician who is not engaged in the investigation and who is 
completely independent of his official relationship. 
 
11. In case of legal incompetence, informed consent should be obtained from 
the legal guardian in accordance with national legislation.  Where physical or 
mental incapacity makes it impossible to obtain informed consent, or when the 
subject is a minor, permission from the responsible relative replaces that of the 
subject in accordance with the national legislation. 
 
Whenever the minor child is in fact able to give consent, the minor's consent must 
be obtained in addition to the consent of the minor's legal guardian. 
 
12. The research protocol should always contain a statement of the ethical 
considerations involved and should indicate that the principles enunciated in the 
present Declaration are complied with. 
 
II Medical Research Combined with Professional Care (Clinical Research) 
 
1. In the treatment of the sick person, the physician must be free to use a new 
diagnostic and therapeutic measure, if in his or her judgement it offers hope of 
saving life, re-establishing health or alleviating suffering. 
 
2. The potential benefits, hazards and discomfort of a new method should be 
weighed against the advantages of the best current diagnostic and therapeutic 
methods. 
 
3. In any medical study, every subject - including those of a control group, if 
any - should be assured of the best proven diagnostic and therapeutic method.  
This does not exclude the use of inert placebo in studies where no proven 
diagnostic or therapeutic method exists. 
 
4. The refusal of the subject to participate in a study must never interfere 
with the physician-subject relationship. 
 
5. If the physician considers it essential not to obtain informed consent, the 
specific reasons for this proposal should be stated in the experimental protocol for 
transmission to the independent committee. 
 
6. The physician can combine medical research with professional care, the 
objective being the acquisition of new medical knowledge, only to the extent that 
medical research is justified by its potential diagnostic or therapeutic value for the 
subject. 
 
III Non-therapeutic Biomedical Research Involving Human Subjects (Non-
clinical Biomedical Research) 
 
1. In the purely scientific application of medical research carried out on a 
human being, it is the duty of the physician to remain the protector of the life and 
health of that person on whom biomedical research is being carried out. 
 
2. The subjects should be volunteers - either healthy persons or subjects for 
whom the experimental design is not related to the subject's illness. 
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3. The investigator or the investigating team should discontinue the research if 
in his/her or their judgement it may, if continued, be harmful to the individual. 
 
4. In research on man, the interest of science and society should never 
take precedence over considerations related to the well-being of the 
subject.
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